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A COMPARATIVE EFFECTIVENESS STUDY OF CONTINUOUS POSITIVE AIRWAY 
PRESSURE (CPAP) RELATED SKIN BREAKDOWN WHEN USING DIFFERENT NASAL 
INTERFACES IN THE EXTREMELY LOW BIRTH WEIGHT (ELBW) NEONATE 
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Nasal continuous positive airway pressure (CPAP) is reportedly superior to mechanical ventilation in 
the neonatal population by reducing bronchopulmonary dysplasia (BPD).  The neonate is vulnerable 
to injury secondary to immature physiological systems and skin structures and the current CPAP 
devices place constant pressure on nares, nasal septum and forehead, increasing injury risk.  
Through the framework of comparative effectiveness research an examination of nasal interfaces 
currently used during neonatal CPAP was conducted in an effort to provide scientifically 
supported recommendations and improve clinical outcomes.   
The primary aim of this study was to determine differences in the frequency, severity and 
specific types of nasal injuries described when comparing different nasal CPAP interfaces 
(prongs/mask/rotation) used in the treatment of neonatal respiratory distress syndrome (RDS). A 
secondary aim of the study was to identify risk factors that may be associated with skin 
breakdown during nasal CPAP administration. A three group prospective randomized 
 v 
 
experimental design was used to study78 neonates <1500 grams receiving nasal CPAP using the 
same delivery system. The subjects were randomized into three groups: 1) continuous nasal 
prong group, 2) continuous nasal mask group, or 3) alternating mask/prongs group. Serial data 
collection included: demographic, biophysical measures and the Neonatal Skin Condition Scale 
(NSCS).  
     This study demonstrated a significant difference in the frequency and severity of skin injury 
when utilizing a method of rotating mask and prong nasal interfaces during neonatal CPAP 
therapy; a useful clinical recommendation. Specific nursing care implications related to study 
findings include; choosing a device for best fit for infant (face shape and infant size); positioning 
of the CPAP device; developmental position of the infant; and focused skin assessment with 
rapid intervention. Standardized care including skin barriers, clinical expertise of nursing and 
respiratory therapy, and skin care management are strategies that warrant additional research. 
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Abstract 
Objective:  Identify factors associated with skin injury during nasal continuous positive airway 
pressure (NCPAP) and describe differences in frequency, severity, and type of skin injuries when 
comparing nasal interfaces used during NCPAP in the preterm infant.   
Data Sources: Scientific databases were searched using provided key terms which yielded 113 
articles.  
Study Selection:  Fourty-six articles were included in this integrative review: 6 case studies; 22 
with identified aim examining skin and nasal injury during NCPAP; 18 included skin care 
considerations during NCPAP. 
Data Extraction:  Studies were categorized into four themes; 1) types of nasal injuries 2) 
associated risk factors that increase incidence of injury; 3) differences between NCPAP devices 
and/or nasal interface and corresponding rate and severity of nasal injury; 4) recommended 
prevention strategies to reduce iatrogenic cutaneous injury. 
Data Synthesis:  Skin injury was a common theme during neonatal NCPAP with skin breakdown 
rates 20-60%.  Increased skin injury risk was associated with smaller infant size, gestational age, 
and duration of therapy. Nursing care strategies to improve skin integrity during NCPAP had 
little supportive evidence. Nursing practice is varied with reportedly little standardized care 
during NCPAP therapy. Limited studies were discovered comparing various types of nasal 
interfaces during NCPAP and the reported frequency and severity of skin injury. 
Conclusions:  Risk factors during NCPAP include nasal injury and trauma secondary to tight 
fitting nasal interfaces necessary to provide continuous distending pressure for respiratory 
stability. Identifying strategies to reduce skin breakdown will support non-invasive treatment 
success, reduce reintubation rates, reduce sepsis, reduce patient discomfort, and improve 
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developmental outcomes during NCPAP use. Specific care strategies described to reduce skin 
injury during NCPAP had limited experimental studies to support recommendations. 
Key words: nasal CPAP of the neonate, CPAP, non-invasive respiratory management of the 
preterm, respiratory devices of the newborn, respiratory pressure sources of the preterm infant, 
nasal trauma, preterm infant nasal skin breakdown, nasal prongs, skin care and pressure ulcer, or 
skin breakdown during NCPAP use. 
Call Outs:  
1) Identifying evidence based strategies to reduce skin breakdown during neonatal nasal 
continuous positive airway pressure can support non-invasive treatment success. 
2) Empirical evidence is needed to support nursing interventions to reduce iatrogenic skin 
injury during nasal continuous positive airway pressure administration. 
3) Half of the reviewed articles included nursing and skin care considerations used to 
prevent skin injuries that developed during nasal continuous positive airway pressure. 
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    Scientific evidence within the field of neonatal respiratory care demonstrates several 
advantages of early nasal continuous positive airway pressure (NCPAP) or early extubation to 
NCPAP.  Reduction in the duration and/or exposure to mechanical ventilation in the preterm 
neonate has many advantages including decreased incidence of chronic lung disease, ventilator 
associated pneumonia, blood stream infections, periventricular leukomalacia (PVL), improved 
neurodevelopmental outcomes and shortened hospital length of stay (Davis, Morley, & Owen, 
2009; DePaoli, Davis, Faber, & Morley, 2008; Squires & Hyndman, 2009; Verder, Bohlin, 
Kamper, Lindwall, & Jonsson, 2009). Preterm neonates require some degree of respiratory 
support to maintain functional residual capacity (FRC) and to decrease the symptoms of 
respiratory distress syndrome (RDS) (Buettiker, Hug, Baenziger, Meyer, & Frey, 2004; Verder, 
2007). NCPAP is often used to meet this need.   
     NCPAP is a non-invasive method for providing a constant distending pressure during both the 
inhalation and exhalation phases of the respiratory cycle. Used in the spontaneously breathing 
preterm neonate, NCPAP provides stability of the neonate’s FRC, improves oxygenation, 
conserves surfactant, aids in the prevention of atelectasis, improves gas exchange, and aids in the 
prevention of obstructive and central apnea (Davis, Jankov, Doyle, & Henscke, 1998; Diblasi, 
2009; Squires & Hyndman, 2009). This non-invasive respiratory therapy was first described as 
“an overpressure apparatus” in a German textbook about the diseases of the newborn (von Reuss, 
1914). Early CPAP, a system of hoses placed into water filled receptacle with a gas source and 
face mask was attached to an infant to provide treatment for respiratory distress of the newborn. 
This early CPAP was useful to provide continuous airway pressure (Diblasi, 2009). Ventilator 
delivered CPAP was used in the late 1970’s (Gregory, Kitterman, Phibbs, Tooley, & Hamilton, 
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1971) and by the late 80’s and 90’s free standing nasal CPAP delivery systems were designed 
and widely accepted (Diblasi, 2009; Verder, 2007). 
     There are three major types of NCPAP, traditionally classified by the technique used to 
control the gas flow to the patient.  These include the constant flow or bubble NCPAP, variable 
flow CPAP devices that have fluidic control to maintain set pressures, and ventilator delivered 
CPAP that is generally delivered through an endotracheal tube (ETT) or bi-nasal pharyngeal 
tubes.  All devices share four components: 1) a heated and humidified blended gas source, 2) a 
nasal interface, 3) a patient circuit, and 4) a pressure-generating apparatus.   
     Risks attributed to NCPAP therapy in the preterm neonatal population include abdominal 
distension, inability to provide enteral nutrition secondary to gut disturbance, slightly increased 
incidence of necrotizing enterocolitis (NEC), pneumothorax, and nasal injury or nasal mucosal 
damage (Janta et al., 2010; Squires & Hyndman, 2009; Verder, 2007). The current CPAP devices 
are effective in maintaining needed positive end expiratory pressure (PEEP) but also place 
constant pressure on the nares, nasal septum, and forehead sometimes leading to decreased skin 
integrity and injury especially in the most immature of preterm neonates (DePaoli et al., 2008; 
Squires & Hyndman, 2009).  As more preterm neonates are managed with NCPAP, the incidence 
and prevalence of nasal trauma and skin injury will likely increase.   
     The primary aim of this review was to determine differences in the frequency, severity, 
location and/or description of nasal injuries when comparing different nasal interfaces 
(prongs/mask) during NCPAP administration. A secondary aim was to describe reported risk 
factors associated with nasal injury and skin breakdown during NCPAP use.  Lastly, strategies 
were identified to support the reduction of nasal injuries during NCPAP administration in 
preterm neonates. 
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Methods 
     Pub Med, Google Science, Web of Science, and CINAHL electronic databases were included 
in the search.  The dates were restricted to the last 16 years (1996-2011) to correlate with the 
widespread adoption of surfactant administration which transformed respiratory care of the 
extremely low birth weight (ELBW) infant to include early extubation strategies and widespread 
NCPAP use. The search was also restricted to English language. Initially a broad search was 
conducted with search terms to include NCPAP of the neonate, continuous positive airway 
pressure, non-invasive respiratory management of the preterm, respiratory devices of the 
newborn, and respiratory pressure sources of the preterm neonate. This broad search was 
completed to obtain background information on NCPAP use in the neonate and identify specific 
skin concerns. This initial search yielded 88 pertinent articles.  A more specific database search 
followed using selective key terms, including nasal trauma, preterm infant nasal skin breakdown, 
nasal prongs and skin care, and pressure ulcer or skin breakdown during CPAP use.  This search 
provided an additional 14 articles for a total of 102 publications. Non-published abstracts or 
articles were not searched or reviewed.   
     A secondary review of individual article citations and recently published research revealed an 
additional eleven articles for a total of 113 total publications representing specialty areas from 
neonatology, otolaryngology, nursing, and pediatrics.  Each article was fully examined by the 
lead author for applicable content and included when criteria for both subject matter and 
identified population of interest were met.   
     Each of the 113 studies were evaluated for content related to neonatal skin breakdown as an 
iatrogenic injury secondary to NCPAP use, regardless of the primary or secondary aim of the 
study. This method was utilized to ensure inclusion of all studies which described skin 
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breakdown and/or identified nursing care strategies to improve outcomes during NCPAP 
therapy. Preterm neonates were defined as < 37 weeks gestation and birth weight restriction was 
<3000 grams. Descriptive studies and global reports of recommended skin care strategies during 
NCPAP use were also included in the findings section of this review. 
     Studies were eliminated if there was no discussion of skin breakdown related to the 
administration of NCPAP (53).  Studies also were eliminated if the sample was not comprised of 
preterm neonates (13).  The methodology of each study was examined for the level of evidence, 
one through seven as described in Melnyk and Fineout-Overholt (2011) (see Table 1; on-line). A 
single interventional study was eliminated from this review based on sample size (n = 5) which 
was not adequately powered to detect significant differences raising questions regarding study 
recommendations. 
Results  
     As described in the methodology section, each article underwent a full review by the author to 
explore findings which corresponded to primary and secondary study aims. The discussion 
section of many articles also included critical information related to aspects of skin care during 
NCPAP use in the preterm population. The 46 studies were classified into three groups to aid in 
clarity when discussing results.  The first group was those studies with the primary or secondary 
aim related to skin breakdown.  Twenty-two articles were included, some which reported 
specific descriptions of the most common types of nasal injuries. Anatomical descriptions 
including diagrams to aid in the explanation of injury risk for the preterm infant were included in 
some of these articles. The second group included case studies of trauma or injury associated 
with NCPAP use. Six individual cases were discussed with descriptions of facial, nasal, and/or 
nerve disruption during NCPAP use. Descriptions of injuries often included strategies for 
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prevention.  Lastly, 18 articles described skin care concerns during NCPAP use in the discussion 
sections of each article.  These findings supported nursing care strategies and/or observations 
during NCPAP care that were often exclusive of the primary and secondary aim of the studies.       
     The study sample sizes ranged from 3 to 989 infants. The largest sample represented 13,719 
NCPAP days.  Duration of NCPAP ranged from 1-32 days. Samples included preterm neonates 
whose birth weight ranged from >800 grams to <3000 grams and most were cared for within 
Level II or III neonatal intensive care units (NICU). 
Summary of Findings  
     The purposes of the reviewed articles can best divided into four topical categories including: 
1) types of nasal injuries that correlate with NCPAP use, 2) associated risk factors that increase 
incidence of injury, 3) the differences between types of NCPAP devices and/or nasal interface 
and the reported rate and severity of nasal trauma injury, and 4) the recommended prevention 
strategies to reduce iatrogenic cutaneous injury (See Figure 2). Several of the reviewed articles 
provided overlapping information applicable in two categories.  These findings are explored 
under each heading as appropriate.  A detailed summary of findings in these categories is 
described below. 
Types of nasal injuries that correlate with NCPAP use 
     Multiple reports of nasal injury were identified including nasal snubbing or the upward 
pressure on the nose, nasal flaring described as the abnormal enlargement of the nare, columella 
nasi (nasal septum) necrosis (Buettiker et al., 2004; Robertson, McCarthy, Hamilton, & Moss, 
1996) crusting or scab formation and/or excoriation of the septum typically at the base (Yong, 
Chen, & Boo, 2005), and nasal hyperemia described as redness or blanching (Rego & Martinez, 
2002).  Disfigurement of the size and shape of the nostrils was described in multiple studies, 
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most commonly associated with the Hudson prongs (Fischer et al., 2010; Owen, Morley, & 
Davis, 2010). Several examples include neonates that were reintubated for mechanical 
ventilation secondary to loss of nasal tissue (nasal erosion) and bleeding, although stable 
respiratory status on NCPAP therapy (Verder, 2007; Yong et al., 2005).  Authors of descriptive 
studies included recommendations for frequent skin assessment intervals and strategies for 
positioning the neonate in an effort to reduce the rate of injury through early identification of 
skin breakdown and/or prevention (Diblasi, 2009; McCoskey, 2008; Squires & Hyndman, 2009).  
Many suggested interventions have not been empirically tested, including the described use of 
barrier protection with silicon between the infant’s skin and NCPAP interface (Gunlemez, Isken, 
Gökalp, Türker, & Arisoy, 2010).   
     Interestingly, case studies of nasal vestibular stenosis were reported. Several preterm infants 
who required NCPAP for treatment of RDS suffered from stenosis or an obstruction of the nasal 
passage thought to be the result of pressure from the NCPAP device or constant CPAP flow 
against fragile nasal tissue. This injury was typically identified several months following NICU 
discharge when care was sought for feeding difficulty (DeRowe, Lansburg, Fishman, Halperin, 
& Fliss, 2004; Smith & Roy, 2006).  Standard assessment and evaluation of the inner nares and 
septum without obvious bleeding/trauma was not mentioned or evaluated in the included articles.  
Given this finding, this area may need to be included in the frequent assessment of the neonate 
during treatment with NCPAP. Anticipatory guidance upon discharge from the NICU should 
also include parental awareness for symptoms of nasal obstruction.  
     Case Study Reports: One case study found in the literature described a neonate who had 
significant nasal septum erosion that would typically require reintubation to allow the area to 
heal; however, the authors describe a method of providing oral CPAP using an ETT fashioned 
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through a pacifier that allowed time required for nasal healing (Carlisle, Kamlin, Owen, Davis, & 
Morley, 2010). This was a single finding and although successful in this case, empirical trials 
would be required to encourage widespread adoption.  A full thickness laceration of the alae nasi 
was documented following treatment with NCPAP for one week (Shanmugananda & Rawal, 
2007). Facial nerve palsy secondary to the pressure against the seventh cranial nerve was 
reported in a case study presented by Maffei (2008) and colleagues secondary to the tight fitting 
Velcro® attachment to the nasal interface that is positioned across the facial nerve causing 
compression.  Forehead pressure necrosis resulting in permanent scarring of both the central 
forehead and left eyebrow was reported as a consequence of tight fitting NCPAP hats creating 
sources of friction and uneven pressure points (Hogeling, Fardin, Frieden & Wargon, 2012). 
Lastly, an auricular seroma was noted in a single neonate secondary to tight fitting strap 
attachments which secure the nasal interface to the cap across the vulnerable ear of the preterm 
neonate (Eifinger, Lang-Roth, Woelfl, Kribs, & Roth, 2005).   
Associated risk factors that increase incidence of injury 
     Universally the smaller birth weight and lower gestational age neonates were identified as 
most at risk for iatrogenic nasal injury while on NCPAP (Kopelman & Holbert, 2003; Rego & 
Martinez, 2002; Robertson et al., 1996; Yong et al., 2005). In a randomized controlled trial by 
Buettiker et al. (2004) larger neonates with birth weights >2500 grams had the fewest reported 
skin and nasal injuries. The reported duration of NCPAP ranged from 1 day to 32 days. Increased 
time on nasal CPAP was identified as a significant risk factor for skin injury although nasal 
trauma was reported in as little as 3 days of continuous use (Robertson et al., 1996; Yong et al., 
2005). A cross-sectional study utilizing a convenience sample in Brazil described the incidence 
of nasal skin injury of nearly 100% of preterm and term infants who were provided NCPAP for 
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greater than 2 days (do Nascimento, Ferreira, Coutinho, & Santos Verissimo, 2009).  A cross-
sectional study by Jatana and colleagues (2010) reported smaller neonates with corresponding 
smaller nasal columella and inferior turbinate along with the complication of immature preterm 
skin and often longer CPAP duration, demonstrated the highest incidence of nasal complications. 
Also noted by these researchers was a correlation between skin injury and low APGAR scores 
that had not been reported by other researchers (Jatana et al, 2010) although the study was not 
powered to detect significant differences among groups for this measure. 
     A recent multi-site prospective cohort study was conducted to examine the incidence of 
pressure ulcers in neonatal patients cared for in the NICU.  Eighty one patients were examined 
with a reported incidence of 16% (14); seven of which occurred on the nose. These researchers 
were the first to examine the incidence and risk factors for pressure ulcer development in the 
ELBW infant. Researchers identified NCPAP as an independent risk factor for nasal pressure 
ulcers in addition to previously described compression necrosis and/or nasal deformities (Fujii, 
Sugama, Okuwa, Sanada, & Mizokami, 2010). 
          Specialist within the field of otolaryngology reported specific injuries related to NCPAP 
use in the preterm neonate. These injuries include nasal vestibular stenosis, described earlier in 
this review, or columellar necrosis that develops in a stepwise fashion with delivered pressure 
from the nasal prongs or air trauma from constant flow against soft nasal mucosa (DeRowe et al., 
2004).  This process over time can lead to ulceration, bacterial colonization and then secondary 
healing with granulation tissue formation leading to disruption of nasal patency (DeRowe et al., 
2004; Jatana et al, 2010; Smith & Roy, 2006). Vestibular stenosis occurred in as early as 8 days 
of continuous NCPAP according to these researchers.  Overall increased incidence of nasal 
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suctioning needs, coupled with an increased rate of coagulase negative staphylococcus was also 
reported (Kopelman & Holbert, 2003; Ronnestad et al., 2005).   
     Researchers reported nasal prong size as a concern during NCPAP therapy. Prongs that are 
too large distend and distort the nares and cause pressure to the inner aspect of the nose leading 
to decreased perfusion and tissue necrosis.  The prong size that is inappropriately small also 
leads to excessive damage with greater mobility in the nare causing friction and traumatic injury 
to the mucosal lining (do Nascimento et al., 2009; Squires & Hyndman, 2009).   
Differences between device types, nasal interfaces and the rate and severity of nasal trauma 
     Hudson prongs were associated with more injuries than the mask or Argyle prongs because of 
failure to meet anatomic positioning against the neonate’s skin. These prongs are not translucent, 
making it difficult to assess the fragile skin under them (Buettiker et al., 2004; Fischer et al., 
2010; Robertson et al., 1996; Yong et al., 2005). The Argyle prong system was reportedly more 
difficult to maintain in the smaller (<1000 gram) neonates but had no greater incidence of trauma 
(Buettiker et al., 2004). The shorter binasal prongs reportedly have clear advantages over the 
single prong devices in the reduction of RDS (DePaoli, 2008). Little difference was detected 
when comparing aforementioned nasal CPAP devices and more evidence is needed to detect 
differences between the types of nasal interface and the rate and/or severity of nasal trauma and 
injury to the preterm neonate (DePaoli, 2008; Fischer et al., 2010; Owen et al., 2010). 
     Rego and colleagues (2002) conducted a randomized prospective study to compare the 
performance and patient tolerance of two difference nasal prongs that are typically used during 
NCPAP administration. The Hudson device that is the typical nasal interface used for bubble 
CPAP and the Argyle device were compared to determine tolerance (incidence and severity of 
nasal breakdown) and efficacy (measured by blood gases and vital signs) of the devices.  This 
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was the first study reviewed which compared nasal interfaces during NCPAP administration with 
the preterm population. The researchers found a significant increase in the incidence of 
hyperemia with the use of the Argyle prongs in the smallest patients (≤ 1000g). There was no 
difference between groups in the other measures of skin breakdown including excoriation, 
bleeding or erythma (Rego & Martinez, 2002). No studies were found that specifically examined 
differences between nasal prongs, nasal mask and the systematic rotation of these nasal 
interfaces thought to relieve pressure points on the nares, nasal columella, forehead, or other 
facial surfaces of the preterm neonate. 
The recommended prevention strategies to reduce iatrogenic cutaneous injury 
     The use of barriers demonstrates efficacy in this population by protecting the nasal columella. 
In a randomized control trial, Gunlemez et al. (2010) studied the application of a silicon gel 
sheeting at the nasal surfaces to protect from direct pressure from the CPAP prongs to the 
maxillary spine located behind the collumella. Researchers in two studies suggested wetting the 
prongs with sterile water or saline to prevent friction during placement and gently shaping 
prongs posterior to best align with the physiological angle of the neonates nares (do Nascimento 
et al., 2009; Robertson et al., 1996). 
     From the results of their descriptive studies researchers suggested nursing implications to 
both assess and prevent iatrogenic nasal injury during nasal CPAP administration (McCoskey, 
2008; Squires & Hyndman, 2009). These included barriers under the device, frequent 
assessment, developmental positioning, and focused examinations to identify hyperemia early. 
Other researchers discuss suggestions for manufactures’ to engineer prongs to coincide with the 
anatomical position of the neonatal nose (Verder et al., 2009; Yong et al., 2005). In addition, 
alternating the nasal mask and nasal prongs in an effort to alter pressure points on the nares and 
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nasal mucosa of the neonate has been suggested as a potential method to reduce tissue injury 
(McCoskey, 2008). Empiric testing of these measures is needed prior to widespread adoption.   
     Nursing care experience and expertise was a common theme throughout several included 
studies.  Verder and colleagues (2009) reported that nasal complications of NCPAP are to a large 
extent avoidable with proper technique, nursing experience and the ongoing skilled care of the 
neonate.  Nursing care during NCPAP was described as of “utter-most importance” in the 
treatment success of NCPAP with several key points for care delivery offered that included: 
providing open nasal passages, optimal body positioning, avoidance of unnecessary suctioning, 
adequate humidification, correct prong size and inspection of skin surfaces (Bohlin, Jonssan, 
Gustafsson, & Blennow, 2008).  Nursing care was described as “exquisite” and paramount to the 
success of NCPAP for the extremely low birth weight (ELBW) neonate during studies at 
Columbia University (Ammari et al., 2005). 
     Of special interest is the development of alternative devices to provide CPAP to neonates 
without placing pressure on the nares, a stated negative consequence of the therapy.  Alternative 
CPAP methods whose design correlates to an early plastic pressure chamber device developed 
by Gregory and others in the 1970’s, made a recent comeback with helmet CPAP devices to 
provide PEEP to the neonate while sparing nasal surfaces (Chidini et al., 2010; Trevisanuto et 
al., 2005; Zaramella et al., 2006). These methods are currently experimental without widespread 
application. 
     High flow nasal cannula (HFNC) and vapo-therm have been used in comparative 
effectiveness studies as a means to compare and contrast supportive strategies while providing 
nasal sparing, non-invasive respiratory support in the preterm neonate (Campbell, Shah, Shah, & 
Kelly, 2006; Sreenan, Lemke, Hudson-Mason, & Osiovich, 2001). These devices clearly have a 
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place in the non-invasive respiratory support of the preterm neonate, but they have not been 
shown as effective in maintaining the extubation status of the preterm neonate (Campbell et al., 
2006; Courney & Barrington, 2007; Shoemaker, Pierce, Yoder, & DiGeronimo, 2007). 
Limitations of described studies  
     There are several limitations to the included studies that must be considered with reported 
findings. Most of the sample sizes were small (less than 15 patients per group) making 
differences difficult to detect.  Most were completed in single NICU settings and none of the US 
studies included multi-centered sites.  Only three studies examined the incidence of nasal trauma 
and breakdown during NCPAP therapy as the primary aim of the study, all other studies either 
mentioned it as part of the discussion or secondary measure.  Descriptive designs were often 
employed with lower assigned levels of evidence, identified as limitations with several studies 
(See evidence Table 1; on-line).  Smaller infants who are most at risk for skin injury secondary 
to their extreme immaturity were often excluded. 
Discussion 
     Early use of NCPAP at delivery or as respiratory support following early extubation has 
shown merit in improving neonatal outcomes and preventing chronic lung disease. Overall 
NCPAP use has increased dramatically throughout NICU’s across both the United States and 
developed nations (Jatana et al., 2010; Pelligra, Abdellatif, & Lee, 2008). This therapy is 
considered by many health care providers who care for preterm neonates as the current standard 
for respiratory support (Ammari et al., 2005; Davis et al., 2009; de Winter, DeVries, & 
Zimmermann, 2010; Verder, 2007). The major focus of recent research in this area is to provide 
evidence on the best strategies to prevent reintubation, to determine when early intubation, 
surfactant administration and then extubation to non-mechanical ventilation therapy is an 
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appropriate component of resuscitation in extremely preterm patients, to provide guidelines for 
weaning neonates from CPAP and the best methods and equipment to provide NCPAP (Davis et 
al., 1998; Pelligra et al., 2008; Verder et al., 2009). Nursing care requirements and skin care 
considerations to prevent nasal skin injuries are a common thread overlapping nearly half of the 
reviewed articles, although few studies identified this concept as a primary or secondary aim of 
the research study. 
     Significant progress has been made over the last 50 years in the understanding of the neonatal 
pathophysiology and the underlying causes of respiratory distress syndrome but there is much 
work left to be done.  Identified gaps in the literature include delivery room decision making 
with regard to choice of intubation for the purpose of surfactant delivery or the immediate 
application of NCPAP.  Clinical decisions with regard to intubation when NCPAP is initiated 
remains ill defined. Empirical evidence is needed to support universal weaning guidelines for 
NCPAP, the prophylactic use of NCPAP in those preterm neonates less than a predetermined 
gestational age, and which types of NCPAP interfaces and/or devices are superior. 
      The overall clinical management of preterm neonates whose respiratory system is supported 
through the use of NCPAP is based on anecdotal experience and unit standards rather than on 
scientific evidence.  Nursing skill level and experience with positioning, frequent assessment and 
intervention, all of which takes significant nursing time has been well described by nearly half of 
the included studies.  Practices vary widely from unit to unit making standardization of nursing 
care to protect vulnerable preterm neonatal skin difficult during this therapy. Most of the injuries 
described can be prevented with careful application of the CPAP device and frequent assessment 
with early identification of skin breakdown or injury. 
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      We clearly understand the advantages of using NCPAP in this population and they definitely 
outweigh the observed risks (DePaoli, Davis, Faber, & Morley, 2008; Squires & Hyndman, 
2009; Verder, Bohlin, Kamper, Lindwall, & Jonsson, 2009). We must now examine different 
delivery methods and nasal interface devices while providing non-invasive NCPAP to preterm 
neonates to best manage the preterm neonate’s respiratory distress syndrome using scientific 
evidence to make recommendations for care and test best clinical practices.  In a meta analysis 
completed on the devices and pressure sources for the administration of NCPAP,  implications 
for further research include determining which nasal interface device is the least traumatic to the 
neonatal nose, particularly the very low birth weight neonate (DePaoli et al., 2008).  A review of 
current non-invasive ventilation of the preterm infant describe NCPAP interfaces as “too rigid, 
oversized or too heavy for smaller infants” recommending manufacture development of 
physiologic appropriate devices (Bancalari & Claure, 2008). Additionally, a systematic review is 
needed of those non-invasive ventilatory strategies describing both nasal prongs and nasal masks 
for use in the neonate.  In a study by Courtney and Barrington (2007), nasal masks reportedly 
required less pressure to remain in place but “will need empiric testing to determine safety in this 
population”.  
     Empiric evidence based on current scientific literature is needed to support nursing 
interventions to reduce iatrogenic skin injury of the nose, face and head during NCPAP 
administration to provide for improved long term outcomes. Specific attention to those details of 
nursing care for this vulnerable patient population is needed to address strategies for optimal 
outcomes.  This integrated review of the current literature offers a springboard for future nursing 
research. 
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Chapter 2 
A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) 
Related Skin Breakdown when using Different Nasal Interfaces in the Extremely Low Birth 
Weight (ELBW) Neonate 
 
Abstract 
Purpose: Identify differences in frequency and severity of nasal injuries when comparing nasal 
CPAP interfaces (prongs/mask) used to treat neonatal respiratory distress syndrome.  Describe 
risk factors associated with nasal injury and skin breakdown during nasal CPAP.  
Design: A three group prospective randomized experimental design. 
Methods:  78 neonates <1500 grams receiving nasal CPAP using the same delivery system were 
randomized into three groups: 1) continuous nasal prong group, 2) continuous nasal mask group, 
or 3) alternating mask/prongs group. Serial data collection was conducted by the Core Research 
Team to include: demographic, biophysical measures and the Neonatal Skin Condition Scale 
(NSCS). 
Results: Significant differences between groups included infant weight at start of nasal CPAP (p 
= <0.001), and CPAP flow rate (p = 0.037).  Repeated measures ANOVA with Bonferroni 
correction was used to measure group differences for frequency and severity of injury. 
Significantly less skin injury was detected in the rotation interface group using the NSCS 
variables of erythma and excoriation when compared to both mask and prong groups.  
     Stepwise regression was utilized to determine significant risk factors within and across groups 
in relation to skin breakdown. In the final model significant differences were found in two 
variables; number of days on NCPAP (beta = 0.031, p<0.001) and the current mean post 
menstrual age (beta =0.030, p 0. 006). 
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Conclusions:  Nasal CPAP is reportedly superior to mechanical ventilation in reducing effects of 
bronchopulmonary dysplasia (BPD).  Current CPAP devices place constant pressure on nares, 
nasal septum and forehead, increasing injury risk. This study demonstrated a significant 
difference in the frequency and severity of skin injury when utilizing a method of rotating mask 
and prong nasal interfaces during neonatal CPAP therapy; a useful clinical recommendation. 
Attention to infant size and CPAP duration is also recommended as these were identified as 
significant risk factors for skin injury. Specific nursing care implications related to findings 
include; choosing a device for best fit for infant (face shape and infant size); positioning of the 
CPAP device; developmental position of the infant; and focused skin assessment with rapid 
intervention. Standardized care including skin barriers, clinical expertise of nursing and 
respiratory therapy, and skin care management are strategies that warrant additional research.     
 
Key Terms: Nasal CPAP of the neonate, CPAP, non-invasive respiratory management of the 
preterm, respiratory devices of the newborn, nasal trauma, preterm infant nasal skin breakdown, 
nasal prongs and skin care, and pressure ulcer or skin breakdown during NCPAP. 
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      The use of nasal continuous positive airway pressure (CPAP) has become the gold standard 
in the care of preterm infants with respiratory distress syndrome (RDS) (Davis, Morley & Owen, 
2009; Verder, 2007; Verder, Bohlin, Kamper, Lindwall, & Jonsson, 2009). Various nasal 
interfaces are currently available to provide neonatal CPAP yet few studies have compared the 
effectiveness of these devices to determine both performance as well as determine differences in 
incidence and/or the severity of nasal skin breakdown, a well described side effect of this useful 
treatment (Ramanathan, 2010; Rego & Martinez, 2002; Yong, Chen & Boo, 2005).  
     Following a systematic review of 113 articles related to the use of nasal CPAP on the preterm 
infant, only two randomized controlled trials (RCT’s) included comparisons of nasal interfaces 
to determine the frequency of skin breakdown or nasal trauma (Rego & Martinez, 2002; Yong, 
Chen & Boo, 2005). Rego and Martinez (2002) conducted their RCT in Sao Paulo, Brazil. They 
evaluated the performance of two types of nasal prongs, Argyle™ and Hudson™, to deliver 
nasal CPAP to preterm infants (Rego & Martinez, 2002). Although both were found to be 
equally effective in the delivery of nasal CPAP, the Argyle™ prong was more difficult to 
maintain in the infant’s nares and had a higher incidence of nasal hyperemia or erythma, the first 
sign of skin breakdown when compared to the Hudson™ prong. Yong, Chen and Boo (2005) 
conducted a RCT to compare the incidence of nasal trauma associated with continuous nasal 
prongs or continuous nasal mask during nasal CPAP in neonates < 1500 grams. Although no 
significant difference in rate of nasal injury was found between the two interfaces (mask and 
prongs) there was a significant correlation between nasal trauma and length of therapy. No 
comparisons between prongs, mask or a rotation of devices often used as a nursing care strategy 
to reduce pressure on nasal skin during the use of NCPAP were found in the literature 
(Robertson, McCarthy et al., 1996; McCoskey, 2008; Squires & Hyndman 2009). Additionally, 
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there was agreement that nasal injury is a potential risk factor when using  nasal interfaces during 
CPAP delivery with clear directives for attention to skin assessment, increased nursing care, and 
clinical expertise which was cited as a concern in 46 of the 113 reviewed articles (Newnam et al, 
2013).  
     Evidence based practice supports clinical decision making based on scientific evidence with 
the clear aim to improve patient outcomes and reduce health care waste (Melnyk &Fineout-
Overholt, 2011). Comparative effectiveness research (CER) has emerged as a method to 
critically evaluate scientific evidence, identifying major gaps in current evidence typically 
identified by systematic reviews, clinical guidelines developed by consensus review and other 
methods to aggregate clinical research and then compare this information with current patient 
care practices (Tricoci, Allen, Kramer, Califf, & Smith, 2010). Clinicians are discovering the 
evidence that emerges from real world settings is a valuable part of evidence based practice. 
Consequently clinicians are placing less emphasis on the previous gold standard of randomized 
controlled trials (RCT) and as described in CER supporting clinical decisions based on results 
from alternative study designs. The conduct of  RCT’s is not always possible in every clinical 
venue and population thereby missing critical information required for the purpose of helping 
patients, clinicians and payers to make informed health-care decisions (Prosser, 2012). 
     Defined as “the generation and synthesis of evidence that compares the benefits and harm of 
best care methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the 
delivery of care, the purpose of CER is to assist consumers, clinicians, purchasers and policy 
makers to make informed decisions that will improve health care at both the individual and 
population levels” (Institute of Medicine of the National Academies, 2009).  CER examines both 
efficacy and effectiveness of practice decisions through clinical research comparing current 
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methods to proposed strategies in order to develop superior “best practices” based on clinical 
evidence (Institute for Integrative Health, 2009). The described research utilized the principals of 
CER as a framework to examine current neonatal nasal CPAP care, specifically the nasal 
interfaces to determine differences in effectiveness and efficacy. Thus, an overall goal of this 
study was to utilize previous and current findings to support practice changes grounded in 
evidence trough increased understanding of the effects of nasal CPAP and nasal interfaces on 
neonatal skin integrity in a single NICU. 
Background and Significance: 
     The dynamic approach to respiratory care of the preterm neonate has progressed following 
scientific evidence which clearly demonstrates advantages to early nasal continuous positive 
airway pressure (CPAP) or early extubation to nasal CPAP  in this population.  It is now well 
understood that reduced mechanical ventilation in high-risk preterm infants has many advantages 
which includes; decreased chronic lung disease, decreased incidence of ventilator associated 
pneumonia as well as overall reduction in blood stream infections, reduction in the incidence of 
periventricular leukomalacia (PVL) previously associated with long term ventilation, improved 
neurodevelopmental outcomes and shortened hospital length of stay (De Paoli, Davis et al., 
2008; Squires & Hyndman 2009).  These very low birth weight (VLBW) preterm infants 
however require some adjunct to maintain functional residual capacity (FRC) as well as improve 
the symptoms of respiratory distress syndrome (Buettiker, Hug et al., 2004).  Nasal continuous 
positive airway pressure (CPAP) is often used to support this need.   
    Nasal CPAP is a non invasive method for providing a constant distending pressure during both 
the inhalation and exhalation phase of respiration. Used in the spontaneously breathing preterm 
infant it provides stability of the infant’s FRC, improves oxygenation, conserves surfactant, aids 
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in the prevention of atelectasis, improves gas exchange and aids in the prevention of obstructive 
and central apnea (Davis, Jankov et al., 1998; Diblasi, 2009; Squires & Hyndman, 2009).  First 
described in 1914 in a German textbook about the diseases of the newborn, a system of hoses 
placed into a water filled receptacle, a face mask with a gas source was used on a newborn who 
had symptoms of respiratory distress to provide continuous airway pressure (Diblasi, 2009). 
Ventilator delivered CPAP first was reported in the late 1970’s and 1980’s that  were adapted 
from adult models (Gregory, Kitterman et al., 1971); then in the 90’s free standing nasal CPAP 
delivery systems were designed and widely adapted into routine practice (Verder, 2007; Diblasi, 
2009). 
     Three major types of nasal CPAP are used in the neonatal population, traditionally classified 
by the technique used to control the gas flow to the patient (Gupta, Sinha et al., 2009).  These 
include constant flow or bubble CPAP, variable flow which are devices that have fluidic control 
to maintain the CPAP pressure and finally ventilator delivered CPAP generally delivered through 
an endotracheal tube (ETT) or a long single nasal pharyngeal tube.  All devices share in four 
components, 1) a heated/humidified blended gas source, 2) a nasal interface, 3) a patient circuit 
and 4) a pressure-generating apparatus (Diblasi, 2009).   
     Risks attributed to the use of nasal CPAP in this population have also been described.  These 
include abdominal distension, inability to provide enteral nutrition secondary to gut disturbance, 
slightly increased incidence of necrotizing enterocolitis (NEC), pneumothorax and nasal injury 
or nasal mucosal damage (Verder, 2007; Squires & Hyndman, 2009).  The current CPAP devices 
are effective in maintaining needed positive end expiratory pressure (PEEP) but also place 
constant pressure on the nares, nasal septum and forehead leading to decreased skin integrity and 
injury (De Paoli, Davis et al., 2008).  Research is needed to 1) compare nasal CPAP interfaces 
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commonly used to determine differences in frequency and severity of skin break down, and 2) 
identify strategies to reduce skin breakdown during nasal CPAP use in extremely low birth 
weight (ELBW) infants.   
     The overall clinical management of preterm infants whose respiratory status is supported 
through the use of nasal CPAP is based on reported anecdotal experience and unit standards 
rather than on scientific evidence.  Nursing level of expertise and experience with positioning, 
frequent assessment and intervention, all of which takes significant nursing time has been well 
described by nearly half of the reviewed articles.  Routine nursing care practices vary widely 
from unit to unit making standardization of nursing care to protect vulnerable preterm infant skin 
during this therapy difficult.   
    The advantages of using nasal CPAP in this population outweigh the observed risk related to 
this therapy. Best practices for choosing and implementing neonatal CPAP delivery methods and 
nasal interface devices to best manage RDS must be guided by scientific evidence. A meta 
analysis was completed to examine different devices and pressure sources for the delivery of 
nasal CPAP which provided implications for further research. These included determining which 
nasal interface device is the least traumatic to the infant nose, particularly in the VLBW infant 
(De Paoli, Davis et al., 2008).  Additionally, a systematic review of non-invasive ventilation 
strategies described care-giving implications related to both nasal prongs and newer nasal masks 
for use in the neonate.  The masks were described to require less pressure to remain in place but 
“will need empiric testing to determine safety in this population” (Courtney & Barrington, 2007). 
     Standards of care based on previous findings and clinical evidence are needed to support 
recommended nursing interventions to reduce iatrogenic skin injury of the nose, face and head 
during nasal CPAP administration, ultimately improving long term outcomes. Thus, the primary 
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aim of this study was to determine differences in the frequency, severity and specific types of 
nasal injuries described when comparing different nasal CPAP interfaces (prongs/mask/rotation) 
used in the treatment of neonatal RDS. A secondary aim of the study was to identify risk factors 
that may be associated with skin breakdown during nasal CPAP administration.  
The hypotheses included: 
1)  There is no difference in the incidence and/or severity of skin breakdown in the 
extremely low birth weight (ELBW) preterm neonate (less than 1500 grams) when nasal 
CPAP is administered using three types of nasal interfaces: 1) continuous nasal prongs, 2) 
continuous nasal mask or 3) alternating the nasal mask and prongs every 4 hours.  
2) There are no differences in the incidence and/or severity of skin breakdown related to 
other predisposing risk factors such as gestational age, birth weight, length of therapy, 
environmental humidity level, amount of CPAP flow administered and/or nursing 
interventions that include positioning techniques, nasal suctioning devices and the use of 
nasal saline during suctioning. 
Methods: 
Design, sample and setting  
     A three group prospective randomized experimental study design was conducted in a 70 bed 
level III Neonatal Intensive Care Unit (NICU) in the southeastern United States. The study was 
approved by the Institutional Review Board (IRB), and parents provided informed consent for 
their infant’s participation in the study. A flow diagram describes the process of screening 
through completion of data collection following Consolidated Standards of Reporting Trials 
(CONSORT) guidelines (Moher, Schulz & Altman, 2001) (see Figure 1). 
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     Each infant admitted to the NICU was screened for inclusion criteria from mid-April, 2012 
through mid-January, 2013. Preterm infants with birth weight 500 to 1500 grams were eligible 
for the study. Exclusion criteria included infants born with airway or other physical anomalies 
that influenced their ability to extubate to nasal CPAP. Infants who were not consented within 8 
hours of nasal CPAP initiation or who had nasal skin breakdown at enrollment were also 
excluded. A sample size estimation was calculated to use 80% power, alpha = 0.05, prior to 
study initiation and was used to direct the enrollment for each group. The group size of 72 total 
subjects, 24 subjects in each of the three groups (continuous nasal prongs, continuous nasal mask 
or alternating nasal mask and prongs every 4 hours) was deemed adequate to determine 
significant differences between groups. 
Procedures  
    After informed consent was obtained and the patients were extubated to nasal CPAP they were 
randomized into one of the three groups, 1) continuous nasal prong group,  2) continuous nasal 
mask group, or 3) alternating mask/prongs every 4 hours group. The specific timing of 
extubation was based on demonstrated clinical readiness (respiratory stability) or self-extubation 
with appropriate clinical indications for nasal CPAP trial. Infants recruited for the study were 
block stratified according to weight into four categories according to birth weight: < 750 grams, 
750-1000 grams, 1001-1250 grams and > 1251-1500 grams. Known differences in the skin 
integrity have been demonstrated with the lowest birth weights proven the most vulnerable; thus, 
stratification according to birth weight was utilized to keep the groups more homogeneous since 
it was expected that the < 750 gram group would contain the fewest patients. All infants were 
managed with the same type of nasal CPAP delivery system, the Cardinal™ variable flow driver 
with Air Life™ prongs/mask. Infants transported from the delivery room or outlying hospitals 
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initially treated with nasal CPAP were also eligible for enrollment. Infants that were extubated to 
other respiratory support devices (high flow nasal cannula, vapor-therm or nasal cannula) based 
on medical decision were excluded from enrollment unless nasal CPAP was medically indicated 
at a later time-frame.    
     The randomization process was conducted by the respiratory therapist assigned to that patient 
during the time of extubation. Randomization into assigned groups was accomplished using 
serially numbered opaque sealed and color coded envelopes developed by the researcher located 
close to the storage area which housed CPAP equipment within the NICU. The respiratory 
therapist was responsible for drawing the next sequentially numbered envelop based on birth 
weight groups as described during departmental education. Once group assignment occurred the 
equipment was collected and placed on the patient to provide nasal CPAP therapy.  
Variables and measures  
     Demographic data, which included gestational age, birth weight and current weight, was 
retrieved from the medical record. Clinical information related to therapy included oxygen liter 
flow, day number of CPAP, humidification of environment as measured on the incubator 
humidity gauge using the Giraffe™ , and temperature of the humidifier device connected to the 
nasal CPAP was extrapolated from direct observation or from the medical record. Information 
regarding suctioning practices and the use of normal saline during suctioning was also collected.  
     The Neonatal Skin Condition Scale (NSCS) is a skin condition scoring system developed by 
Lane and Drost (1993) which was later modified by Lund et al. (2001) for the development of 
neonatal skin care guidelines. The tool uses three clinical outcome categories which includes 
dryness, erythma and breakdown or excoriation of the skin. Each category is graded one through 
three. The score of one in each category indicates a healthy skin assessment and the score of two 
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or three indicates an increasing level of skin breakdown with a total score of nine (three in each 
category) being the worse skin evaluation score possible. The tool was tested for both validity 
and reliability and for interrater reliability (r = 0.6 to 0.7). Kappa values were also significant at 
the < p=0.001 (Lund, Kuller et al. 2001; Lund and Osborne 2004). In the current project neonatal 
skin assessments using the NSCS were performed by the Core Research Team every 10 to 12 
hours in coordination with the participant’s routine nursing care. A brief educational session for 
the Core Research Team was required prior to study initiation and interrater reliability was 
measured between team members.  
     In the current study interrater reliability using the kappa statistic was performed to determine 
consistency among NSCS scores. It was established a priori that 10% of the data collection 
points would be conducted by 2 members of the Core Research Team for purposes of reliability 
measure. The interrater reliability for the NSCS was found to be kappa = 0.74 (p < 0.001), 95% 
CI (0.432, 0.914). The internal consistency of the NSCS tool was measured using the Cronbach’s 
α (0.416) which was lower than reported in the literature. Analysis of which variable was 
significant for reduced internal consistency was completed and through the elimination of the 
dryness variable of the tool in the study population changed the Cronbach’s α to 0.721 which is 
above the acceptable value of 0.7 (Devillis, 2003).  
Data collection procedures  
     A team of skin experts, described as the Core Research Team was made up of the principal 
investigator and three advanced practice nurses. This research team was responsible for 
obtaining parental consent and conducting serial skin care evaluations on enrolled subjects 
during routine nursing care in an effort to protect the infant’s quiet environment. The initial skin 
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assessment was completed within 8 hours of extubation and at intervals of every 10-12 hours 
while receiving nasal CPAP therapy. 
     Tool and interrater reliability of the NSCS (reported as Cohen’s Kappa and chronbach’s 
alpha) was conducted through the use of two experts assessing 10% of the study subjects. This 
information was collected in conjunction with scheduled skin care assessments.      
Statistical analysis 
     Demographic information was collected for descriptive analysis. Variables included 
gestational age, birth weight, post menstrual age at time of CPAP, current weight, number of 
days on nasal CPAP, liter flow of CPAP, and environmental humidity. Counts and percentages 
were reported for categorical variables and range, median, mean and standard deviation for 
continuous/ordinal data. The means of both demographics and clinical characteristics were 
computed and reported for the total sample and by group.  Group means were compared using a 
one way analysis of variance (ANOVA) to identify group differences in an effort to demonstrate 
homogeneity among randomized interface groups. Significant differences among group means 
were analyzed using the Tukey multiple comparison test.     
     Statistical analysis for the primary aim of the study, to determine differences in the incidence 
and severity of skin breakdown when comparing three types of nasal CPAP interfaces included 
repeated measures ANOVA. The NSCS means for each category (erythma, dryness and 
excoriation) and NSCS sum score was calculated by using three time points universal to all 
subjects in an effort to mitigate the variance of data collection points among the subjects. Within 
group means were compared through repeated measures ANOVA. The assumption of sphericity 
was evaluated using Mauchly’s test and the Bonferroni method was used to perform the pairwise 
comparisons.   
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     Statistical analysis to determine those risk those factors associated with nasal injury and skin 
breakdown during nasal CPAP administration, the secondary aim of the study was completed 
using stepwise multiple regression. The stepwise approach was supported through use of 
scientific evidence and literature review. Bivariate correlations between number of CPAP days 
and NSCS sum scores and the post menstrual age of subjects and NSCS sum scores using 
Spearman rho was conducted following modeling.  
Results 
     A total of 377 admissions to the NICU were screened for eligibility criteria during the study 
period. Of these, 140 patients met birth weight criteria of 500-1500 grams. Two patients were 
diagnosed with airway deformities that compromised their ability to successfully extubate to 
nasal CPAP and were eliminated. Parental consent was obtained on 90 patients (65%). Two 
parents refused study participation for their infant (1%). Fourteen patients (10%) expired prior to 
obtaining study consent and 32 patients (23%) were missed. The missed patients were typically 
patients who were admitted on nasal CPAP or quickly extubated with limited ability to obtain 
consent within the 8 hour time limitation (see Figure 1). The final sample of 78 patients was 
randomized into three groups (nasal prongs, n = 21; nasal mask, n = 35; and alternating 
mask/prongs, n = 22). Each of the three groups was block stratified according to the patient’s 
birth weight. These four categories included: < 750 grams, 750-1000 grams, 1001-1250 grams, 
and > 1251-1500 grams. There were no significant differences between nasal interface grouping 
and birth weight stratified during randomization (see Table 1).  Infants whose size prevented 
correct fit with nasal prongs according to manufacture guidelines were defaulted to the mask 
group, regardless of group assignment. This safety maneuver although necessary accounted for 
the unequal group distribution.   
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     Demographics for both total sample and per group are presented in Table 2 and 3. The 
number of days on nasal CPAP ranged from 1 to 16 days with 730 data collection time points 
representing 365 CPAP days with a mean of 4.68 days (± 3.45). The frequency of skin injury 
reported for the group was 24.2% and the area of the face most frequently assessed and reported 
with skin breakdown was the nasal septum (85.3%). The nasal bridge (29.9%) and forehead 
(26.6%) were locations with the second and third highest frequency. There were no significant 
differences between the groups and location of skin injury reported.  
     The demographic variables of each group were evaluated to determine homogeneity using a 
one-way analysis of variance (ANOVA) to determine significant differences between groups. 
Significant differences were reported between the mean current weight at the time of nasal CPAP 
(p = <0.001) and the mean CPAP liter flow delivered during therapy (p = 0.037).  The variable 
current weight at time of CPAP, a Tukey multiple comparisons test performed at the 0.05 
significance level found significant differences between the mask and other two groups (prong 
and rotation group). This finding was most likely related to the necessary default to mask group 
when prongs could not fit safely into small nares. For the variable CPAP liter flow the Tukey 
multiple comparisons performed at the 0.05 significance level found significant differences 
between the prong and rotation groups (see Table 3). 
     Correlations were performed to explore relationships among the study variables. These 
variables included; gestational age, birth weight, weight at start of CPAP, post menstrual age 
during CPAP, oxygen delivered, time between birth and CPAP introduction, number of days on 
CPAP, temperature and flow amount of CPAP, environmental temperature and humidity, 
developmental positioning of the infant, nasal suctioning, use of nasal saline during suctioning, 
and the individual and sum NSCS scores (see Table 4). Expected significant relationships were 
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found between birth weight and gestational age; gestational age and the number of CPAP days, 
the amount of oxygen required and amount of environmental humidity provided.  There was also 
a significant correlation between time to nasal CPAP and number of CPAP days.  
     A repeated measures design was necessary to determine the mean NSCS scores (erythma, 
dryness, excoriation, and sum score) since many subjects had multiple timed data collection 
points, and were therefore not independent samples. To best control for the repeated measures, 
three specific time points were selected that were common to each participant, time 1 at initiation 
of nasal CPAP, time 2 mid-point during therapy and time 3 the last data collection prior to the 
completion of nasal CPAP. Means were calculated on these values and the repeated measures 
analysis of variance (RMANOVA) was conducted using pairwise comparisons with Bonferonni 
correction to determine differences within and between groups for the NSCS (see Table 3). Tests 
for homogeneity of variance and Mauchly spericity for RMANOVA were preformed. Spericity 
was assumed χ2 (2) = 2.94, p = 0.23. 
     To determine differences in the severity of nasal injuries, part of the primary aim, we 
compared nasal CPAP interface groups with mean NSCS sum scores using RMANOVA. The 
results of this analysis were not statistically significant (see table 3). However, when examining 
the mean NSCS score for each of the three categories within the scale, specifically erythma (p < 
0.001) and excoriation (p = 0.007), significant differences were found. Erythma and excoriation 
as well as hyperemia was noted in the literature to be specifically linked to skin breakdown and 
thereby examined for differences among groups. 
     To best evaluate the effect of additional risk factors and their influence on the incidence and 
frequency of skin breakdown, a regression model was developed. This model was guided by 
factors identified in the literature. Factors included in the model were birth weight, length of 
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therapy, post menstrual age at the time of CPAP, environmental temperature, amount of CPAP 
flow administered and/or nursing interventions that include positioning techniques, nasal 
suctioning type (oral/nasal), suctioning interval and the use of nasal saline during suctioning (see 
Table 5a). Post menstrual age at the time nasal CPAP explained 16% of the variance in the 
incidence of skin breakdown using the mean NSCS sum score as the dependent variable. 
Additionally the number of CPAP days placed in the model explained 25% of the variance. The 
mean post menstrual age made the largest unique contribution (beta = 0.46) although the number 
of CPAP days also made a statistically significant contribution (beta = 0.31) (see Table 5b). 
Discussion 
     This study was conducted to determine differences in the frequency, severity and specific 
types of nasal injuries described when comparing different nasal CPAP interfaces 
(prongs/mask/rotation) used to treat RDS in the preterm neonate < 1500 grams. The secondary 
aim of the study was to identify additional risk factors that may be associated with skin 
breakdown during nasal CPAP administration. The incidence of skin breakdown reported in the 
literature associated with nasal CPAP in the neonate was 20 to 60% (Fischer, Bertelle, Hohlfeld, 
Forcada-Guex, Stadelmann-Diaw, & Tolsa, 2010). This study demonstrated an overall skin 
breakdown rate of 24.2% which provides clear opportunity for clinicians to improve skin care 
outcomes. 
     Using the NSCS to determine differences in severity of nasal injury between nasal interface 
groups, significant differences in both excoriation and erythma were found.  A reduction in skin 
injury was detected between the rotation mask/prong group and the other two nasal interface 
groups. Previous literature reported nasal interfaces (prongs/mask) are effective in the treatment 
of RDS (DePaoli, Davis, Faber, & Morley, 2008). In the RCT’s conducted by Rego and Martinez 
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(2002) and Yong, Chen and Boo (2005), no significant differences in the frequency of skin 
injury (excoriation, bleeding or erythma) was found when comparing various nasal interface 
groups. Although no studies were discovered that specifically examined differences between 
nasal prongs, nasal mask, and the systematic rotation of these nasal interfaces thought to relieve 
pressure points on the nares, nasal columella, forehead or other facial surfaces of the preterm 
neonate. Providing knowledge that each interface is effective during CPAP treatment and the 
systematic rotation of interfaces was shown to reduce the risk of skin injury offers clinician’s the 
ability to best manage neonatal CPAP. It is still clear that the clinician must choose the interface 
that best seals, comforts, and fits the neonate and one interface is best for all infants. 
     The significant correlation reported between the incidence of skin breakdown and number of 
days on nasal CPAP was not surprising and mirrors findings from previous research ((Robertson 
et al., 1996; do Nascimento, Ferreira, Coutinho, & Santos Verissimo, 2009; Yong et al., 2005).  
It is well understood that long term therapy (> 3 days) places infants at greater risk for skin 
breakdown resulting in significant clinical implications. Close observation at more frequent 
intervals is needed to identify/treat early signs of hyperemia or breakdown for those patients that 
require nasal CPAP for longer periods of time (> 3 days). Clinicians may consider the rotation 
from nasal CPAP to other therapy (Nasal Cannula/vapo-therm) during intervals when clinically 
appropriate to reduce skin breakdown from nasal CPAP pressure. These devices clearly have a 
place in the non-invasive respiratory support of the preterm neonate, but have not been as 
effective in maintaining the extubation status of the preterm neonate (Campbell et al., 2006; 
Courney & Barrington, 2007; Shoemaker, Pierce, Yoder, & DiGeronimo, 2007). Additional 
empiric testing is required prior to recommendation of this rotation strategy. What is clear from 
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the literature is the negative effects of mechanical ventilation should be avoided whenever 
possible (Verder, 2007; Ramanathan, 2010).   
     A second significant correlation reported between the incidence and severity of skin 
breakdown as the current weight of the infant during nasal CPAP administration, specifically 
smaller infants are at the greatest risk. Although the current study did not specifically identify 
that weight where the infant’s risk is greatest, previous literature reported that infants <1250 
grams were most at risk (Kopelman & Holbert, 2003; Rego & Martinez, 2002; Jatana et al, 2010; 
Yong et al., 2005). As we strive to extubate or not intubate smaller infants in our delivery rooms 
and NICUs, the use of nasal CPAP will continue to be a significant risk factor for skin injury.   
     Following a systematic review of literature multiple clinical factors were linked to nasal 
injury and breakdown during nasal CPAP in the preterm neonate (Newnam et al., 2013). Specific 
independent risk factors included nasal CPAP use, length of therapy, infant age and size, 
environmental humidity and temperature. These factors were significant indicators for the 
development of nasal pressure ulcers, compression necrosis, and/or nasal deformities (Fujii, 
Sugama, Okuwa, Sanada, & Mizokami, 2010).  
     In descriptive studies by McCoskey (2008) and Squires and Hyndman (2009) multiple care 
recommendations were described to reduce nasal skin injury during neonatal CPAP.  These 
strategies included frequent skin assessment intervals and developmental positioning of the 
neonate in an effort to reduce the rate of injury through early identification of skin breakdown 
and/or prevention. Increased frequency of nasal suctioning needs was noted during nasal CPAP. 
Suctioning known to cause nasal trauma was coupled with an increased rate of coagulase 
negative staphylococcus (Kopelman & Holbert, 2003; Ronnestad et al., 2005).  These identified 
factors were used to develop a stepwise regression model to explore the relationship between 
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these various independent variables and the dependent variable mean NSCS sum score. As noted 
previously, the mean post menstrual age made the largest unique contribution (beta = 0.46) and 
number of CPAP days also made a statistically significant contribution (beta = 0.31) to the 
model (see Table 5b). 
Implications 
     The significant findings in both the frequency and severity of skin breakdown among 
different randomized groups, representing current nasal CPAP care in a single NICU setting has 
significant clinical implications. These findings aid the clinician with selecting the interface that 
best fits the size and shape of the infants face and nose without bias that one device is superior to 
others.  Newly designed masks and nasal prongs which are small enough to fit infants to 500 
grams have provided greater options for clinicians to select and/or rotate interfaces to reduce 
pressure points during therapy. Adequate supplies from manufactures continue to be a concern as 
appropriate sized masks and prongs to fit the ELBW are needed to be readily available to support 
non-ventilatory respiratory strategies in the neonate. 
      The use of the NSCS to measure specific skin injury or ulceration should be examined. As 
reported earlier, the internal consistency of the NSCS tool was measured in the study population 
using the Cronbach’s α (0.416). This result was significantly lower than reported in the literature 
during the AWHONN/NANN skin care research based project. Our analysis revealed the 
specific variable responsible for the reduced internal consistency was dryness. As this variable is 
an expected physiological change that occurs as part of normal neonatal skin development during 
the first few weeks of life, it may have influenced the overall findings.  Through the elimination 
of the dryness variable of the tool in the study population changed the Cronbach’s α to 0.721, an 
acceptable result. The clinical observation of pressure or indentation of the tissue without 
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erythma or excoriation, a well described effect of nasal CPAP and one that was often observed 
during the current study may be a more valuable variable to consider during skin assessments.  
     Previously literature has described specific examples of neonates who were reintubated for 
mechanical ventilation secondary to loss of nasal tissue (nasal erosion) and bleeding, although 
the infants had a stable respiratory status on NCPAP therapy (Verder, 2007; Yong et al., 2005). 
Although this specific measure was not examined during this study, reintubation for skin 
breakdown while respiratory status remains stable is clinically significant and should be avoided. 
     A specific area of concern related to nasal CPAP is injury to the forehead, an area of pressure 
when mid face variable flow drivers are utilized. The report of forehead pressure necrosis 
resulting in permanent scarring of both the central forehead and left eyebrow was reported as a 
consequence of tight fitting nasal CPAP hats (Hogeling, Fardin, Frieden & Wargon, 2012) is 
beginning to appear in the literature. Forehead necrosis and injury has clinical significance 
related to nasal CPAP design, focused skin assessments and nursing care.  
Limitations 
     The study utilized a convenience sampling method, which may generate a non-representative 
sample.  The study was conducted at a single NICU site which may not be representative of all 
neonatal patients in the NICU that are 500-1500 grams and require nasal CPAP.  Control for 
extraneous variables was challenging and often impossible during the care of these acutely ill 
neonates, cared for in the NICU.  During the data collection phase, originally estimated to be 
between 4 and 6 months was extended to 9 months (April, 2012-January, 2013), we encountered 
multiple changes in the NICU including the implementation of an electronic medical record 
(EMR) and staffing pattern changes to accommodate the national reduction in resident and intern 
working hours. Any of these universal changes could have influenced results. 
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     Power analysis conducted a priori demonstrated group size requirement of 24 each and total 
of 72 subjects necessary to demonstrate significant differences between groups. The prong group 
had 21 subjects enrolled; the rotation group had 22 subjects both of which were less than 
optimal. Care providers could override the randomized assignment if the CPAP interface did not 
fit the infant; we had a large number of smaller infants participate in this study and as such the 
number assigned to the mask group was larger. Single type of CPAP was used on all subjects in 
this study to reduce variability; further testing on other types of nasal CPAP (fluidic and variable 
flow) is needed. 
     Using the NSCS as a tool to assess neonatal skin injury was useful, however as the 
keritinazation of the neonatal skin occurs as a normal physiological process this category 
demonstrated poor correlation to skin breakdown or pressure injury, the goal of the project.  
Dryness as variable of the NSCS was independently responsible for lower than previously 
reported (Cronbach’s α = 0.416 vs. 0.6 to 0.7) showing the lack of reliability of this variable with 
the tested sample. 
Summary & Conclusions 
     Early use of NCPAP at delivery or as respiratory support following early extubation has 
shown merit in improving neonatal outcomes and preventing chronic lung disease. Overall, nasal 
CPAP use has increased dramatically throughout NICUs across both the United States and 
developed nations (Jatana et al., 2010; Pelligra, Abdellatif, & Lee, 2008). This study examined 
differences in the frequency, severity and specific types of nasal injuries described when 
comparing different nasal CPAP interfaces (prongs/mask/rotation) used to treat RDS through a 
three group prospective randomized experimental study design. Significant differences between 
groups included current weight at start of nasal CPAP (p = <0.001), CPAP flow rate (p = 0.037).  
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Repeated measures ANOVA with Bonferroni correction was utilized to measure group 
differences for frequency and severity of injury. Significant differences between groups were 
found with individual NSCS scales (erythma & excoriation) two important aspects of skin 
breakdown in the neonate.  Consideration of adding the variable of indentation or skin 
depression without redness/edema or excoriation may be valuable in future studies to measure 
skin injury related to various pressure devices. 
     An examination of additional risk factors that may be associated with skin breakdown during 
nasal CPAP administration was conducted. Stepwise regression was utilized to determine 
significant risk factors within and across groups in relation to skin breakdown. In the final model 
significant differences were found in two variables; number of days on NCPAP (beta = 0.031, 
p<0.001) and the current mean post menstrual age (beta =0.030, p 0. 006). Both variables were 
supported by scientific evidence, mirroring previous findings. This clinically significant finding 
supports guideline development to standardize neonatal CPAP care with raised awareness that 
smaller infant treated with nasal CPAP and longer duration of therapy increases risk for skin 
injury. Additional nursing care implications such as choosing a device for best fit for infant (face 
shape and infant size); positioning of the CPAP device; developmental position of the infant; and 
focused skin assessment are recommended. Standardized care including skin barriers, clinical 
expertise of nursing and respiratory therapy and skin care management are strategies that warrant 
additional research.     
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Chapter 3 
 
Supportive Tables and Figures for Chapter 1  
 
An Integrative Review of Skin Breakdown in the Preterm Infant  
Associated with Nasal Continuous Positive Airway Pressure  
 
 
Table 1: Skin breakdown and the neonate during nasal continuous positive airway 
pressure 
 
 Figure 1: Decision Tree for inclusion/exclusion in the Integrative Review 
 
Figure 2: Decision Tree (articles categorized into 3 major topical headings, then 
delineated into four subject categories)   
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STUDY 
Citation 
 
Location (Country) 
 
Level of Evidence 
PURPOSE 
Research questions 
or stated hypotheses 
 
 
Design  
SAMPLE/METHODS 
Subjects/Sample Size 
  
Selection criteria 
 
Measures (Primary/secondary outcome) 
RESULTS 
Statistical Tests 
 
Key findings 
 
Feasibility of implementation 
COMMENTS 
Clinical implications 
 
 
 
Study Limitations 
Robertson, N. J., 
McCarthy, L. S., et al. 
(1996). Nasal 
deformities resulting 
from flow driver 
continuous positive 
airway pressure. 
Archives of Disease in 
Children, Fetal and 
Neonatal Edition, 
75(3), F209-212. 
 
 
United Kingdom 
(London) 
 
Level of evidence:  
IV 
Purpose: describe 
incidence of nasal 
trauma following the 
use of flow driver (type) 
of continuous positive 
airway pressure in 
preterm infants ≤ 1500 
grams  
 
Design:  Descriptive   
Subjects/Sample Size:  
74 infants ≤ 1500gms born during enrollment 
period   
35 infants required NCPAP  
7 infants had nasal trauma (20% injury rate)  
   
Selection criteria: All infants were included that 
had reported incidence of nasal trauma or 
breakdown (n = 7). 
 
Measures: Little description regarding specific 
measures, only global descriptions of injury 
classified into three primary types, but how 
many infants fell into which type was not 
identified.  
Findings: Three primary types of injury were 
reported 
 
 Nasal snubbing occurring after more 
than 60 days of NCPAP 
 Flaring of the nostrils with nasal rim 
becoming circular with progressive 
duration of NCPAP  
 Columella Nasi necrosis that may 
have progressed to septal necrosis 
was reported to occur in as little as 3 
days on NCPAP.  
 
Feasibility:  Descriptive design could be 
replicated in most NICU settings. 
Clinical implications:   
 NCPAP interface not anatomically 
correct increasing risk for injury.   
 Clinical recommendations included:  
o appropriate fit (prongs to 
nares) 
o avoid tight fit 
o tie hats horizontally 
preventing the upward 
pull on the nose 
o support the weight of the 
tubing; rest the nose for 
half hour every 4-6 hours 
o use barriers under device 
o refresher training for staff; 
emphasis on fixation of 
device and assessment. 
Rego, M.A., & 
Martinez, F.E. (2002). 
Comparison of two 
nasal prongs for 
application of 
continuous positive 
airway pressure in 
neonates.  Pediatric 
Critical Care 
Medicine, 3(3) 239-
243. 
 
 
Brazil, Sao Paulo 
 
Level of Evidence: II 
 
 
Purpose:  determine 
differences in tolerance 
and efficacy between 
two types of nasal 
prongs commonly used 
in a single NICU 
setting.   
 
Design:  Prospective, 
randomized trial 
Subjects/Sample size: n = 99 randomized to two 
groups (Argyle vs. Hudson Prongs) and then 
stratified into three weight categories   
Argyle prongs (≤ 1000 g) n= 19,  
Hudson prongs (1000 g) n = 14,  
Argyle prongs (1000-1500 g) n = 18,  
Hudson prongs (1000-1500 g) n = 18  
Argyle prongs (1500-2500g) n = 11 
Hudson prongs (1500-2500 g) n = 19 
 
Selection criteria:  Patients admitted to the 
NICU who required NCPAP  
 
Measures:   
Tolerance was assessed by time (hours) 
receiving NCPAP, number of times the catheters 
were out of the nostrils, feeding during therapy, 
abdominal distention, nasal hyperemia, nasal 
bleeding, and septum necrosis.  
Efficacy was measured by examining RR and 
HR, Silverman-Andersen retraction score and 
blood gas analysis. 
Findings: Hyperemia was significantly 
increased in the Argyle prong (≤ 1000g) 
group.  There was no difference between 
groups in the other measures of skin 
breakdown.   
 
Efficacy of nasal CPAP: Little changes in 
measured vital signs between groups and all 
groups showed an improvement in the 
Silverman-Andersen retraction score.   
 
The frequency of success did not differ 
between groups except for those babies who 
weighted >1500-2500 using the Hudson 
prong.   
 
 
Clinical implications:  This was clearly one 
of the first research designs to incorporate the 
differences between nasal interface, examining 
tolerance and efficacy to include skin 
breakdown.   
 
 Nasal hyperemia was identified as the first 
sign of tissue aggression. 
 
No discussion of nursing care for the nasal 
interfaces  
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Kopelman, A.E. & 
Holbert, D. (2003). 
Use of oxygen 
cannula's in extremely 
low birth weight 
infants is associated 
with mucosal trauma 
and bleeding, and 
possibly with 
coagulase-negative 
staphylococcal sepsis.  
Journal of 
Perinatology, 23(2), 
94-97. 
 
United States 
 
Level of Evidence: IV 
Study purpose: #1: 
describe association 
between oxygen 
cannula (OC) and 
incidence of nasal 
trauma in the extremely 
low birth weight 
(ELBW) infant; #2: 
describe association 
between the use of OCs 
in the ELBW infant and 
incidence of coagulase-
negative staphylococcal 
sepsis (CNSS). 
 
Design: Retrospective 
 
Subjects/Sample size: 
#1:  n = 24 
#2:  n = 57 
 
Selection criteria: 
#1: First 2 ELBW infants who were extubated 
each month during the year of 1997 in a single 
site (East Carolina University Hospital, 
Greenville, NC)  
#2: All ELBW infants extubated within 28 days 
of birth during 1999 in a single site 
   
Exclusion criteria:   
None declared 
 
Measures:  #1: Nasal trauma measured by nasal 
suctioning with and without blood in the nasal 
secretions.   
#2: Incidence of CNSS measured by lab 
confirmation. Comparison between OC/nasal 
CPAP and oxyhood also conducted. 
 
 
Findings: #1: Infants who were treated with 
OCs had statically significant increased 
suctioning times daily (2.6 vs. 1.3 times daily) 
with significantly higher incidence of bloody 
nasal secretions (34.6% vs. 4.6%). Incidence 
in both suctioning and nasal trauma increased 
with > number of days of OC use.    
#2: Incidence of CNSS  
 occurred less frequently in infants 
with oxyhood treatment compared to 
CPAP or OC (1/13 or 8% vs. 10/44 
or 23%); not significantly different.   
 most CNSS occurred at day #3 or 
day #7—may be of clinical 
significance. 
 
Feasibility:  Easily replicated; retrospective 
chart review without intervention. 
Clinical Implications: 
Secondary nasal mucosa damage possible with 
CPAP or OC highlights need for improved 
care practice strategies.   
Highlight possible use of the oxyhood as 
treatment modality. 
 
Limitations: 
 No conceptual definition of ELBW.   
 Retrospective review; assumption 
charting was accurate. 
 Two studies evaluated at different 
time frames reported in the same 
article; although linked were 
different studies and the discussion 
was confusing.   
 The purpose for #2 was association 
between OC and CNSS; discussion 
explored the time to extubation and 
rates of nosocomial infection with 
CNSS. Hypothesis and discussion 
should agree. 
Buettiker, V., Hug, M. 
I., Baenziger, O., 
Meyer, C., & Frey, B. 
(2004).  Advantages 
and disadvantages of 
different nasal CPAP 
systems in newborns. 
Intensive Care 
Medicine, 30, 929-
930. 
 
Switzerland, Zurich 
 
 
Level of Evidence: II 
Purpose:  compare 
three different systems 
of nasal CPAP; the 
naso-pharyngeal tube 
and two pronged 
systems on newborns. 
 
Design: Randomized 
clinical study. 
 
 
 
Subjects/Sample size:   
N = 40; stratified into 2 weight groups (1250-
2500 and >2500 grams). 
Randomized into three groups (types of CPAP) 
Naso-pharyngeal tube n = 8,  
Hudson prongs n = 6, 
Infant Flow system, n = 6. 
 
Selection criteria:  Newborn infants (<28 days) 
born between July 2000 and Sept 2001 in a 
single NICU, University Children’s Hospital, 
Steinwiesstrasse, Zurich, Switzerland treated 
with CPAP.    
Exclusion criteria:  CHD, NEC, or upper 
airway abnormalities. 
 
Measures:   
Treatment length, appropriateness for different 
weight classes, side effects and cost of individual 
therapy. 
 
 
Findings:   
 Weight group > 2500 grams  
o median duration of CPAP 
1.1 days 
o median time on NP 1 day 
o Hudson prongs 1.6 days 
o Infant Flow system 0.7 
days 
 Weight group of 1250-2500   
o median duration of CPAP 
1.1 days  
o median time on NP  0.9 
days 
o Hudson prongs 1.1 days  
o Infant Flow system 1.3 
days 
Nasal injury analysis: 
 Weight group > 2500 grams  
o NP CPAP, 2 infants with moderate 
nasal injuries.   
o Hudson prong system, 2 developed 
moderate and 3 mild nasal injuries  
o Infant Flow system showed one 
mild and one moderate injury.   
Clinical implications:  Hudson system 
showed more injuries to the nose than the 
other systems.  The NP prongs were noted to 
have blockage of secretions and had to be 
replaced q 24 hrs. 
 
Limitations:   
 80% of infants required CPAP for < 
2 days. 
 Small groups not powered to 
provide statistically significant 
differences.   
 Meta analysis did not well support 
the use of the naso-pharyngeal tube 
despite these study findings (see 
Cochrane review- 2008).   
 Cost seemed to drive the need to 
provide “equal” care (bias).   
 Weight stratifications too broad 
(1250-2500 and >2500). 
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 Group 1250-2500 grams  
 NP CPAP, one mild and one 
moderate nasal injury 
 Hudson prong system, 2 patients 
developed moderate nasal injuries  
 Infant Flow system showed one 
severe and 2 mild injuries.   
Groups did not significantly differ.   
Yong, S.C., Chen, S.J., 
& Boo, N. Y. (2005).  
Incidence of nasal 
trauma associated with 
nasal prong versus 
nasal mask during 
continuous positive 
airway pressure 
treatment in very low 
birth weight infants: A 
randomized control 
study.  Archives of 
Disease in Children,  
Fetal and Neonatal 
Edition, 90(6), F480-
483. 
 
Kuala Lumpur, 
Malaysia 
 
Level of Evidence:  II 
Purpose:  compare the 
incidence of nasal 
trauma; nasal mask vs.  
nasal prongs during 
NCPAP treatment. 
 
 
 
Design: Randomized 
controlled clinical trial. 
 
 
 
Subjects/Sample size:  
N = 137 (randomly assigned into two groups) 
* nasal mask group;  n = 89   
* nasal prong group;  n = 48 
Additional stratification between infants who 
had and who had not been intubated prior to 
NCPAP. 
 
Selection criteria:   Very low birth weight 
(VLBW) infants; <1500 grams admitted to a 
single NICU in Malaysia. All diagnosed with 
respiratory distress treated with NCPAP via the 
Infant flow driver. 
Exclusion criteria:  Other NCPAP methods 
(classical via ETT or bubble) or identified major 
congenital malformations. 
 
Measures:  Presence of nasal trauma, interval 
between application of NCPAP and onset of 
trauma (days), age at onset of trauma (days), 
duration of CPAP (days), duration of 
conventional ventilation (days) prior to NCPAP, 
duration of NICU stay (days), oxygen 
requirement at 28 days and 36 weeks gestation 
and infant mortality. Demographic measures also 
included for analysis as additional risk factors. 
Findings:   
 No significant demographic 
differences were discovered between 
groups.    
 No reported differences between 
duration of conventional and HF 
ventilation, duration of oxygen 
requirement or hospital stay.   
 No significant difference in measure 
of nasal trauma between groups. 
 Nasal prong group demonstrated a 
longer duration of CPAP. 
 Nasal prong group had nasal trauma 
reported earlier than the nasal mask 
group.  
 Correlation between nasal injury and 
additional risk factors; lower birth 
weight and longer mean duration of 
NCPAP. 
 
Overall, 12 infants in the mask group and 17 
infants in the nasal prong group sustained 
nasal trauma.   
Clinical implications:  This study was 
described as the first randomized controlled 
study comparing nasal prong with nasal mask 
in VLBW infants who received treatment with 
nasal CPAP.   
 
Clearly designed result tables: #1 comparison 
of demographics, #2 clinical outcomes, and #3 
associated risk factors. 
 
Limitations:   
 Single site in Malaysia may not be 
easily replicated.   
 Discussed other characteristics of 
preterm infant care that were 
contemporary and evidence based, 
which may have influenced study 
results. 
 Small sample sizes and not powered 
for less than 20% nasal breakdown 
rate. 
 Few nursing implications or 
strategies to reduce observed nasal 
trauma. 
Rønnestad, A., 
Abrahamsen, T. G., 
Medbø, S., Reigstad, 
H., Lossius, K., 
Kaaresen, P. I., 
Engelund, I. E., Irgens, 
L. M., & Markestad, 
T. (2005). Septicemia 
in the first week of life 
in a Norwegian 
national cohort of 
extremely premature 
infants. Pediatrics, 
Purpose:  investigate 
causes, predictors, 
incidence, and the 
outcomes of septicemia 
of extremely premature 
infants during the first 
week of life. 
 
Design:   Prospective 
descriptive  
 
 
Subjects/Sample size:   
N = 462  
 
Selection criteria:  Gestational age <28 weeks 
or birth weight of < 1000 grams born in Norway 
in 1999-2000. 
 
Measures:   
Infant survival 
Septicemia (early onset) indicated by positive 
blood culture on day 2-7; (very early onset) with 
initial blood culture positive. 
. 
Findings:   
 VEOS occurred in 15/462 patients. 
 Escherichia coli were identified as 
most prevalent bacteria reported. 
 EOS in 15/462 patients with 
staphylococcus aureus and 
coagulase-negative staphylocci 
being the most prevalent bacteria.   
 No patients were diagnosed with 
both VEOS and EOS.   
 Case fatality rates were 40% in the 
VEOS group and 13% in the EOS 
group.   
Clinical implications:   
 The discussion states that n-CPAP 
treatment at 24 hours was a strong 
predictor of EOS, which suggests 
that the healthiest infants were at the 
greatest risk.   
 The link was discussed between the 
introductions of EOS through nasal 
route with nosocomial bacterial 
isolates found in the lower airway.  
 Additional suctioning requirements 
and irritation to the nasal mucosa 
may lead to systemic introduction of 
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115(3), e262-8. 
 
Norway 
 
Level of evidence:  III 
  Independent predictors for VEOS 
were clinical chorioamnionitis and 
increased maternal age.  
 In the EOS group independent 
predictors were not receiving 
systemic antibiotic therapy within 2 
days of age and receiving nasal 
CPAP support at 24 hours of age. 
these nasally colonized bacteria. 
  
Limitations:  Association between NCPAP 
and EOS was based on author opinion, not 
specific outcome measure.   
 
Peake, M., Dillon, P., 
& Shaw, N.J. (2005). 
Randomized trial of 
continuous positive 
airways pressure to 
prevent re-ventilation 
in preterm infants. 
Pediatric 
Pulmonology, 39 (3), 
247-250. 
  
United Kingdom 
 
Level of evidence: III 
Purpose:  compare the 
use of a short period (24 
hours) of postextubation 
nasal CPAP vs. direct 
extubation into head 
box (oxygen hood) 
oxygen. 
 
Design:   Prospective 
randomized controlled 
trial 
 
 
Sample size:   
Total: N = 96  
n = 47 randomized to receive nasal CPAP  
n = 49 randomized to head box oxygen.  
 
 
Selection criteria:  Infants less than 32 weeks; 
gestation infants (October 1998-July 2001) with 
mechanical ventilation in the first 28 days of life, 
now extubated for the first time. 
 
Measures:   
Tolerance was successful extubation for up to 
one week with secondary measure at 2 weeks.  
Incidence/severity was nasal damage assessed 
during the study for each study group. 
Findings:   
 Theoretical risk of nasal damage 
was minimized by frequent skin 
assessment and nasal prong position 
hourly and every 6-8 hours 
thereafter was an hour off nasal 
CPAP. 
 The nursing staff was trained in the 
use of the nasal CPAP device.      
 No statistical differences were found 
between the two group regarding 
reintubation rates.   
 The infants in the nasal CPAP group 
had a trend toward longer timeframe 
prior to reintubation. 
Clinical implications:  The importance of 
nasal CPAP nursing expertise noted as well as 
listing the possibility of nasal trauma with this 
therapy. 
  
Limitations:  The practice of nasal CPAP 
with scheduled “time out” to some other 
device has been clearly shown in the literature 
to increase atelectasis in the preterm infant.   
 
 
Campbell, D. M., 
Shah, P. S., & Kelly, 
E. N. (2006). Nasal 
continuous positive 
airway pressure from 
high flow cannula 
versus Infant Flow for 
Preterm infants. 
Journal of 
Perinatology, 26(9), 
546-549. 
 
Canada 
 
Level of Evidence: II 
Purpose:  compare the 
feasibility of continuous 
positive airway pressure 
(CPAP) support 
generated by high flow 
nasal cannula with 
conventional CPAP for 
prevention of 
reintubation among 
preterm infants with a 
birth weight of <1250 g. 
 
Design:   RCT (pilot 
study) 
 
 
Subjects/Sample size:  2 group of 20 infants 
each group; N = 40  
 
Selection criteria:  <1250 grams who were 
extubated from mechanical ventilation were 
randomized into either group (HF-CPAP) or 
Infant Flow system using nasal prongs (brand 
not identified). 
 
Measures:  
Tolerance was the number of patients who 
required reintubation within 7 days.  
Efficacy was the change in oxygen use and 
frequency of apnea and bradycardia after 
extubation. 
Incidence/severity was nasal damage assessed 
during the study. 
Findings:   
 Twelve infants in the HF- CPAP 
were reintubated compared to three 
Infant Flow (P = 0.003).  
 The high flow cannula group had 
increased oxygen use and more 
frequent apnea/bradycardia. 
 CPAP delivered by high flow nasal 
cannula failed to maintain 
extubation status among preterm 
infants <1250 grams as effectively 
as Infant Flow CPAP. 
*No infants had evidence of nasal injury 
according to the findings although the authors 
report that this may have been influenced by 
the “study effect.” 
*Digital photography utilized as record. 
Clinical implications: 
 Rapid flow from a simple NC can 
cause drying and bleeding of the 
nasal mucosa.   
 Head to head studies with nasal 
CPAP and HFNC or simple NC 
showed increased reintubation rates 
and increased oxygen requirements. 
 HF-CPAP not equal to efficacy of 
classic CPAP. 
 
Limitations:   
Study premise based on previous study which 
measured infants over a 6 hour period of time. 
 
Pilot study with limited sample size 
Smith, L. P., & Roy, 
S. (2006).  Treatment 
strategy for iatrogenic 
nasal vestibular 
stenosis in young 
children.  Pediatric 
Purpose:  describe the 
diagnosis and treatment 
of infants who suffered 
from iatrogenic nasal 
vestibular stenosis as a 
result of treatment with 
Selection criteria:  All patients presented to the 
pediatric otolaryngology service of a large 
academic tertiary care center between 2003 and 
2004.  Infants who were treated with this type of 
iatrogenic nasal vestibular stenosis at the 
University of Miami (Miller School of Medicine) 
Findings:  Three former preterm infants at 25-
34 weeks gestation that developed vestibular 
stenosis after extended use of nasal prongs for 
NCPAP.   
Common chief complaint was nasal airway 
obstruction with nasal blockage and 
Clinical implications:  Three examples of 
iatrogenic nasal vestibular stenosis; this tends 
to be an uncommon occurrence (according to 
other literature).  
Internal damage not obvious to external 
examination unless bleeding/other symptoms.  
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Oto –
rhinolaryngology, 70, 
1369-1373. 
 
USA 
 
 
Level of Evidence: VI 
NCPAP as a preterm 
infant. 
 
 
Design:   Case Report 
secondary to nasal CPAP or feeding tube use as 
part of NICU care. 
 
Sample size:  N = 4 (one not described here as 
vestibular stenosis determined as a result from 
nasal-gastric feeding tube use)  
N = 3 secondary to NCPAP. 
 
Measures:  Physical examination/OR reports/CT 
in one case prior to surgical 
exploration/correction. 
 
 
significant cosmetic deformity.   
 #1 a 4 month old ex-26 week 
preterm infant; 80% obstructed with 
adhesions within the nasal turbinate, 
vestibular retraction.   
 #2 a 5 year old ex-34 week preterm 
infant; 70% obstruction, adhesions 
within right nasal vestibule and 
collapse of the right nasal alar 
cartilage.   
 #3 a 5 month old ex-25 week 
preterm infant; 95% obstruction and 
adhesions within her nasal 
vestibule.   
Additional risk factors identified included 
very low birth weight (<1000), prolonged 
CPAP or nasal prong use. 
May display symptoms later such as breathing 
difficulties/noisy breathing/difficulty 
feeding/FTT. 
Much less incidence in nasal trauma from 
CPAP has been reported per the authors as 
compared to previous literature on 
nasopharyngeal intubations.  
 
Limitations:  Descriptive of case cluster, little 
to link to additional findings nationally or 
internationally. 
Askin, D.F. (2007) 
Noninvasive 
ventilation in the 
neonate.  
Journal of Perinatal & 
Neonatal Nursing, 
21(4), 349-60. 
 
Canada 
 
Level of Evidence : V 
Study purpose:  
Systematic review of 
the topic of noninvasive 
ventilation (NIV) 
including history of 
therapy and nursing 
considerations. 
 
Design: Limited 
systematic review 
 
 
Subjects/Sample size:  78 references cited; 
number of articles included in limited review not 
listed. 
 
 
Selection criteria:  not listed 
Exclusion criteria:  not listed 
 
 
Findings:  Nursing care considerations:  
 Prongs need frequent repositioning, 
mouth closed to prevent leak.   
 Careful patient assessment required; 
determine effectiveness of therapy, 
readiness for weaning, change in 
clinical assessment.  
 Positioning infant with proper 
developmental/bundling techniques 
decreased excessive movement of 
prongs against the nasal septum.      
 Required assessment every 2-3 
hours and maintain patency of the 
nasal prongs.      
*Nasal injuries reported 20% with flow driver.  
*Injuries included necrosis of the columella 
nasi, flaring of nostrils and nasal “snubbing.”   
*Injuries usually the result of friction, pressure 
and/or excessive moisture. 
Clinical implications:   
Key statement: “The literature has clearly 
demonstrated that the success of NIV therapy 
increases with the increasing experience of the 
clinicians administering the therapy.” 
 Time intensive requirement for 
nursing staff.   
 
Limitations:  Limited review without clear 
methodology regarding selection/exclusion 
criteria. 
 
 
McCoskey, L. (2008).  
Nursing care 
guidelines for 
prevention of nasal 
breakdown in neonates 
receiving nasal CPAP.  
Advances in Neonatal 
Care, 8(2), 116-124. 
 
USA 
 
Purpose: describe the 
background and clinical 
indications of NCPAP 
use.  To review the 
embryology/ 
pathophysiology of the 
nares and respiratory 
system of the neonate.  
Describe needed 
nursing assessment and 
care of the neonate with 
Methodology:  Descriptive article that examined 
the global issue of NCPAP use in the preterm 
infant population.  Included was the issue of skin 
breakdown of the preterm infant during NCPAP 
use, pathway to injury and nursing care strategies 
to assess and correct problems.   
Findings:  
 Pathophysiology review; including 
brief embryology on nasal 
development.   
 Description of CPAP mechanics 
with comparisons of types including 
clinical implications for use in the 
preterm population (excellent photos 
to illustrate description).   
 Example of a focused physical 
examination (systematic approach 
Clinical implications:   
 Prevention stressed as the best 
strategy for decreased skin 
breakdown.   
 Focused exam utilized to identify 
areas that are at risk for 
excoriation/necrosis.  
 Positioning stressed as a strategy 
with suggestions to use body parts, 
hands and blanket rolls to assist with 
developmental positioning.   
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Level of Evidence: VI 
 
NCPAP in use.  
 
Design:  Descriptive 
 
  
 
encouraged) to assess infant with 
CPAP in place.  
 Description of nasal breakdown with 
strategies for intervention/ 
prevention. 
 Barriers are useful as preventative. 
 Importance of the bedside RN’s role 
in NCPAP care highlighted. 
 
Limitations:  Descriptive with little scientific 
evidence cited to support recommended 
strategies.   
DePaoli, A. G., 
Morley, C. J., Davis, 
P. G., Faber, B. B., & 
Morley, C. J. (2008). 
Devices and pressure 
sources for 
administration of nasal 
continuous positive 
airway pressure 
(NCPAP) in preterm 
neonates.  Cochrane 
Database of 
Systematic Reviews, 1, 
CD002977. 
 
USA 
 
Level of evidence: I 
Purpose:   determine 
which technique of 
pressure generation and 
which type of nasal 
interface for NCPAP 
delivery most 
effectively reduces the 
need for additional 
respiratory support in 
preterm infants.  
 
Design:   Meta-analysis  
of randomized or quasi-
randomized trials  
 
 
 
Subjects/Sample size:  N = 7 
 
Selection criteria:  A total of seven studies met 
inclusion criteria; randomized and quasi-
randomized studies were included with the 
following types of participants: Preterm infants 
(<37 weeks) extubated to nasal CPAP after IPPV 
for RDS. Preterm infants (<37 weeks) initially 
treated with nasal CPAP within 24 hours. 
 
Measures:   
Efficacy: patients who required additional 
respiratory support by ETT and IPPV or NIPPV 
within a 7 day period.   
Tolerance: measured by demonstrated symptoms 
of respiratory failure, rescue by alternate nasal 
CPAP device or mode of pressure generation, 
CLD as measured by supplemental O2 at 28 days 
of life or supplemental O2 at 36 weeks gestation, 
effectiveness of gas exchange (RR/blood 
gas/saturations), NEC, weight gain, rate of 
sepsis, incidence of PVL and IVH, mortality, 
incidence of air leak (pneumothorax), apnea and 
bradycardia. 
Findings:   
Four major categories 
 preterm infants extubated to nasal 
CPAP following a period of IPPV   
 preterm infants initially treated with 
nasal CPAP  
 randomized preterm infants to 
different nasal CPAP systems  
 awaiting further assessment to 
identify theme. 
*VLBW infants were included and most used 
methylxanthine (caffeine) to aid in treatment 
of RDS/apnea of prematurity.   
*Most studies used NCPAP settings of 4-6 cm 
H2O with outcome measure of reduction in 
the RDS symptoms; extubated >7 days. 
*Single study with older neonates (<36 weeks) 
was included. 
*NCPAP devices compared included 
measures of length and success of treatment. 
*Comparison between NCPAP types and 
treatment success (only Hudson prongs used). 
* Both devices provided adequate reduction in 
RDS symptoms.   
Clinical implications:   
 Short binasal prongs seem to be 
more effective than the single prong 
devices in the reduction of RDS.   
 Argyle prong has a relatively high 
resistance to flow compared to the 
other form.   
 Argyle prongs caused the most nasal 
hyperemia when compared to 
Hudson prongs with significant 
differences in the rate of nasal 
trauma in most weight classes and 
gestational age neonate.   
 Larger babies showed fewer injury 
rates. 
 The most effective and least 
traumatic device REMAINS to be 
determined. 
 
Limitations:  No conclusive evidence as to 
the best type of nasal CPAP device or nasal 
interface in this population.  Defining the 
optimal short binasal prong device that proves 
to be less traumatic to the infant’s nasal 
structures is needed. 
Squires, A. J., & 
Hyndman, M. (2009).  
Prevention of nasal 
injuries secondary to 
NCPAP application in 
the ELBW infant.  
Neonatal Network, 28 
(1) 13-27. 
 
 
USA 
 
Level of Evidence: 
VI 
Purpose:   integrated 
review (limited) of 
studies that reported 
nasal injury secondary 
to NCPAP use in 
neonates since 1980. 
 2) description of 
nursing strategies to 
prevent nasal injury 
from CPAP in the 
extremely low birth 
weight (ELBW) infant.  
 
 
Design:  Descriptive 
Sample:  The integrated review included 8 
studies which described nasal injuries, type of 
CPAP used, additional patient risk factors and 
recommendations from each study.  
 
Included studies were a mixture of descriptive, 
retrospective, randomized controlled, and 
prospective randomized clinical studies.   
 
Findings:   
 Integrated review (significant 
findings from each study) used to 
support the problem. 
 Description of the most common 
types of nasal injuries reported with 
anatomical descriptions/diagrams to 
aid in explanation.  
 Potentially better practices (PBPs 
were reported from the Vermont 
Oxford) which included frequent 
assessment (q4hrs), using the correct 
nasal interface for the patient, 
alternate between mask and prongs, 
application of protective barrier and 
Clinical implications:   
 Review of the affected anatomy with 
diagrams including risk factors for 
breakdown in this population.   
 Strategies offered for bedside 
practice without strong clinical 
evidence to support practice change. 
 Limited list of current manufactures 
of NCPAP interfaces/equipment and 
barriers.   
 
Limitations:  Integrated review limited to 8 
studies which described mixed research 
methodologies without clearly defined 
methodology for inclusion. 
Formatted: Font: Not Bold
Formatted: Font: Not Bold
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use a minimal 2mm separation 
between the nasal septum and 
interface.   
 Excellent photos demonstrated nasal 
trauma/breakdown. 
Several key strategic clinical 
recommendations were not cited or supported 
with evidence.  
Diblasi, R. M. et al.  
(2009). Nasal 
continuous positive 
airway pressure 
(CPAP) for the 
respiratory care of the 
newborn infant. 
Respiratory Care, 
54(9), 1209-1235. 
 
USA 
 
Level of Evidence: VII 
Purpose:  “Provide 
clinicians with a 
comprehensive updated 
summary of the 
literature to better 
determine the clinical 
responses in infants 
supported by CPAP, 
describe the operational 
principles and 
physiologic effects 
related to CPAP 
systems and define the 
role of CPAP for 
improving outcomes in 
premature infants with 
RDS.” 
 
Design:   Systematic 
Review 
Subjects/Sample size:  Not specifically 
identified; review tables included 15, 16 &12 (N 
= 43) articles under separate headings. 
 
Selection criteria:  not well defined 
 
Findings:   
 Excellent review of the history and 
effects of CPAP.   
 Various types of CPAP and 
interfaces described.   
 Recommendations for clinical 
management including NCPAP in 
preterm infants with RDS are given.  
 Recommendations for clinical 
management of secondary 
complications of NCPAP including 
a description on nasal injury. 
 
Clinical implications:  Sound clinical 
management section including implications 
and guidelines useful during routine nursing 
care:  
 5cm H20 or > to  maintain FRC than 
lower levels of NCPAP 
 Proper airway positioning of the 
infant 
 Close monitoring for changes in 
respiratory assessment critical. 
 Strong recommendation for standard 
NCPAP bedside practice based on 
scientific evidence.  
 
Limitations:  No description of methodology 
or selection for articles included in review.  
Clinical management of these infants 
supported by CPAP was based primarily on 
anecdotal experience and opinion than on 
scientific evidence.   
Practices vary widely among individual 
NICU’s with little consensus regarding 
aspects of care, weaning, and equipment. 
Davis, P. G., Morley, 
C. J., & Owen, L. S. 
(2009).  
Non-invasive 
respiratory support of 
preterm neonates with 
respiratory distress: 
Continuous positive 
airway pressure and 
nasal intermittent 
positive pressure 
ventilation.  Seminars 
in Fetal &Neonatal 
Medicine, 14(1), 14-
20. 
  
Australia 
 
Level of Evidence: V 
Purpose:  review of 
literature on the topic of 
non-invasive respiratory 
support of the preterm 
neonate with respiratory 
distress (RDS). 
 
Design:   Limited 
systematic review 
 
 
Subjects/ Sample size:   
N = 75 cited articles with n = 8 indicated by the 
authors as key works.  The total number of 
reviewed studies was not indicated. 
 
Selection criteria:  RCTs or metal analysis of 
these trials. 
 
Measures:  
Major headings included; how does CPAP work, 
CPAP delivery, practical problems of NCPAP 
(to include nasal trauma), clinical indications for 
NCPAP, nasal intermittent positive pressure 
ventilation (NIPPV), clinical indications for 
NIPPV, what do we still need to learn about 
NIPPV and conclusions.  Subheadings for each 
sections included highlighted findings and lapses 
discovered in the literature. 
Findings:   
 Nasal prongs and nasal mask have 
advantages over other CPAP 
interfaces; infant’s nose and mouth 
can be more easily observed and 
cared for during the therapy. 
 Nasal trauma most often caused by 
incorrect positioning of the prongs.   
 Correct space allowance between 
the prongs and nasal columella has 
been demonstrated helpful.  
 Injury also reported inside the nose.   
 Proper prong size, constant nursing 
vigilance and attention to the correct 
prong position are required for 
therapy success. 
 
Clinical implications:   
 Short bi-nasal prongs were more 
effective than NP prongs and single 
nasal prongs.   
 NCPAP provided as initial therapy 
in the delivery room provides an 
alternative to mechanical 
ventilation. 
 NCPAP administration provides 
improved success rates when 
transitioning patients from 
mechanical ventilation to NIPPV. 
  
Limitations:  Only used RCTs in review may 
have been useful studies to include that were 
not randomized. 
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do Nascimento, R. M., 
Ferreira, A. L., 
Coutinho, A. C., & 
Santos Veríssimo, R. 
C. (2009). The 
frequency of nasal 
injury in newborns due 
to the use of 
continuous positive 
airway pressure with 
prongs. Revista 
Latino-Americana de 
Enfermagem, 17(4), 
489-494. 
  
 
Brazil 
 
Level of Evidence: V 
 
Purpose:  determine 
the frequency of nasal 
injuries in newborns 
through the use of 
continuous positive 
airway pressure with 
prongs. 
 
Design:   Descriptive 
cross-sectional 
 
 
Subjects/ Sample size:  N = 147; convenience 
sample housed in single Brazil NICU from 
10/2007 to 2/2008. 
 
Selection criteria:  Newborns (term and 
preterm) located in a single NICU in Brazil who 
required nasal CPAP with prongs for ≥ 2 days. 
 
Measures:   
Incidence described as the number of 
occurrences. 
Severity classified as mild (hyperemia), moderate 
(hyperemia and erosion) and severe (bleeding 
and erosion).   
Findings: Lesions were observed in all 
newborns who received treatment for ≥ 2 days. 
 Severity was classified as: mild 
(hyperemia) (79.6%), moderate 
(19.7%) (hyperemia and erosion) 
and severe (0.7%) (bleeding and 
erosion).  
 The use of prongs for more than two 
days represents a risk factor for the 
lesions to develop.   
 The infants who had CPAP in place 
for > 2 days had a higher incidence 
of moderate or severe nasal lesion. 
*Barriers were used in 97% of the infants 
observed. 
*Greater than 50% of the infants had smaller 
prongs in place than manufacture 
recommendation. 
Clinical implications: 
 Appropriate size of nasal prong 
should be reinforced. 
 Appropriate cap size for the infant 
critical as too much movement can 
lead to increased incidence of nasal 
trauma. 
 Training and educational programs 
should be administered to improve 
newborn care with CPAP. 
 
Limitations:   
Study population included preterm and term 
infants not stratified to gestational age or birth 
weight. 
 
Owen, L. S., Morley, 
C. J., & Davis, P. G. 
(2010).  Pressure 
variation during 
ventilator generated 
nasal intermittent 
positive pressure 
ventilation in preterm 
infants. Archives of 
Disease in Children, 
Fetal and Neonatal 
Edition, 95(5),  F359-
364. 
 
Australia, Melborne 
 
Level of Evidence: IV 
Purpose:   quantify the 
delivered peak 
pressures during the 
administration of non-
synchronized ventilator-
generated NIPPV using 
nasal prongs. 
 
Design:   Observational 
cohort study 
Subjects/ Sample size:   
N = 11 convenience sample, 
(a total of 9456 mechanical inflations). 
 
Selection criteria:  Infants born < 30 weeks 
gestation and more than 48 hours old that were 
receiving ventilator-generated NIPPV delivered 
via Hudson prongs.   
 
Measures:   
Descriptive data were collected to describe 
groups.   
Efficacy was measured using a calibrated 
respiratory function monitor at the inspiratory 
limb of the Hudson prong.   
Tolerance was measured by RR, oxygen sats, 
spontaneous breathing and tidal volume which 
were recorded using various tools.    
 
Findings:   
 Wide variability in the inflation 
rates and peep measurements 
(usually 5 cm below set parameters).  
 Delivered pressure varied 
considerably even when the infant 
was quiet/sleeping (stable resp 
pattern) based on video information.   
 Highest pressures were recorded 
with infant movement and noted 
desaturations occurred most 
commonly after these episodes.   
 Loss of pressure was noted with 
mouth leak, laryngeal resistance and 
glottis size.  
 NO documented correlations 
between the prong size and either 
delivered pressure, duration of nasal 
prong support or infant weight. 
 The only significant mention of 
nasal trauma/skin issue was “size 
and shape of the infant’s nostril 
changes making it difficult to fit 
prongs consistently to infants who 
received CPAP or NIPPV.” 
Clinical implications: 
 No differences were found between 
the delivered pressures whether the 
PIP was set at 20 or 25 cm as the 
leak was noted to be greater with 
increasing pressure; utilizing the 
lower end of the spectrum is 
encouraged with titration to infant 
effect/need.   
 Loss of pressure with mouth leak 
and other factors should be 
considered during positioning and 
care of the neonate on NCPAP or 
NIPPV. 
 
Limitations: 
No correlation with either the length of time 
the infant had prongs in place or size of 
prongs. 
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Fischer, C., Bertelle, 
V., Hohlfeld, J., 
Forcada-Guex, M., 
Stadelmann-Diaw, C., 
& Tolsa, J. (2010).  
Nasal trauma due to 
continuous positive 
airway pressure in 
neonates.  Archives of 
Disease in Children; 
Neonatal-Fetal 
Edition, 95, F447-
F451. 
 
 
Lausanne, Switzerland 
 
Level of Evidence: III 
 
 
Purpose: describe the 
incidence and the 
severity of nasal trauma 
secondary to NCPAP in 
neonates. 
 
Design:  Prospective 
observational study 
 
. 
Subjects/Sample size:  
N = 1133 (eligible- treated with NCPAP).   
n = 144 patients (lost to follow up) 
Final sample n= 989 infants for a total of 13,719 
CPAP days. 
 
Selection criteria: Infants admitted to the 
neonatal intensive care unit (NICU) at the 
University Hospital of Lausanne, Switzerland 
between January 2002 and December 2007 who 
were treated with NCPAP.   
 
Measures:  Incidence and severity of nasal 
trauma as measured by the US National Pressure 
Ulcer Advisory Panel (NPUAP) as stage I/II or 
III. Stage I was persistent erythma, II was 
superficial ulceration, and stage III was necrosis. 
Demographic neonatal variables were also 
recorded for analysis. 
 
Findings:   
 Nasal trauma was reported in 420 
(42.5%) of the patients.  Most of the 
incidence was stage I (88.3%), stage 
II (11%), and stage III (0.7%).   
 The severity of nasal trauma was 
inversely correlated with the 
gestational age and birth weight.   
 Significant correlation was also 
noted with those infants staying in 
the NICU >14 days or having 
NCPAP for > 5 days in duration.   
Of note: The incidence of nasal trauma was 
usually noted by day 2 of use and rarely after 
the 9th day of CPAP use.   
 
Feasibility:  The length of time (>5 yrs) that 
data collection continued made this study 
difficult to conduct/replicate.  
Clinical implications: 
Nasal trauma secondary to NCPAP identified 
as a significant adverse complication with 
confirmed incidence ~ 40%.  
   
Limitations:  Single site although large 
sample size.  Single CPAP device (Infant 
Flow driver system). 
Difficult to compare studies with varied 
classification used to measure severity of nasal 
breakdown 
 
Tagare, A., Kadam, S., 
Vaidya, U., Pandit, A., 
& Patole, S. (2010). A 
pilot study of 
comparison of BCPAP 
vs. VCPAP in preterm 
infants with early 
onset respiratory 
distress.  Journal of 
Tropical Pediatrics, 
56(3), 191-194. 
 
India 
 
Level of evidence: III 
Study purpose:  
compare efficacy and 
safety of bubble CPAP 
(BCPAP) and ventilator 
CPAP (VCPAP) in 
preterm neonates with 
moderate respiratory 
distress syndrome 
(RDS). 
 
Design:  Prospective 
RCT (Pilot) 
 
 
Subjects/Sample size:   
N =30; randomization into two groups (BCPAP 
or VCPAP). 
 
Selection criteria:  Preterm neonates (gestation 
<37 weeks) with a diagnosis of RDS and oxygen 
requirement >30% within the first 6 hrs of life.  
Study timeframe August 2007-April 2008 in a 
tertiary NICU in Pune, India. 
 
Study Variables:   
Efficacy was measured by the improvement in 
either oxygen requirement and/or Silverman-
Anderson score (RDS measure).   
Findings:   
 The success rate between the two 
types of CPAP (bubble vs. 
ventilator) was comparable in those 
preterm infants with moderate RDS.   
 Most common problem with 
NCPAP was the dislodgement of the 
short binasal prongs (Fischer Paykel 
in the bubble device and Argyle for 
the VCPAP).   
 The mean duration of CPAP was 
comparable between groups.  
 Nasal septal injury was seen in 27% 
of the BCPAP group (4/15) without 
incidence with the VCPAP group. 
Clinical implications:  Bubble CPAP is less 
costly to deliver than vent CPAP so would be 
important to ensure efficacy and safety of this 
method for potential use in NICUs with 
limited resources.   
  
Limitations:  Small sample size; small 
number in each group, statistically difficult to 
determine differences. 
Specifically tested on patients with moderate 
RDS.   
Results may be not be generalized to all 
preterm infants. 
Need for cost containment may create bias. 
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Günlemez, A., Isken, 
T., Gökalp, A. S., 
Türker, G., & Arisoy, 
E. A. (2010).  
Effect of silicon gel 
sheeting in nasal 
injury associated with 
nasal CPAP in preterm 
infants.  Indian 
Pediatrics, 47(3), 265-
267. 
 
India 
 
Level of Evidence: II 
 
Purpose:  describe 
whether the use of 
silicon gel sheeting on 
nares during NCPAP 
could reduce the 
incidence and severity 
of nasal injury in 
premature infants. 
 
Design:   Randomized 
Control Trial 
 
 
Subjects/ Sample size:  
N = 179;  randomized into two groups 
Group 1 (n = 87) with no silicon gel application 
Group 2 (n = 92) with silicon gel sheeting on the 
surface of nares during NCPAP. 
 
Selection criteria:  Preterm infants admitted to 
the NICU 11/2005 to 7/2007 who were receiving 
NCPAP. 
 
Measures:  Incidence described as the number of 
occurrences. 
Severity described as bleeding, crusting, 
excoriation or columella necrosis). 
Findings:  
 Nasal injury developed in 13 
(14.9%) neonates in Group 1 and 4 
(4.3%) newborns in Group 2 (OR: 
3.43; 95% CI: 1.1-10.1; P<0.05).  
 The incidence of columella necrosis 
was also significantly higher in the 
Group 1 (no silicon sheeting) (OR: 
6.34; 95% CI: 0.78-51.6; P<0.05).  
 It was concluded that the silicon gel 
application may reduce the 
incidence and the severity of nasal 
injury in preterm infants on nasal 
CPAP. 
Clinical implications: 
 Major underlying mechanism of 
nasal injury is pressure generated on 
the columella by prongs. 
 The maxillary spine behind the 
columella and its surface is very 
small; CPAP places direct pressure 
on this area.   
 Infants should be closely monitored 
during CPAP administration.   
 Adequate nursing care and vigilance 
(not well defined) described as 
important to improved outcomes. 
 
Limitations: Single site/single flow driver 
CPAP device. 
 
 
Table 1: Skin breakdown of the neonate during nasal continuous positive airway pressure (CPAP) use 
Level of evidence taken from: 
Melnyk, B. M., & Fineout-Overholt, E. (2005). Evidence-based practice in nursing and healthcare: A guide for best practice. Philadelphia: Lippincott, p. 10. 
1 
 
 
 
Those 46 remaining studies were evaluated for the 
description of secondary effects of nasal CPAP as 
primary or secondary outcome vs. antidotal mention. 
The level of evidence was assigned for each article. 
Total 102 articles 
Citations reviewed for additional studies which included 
inclusion criteria (timeframe, preterm infant with CPAP and 
nasal skin breakdown); 11 additional studies were identified  
Total 113 articles 
 
Timeframe: 1996-2011 
Electronic databases: CINAL, PubMed, Goggle Science 
and Web of Science. 
 
Key terms: nasal trauma, preterm infant nasal skin 
breakdown, nasal prongs & skin care, skin 
breakdown with cpap use. 
 
Found additional 14 articles 
Timeframe: 1996-2011  
Electronic databases: CINAL, PubMed, Goggle 
Science and Web of Science. 
Key terms: nasal CPAP of the neonate, CPAP,  non-
invasive respiratory management of the preterm, 
respiratory devices of the newborn and respiratory 
pressure sources of the preterm infant. 
 
Found 88 articles 
22 articles: Included in Discussion (on-line table 1) (outcome measures = inclusion criteria) 
18 articles: Included in Discussion Section (on-line table 1) (general discussion = inclusion criteria) 
 
 
Each article fully reviewed and evaluated for inclusion criteria:  
 Outcome criteria or description of skin or nasal trauma, skin breakdown.  
 Risk factors which included nasal or facial injury related to NCPAP use.    
 67 studies- deleted after detailed review - containing general and/or specific 
CPAP information without description of skin injury.  
Total 46 articles 
 
Figure 1: Decision Tree for inclusion/exclusion in the Integrative Review 
Case studies: reporting injuries secondary to 
CPAP were identified and included in a 
separate discussion section.  
Total 6 articles 
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Study aim included skin 
breakdown, nasal trauma or 
injury: 
n = 22 
Types of nasal injuries that 
correlate with nasal 
continuous positive airway 
pressure (NCPAP) use: 
 
n = 21 
Total reviewed articles:  
N = 113 
Excluded:  n = 67 
Total included in integrative review: 
n = 46 
 
Recommended prevention 
strategies to reduce iatrogenic 
cutaneous injury: 
 
 
n = 8 
Discussion included importance 
of skin assessment and nasal 
care to reduce injury: 
n = 18 
Case studies: 
 
n = 6 
Differences between types 
of NCPAP devices and/or 
nasal interface and the 
reported rate & severity of 
nasal skin injury: 
n = 12 
 
Associated risk factors that 
increase the incidence of 
injury: 
 
 
n = 21 
Figure 2: Decision Tree (articles categorized into 3 major topical headings, then delineated into four subject categories)   
Note: There were 16 articles that included information applicable to more than a single subject category and, thus, are listed 
within more than one subject category. 
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Supportive Tables and Figures for Chapter 2 
 
A Comparative Effectiveness Study of Continuous Positive Airway  
Pressure (CPAP) Related Skin Breakdown when using Different Nasal  
Interfaces in the Extremely Low Birth Weight (ELBW) Neonate 
 
Table 1: sample representation for each stratified birth weight per group with 
comparisons among groups for consistency 
 
Table 2: Demographic variables for total sample 
 
Table 3: Demographic for each nasal interface group. Comparisons between 
groups conducted with p value reported for each comparison. 
 
Table 4: Variable correlation table 
 
Table 5a: Independent variables entered into the multiple regression model 
 
Table 5b: Predictors of skin breakdown risk factors during nasal CPAP use in the 
neonate <1500 grams 
 
Figure 1: Consort table for study screening and enrollment 
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Block Stratification according 
to birth weight 
Continuous Mask Continuous Prongs Rotation Mask/Prongs p 
value 
ELBW #1 (500-750 grams) 13 (37.1%) 4 (19%) 6 (27.3%) 0.123 
 ELBW #2 (751-1000 grams) 16 (45.7%) 10 (47.7%)  9 (47.9%) 0.67  
ELBW #3  (1001-1250 grams) 5 (14.3%) 4 (19%) 7 (31.8%) 0.99 
VLBW #1 (1251-1500 grams) 1 (2.9%) 3 (14.3%) 0 (0%) 0.114 
 Total sample N = 35 N = 21 N = 22  
Table 1: sample representation for each stratified birth weight per group with comparisons among 
groups for consistency.   
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Variable N Mean Minimum Maximum SD 
Birth weight (grams) 78 ∆ 873.36 500 1460 220.70 
Birth gestational age (weeks) 78 ∆ 26.77 23.00 32.00 1.90 
Current weight (grams) 730● 1065.24 720 3170 373.99 
Current age ( weeks) 726● 3.87 0.14 14.43 3.23 
Time to CPAP initiation (weeks) 726● 3.87 0.14 14.43 3.23 
Number of CPAP days  730● 4.32 1 16 3.22 
CPAP temperature 730● 36.38 0 38 2.70 
CPAP flow rate (lpm) 730● 5.35 4 7 0.66 
Oxygen supplementation (%) 730● 0.25 0.21 0.60 0.6 
Amount of humidity provided (C) 730● 25.59 0 86 34.26 
Table 2: Demographic variables for total sample 
∆ Total number of participants in the study 
 ● Number of data collection episodes  
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Table 3: Demographics for each nasal interface group. Comparisons between groups conducted with resulted p value for each comparison 
 Groups (        ) Continuous Mask (N = 35) Continuous Prongs (N = 21) Rotation Mask/Prongs (N = 22) P value  
Variable (        ) Mean      Minimum Maximum Mean Minimum Maximum Mean Minimum Maximum  
Birth gestational age (grams) 26.65 23.29 31.14 27.26 24.00 32.00 26.51 23.00 30.14 0.388    
Birth weight (grams) 826 500 1420 941 610 1460 884 520 1170 0.164 
Current weight during CPAP (grams) 934 520 1720 1142 750 2145 1196 710 3170 0.000* 
Post menstrual age during CPAP (weeks) 2.32 0.14 9 2.90 0.14 14.14 3.33 0.14 9.86 0.109 
Mean FIO2 administered (%) 0.26 0.21 0.60 0.24 0.21 0.47 0.24 0.21 0.34 0.189 
Time to NCPAP (weeks) 3.47 0.14 10.71 3.47 0.14 14.43 4.65 0.14 11.00 0.109 
Number of CPAP days   4.79 1 15.50 3.45 1.50 8.50 5.68 1.50 15 0.093 
CPAP temperature (C) 36.20 0 38.00 36.10 0 37.30 36.70 26.00 37.50 0.173 
CPAP flow rate in LPM  5.38 4.38 6 5.59 4.50 6.50 5.30 4.58 6.07 0.037* 
Incubator humidity during CPAP (C) 37.15 0 81.67 29.44 0 81.25 29.37 0 72.60 0.287 
Developmental positioning  1.81 1 2 1.77 1 2 1.83 1 2 0.229 
Nasal suctioning 0.94 0 5 0.70 0 4 0.80 0 4 0.323 
Use of Normal Saline during suction 2.78 1 3 2.90 1 3 2.83 1 3 0.059 
NSCS score (erythma) 1.31 1 2 1.28 1 2 1.18 1 3 0.001* 
NSCS score (excoriation) 1.19 1 3 1.18 1 3 1.10 1 3 0.007* 
Summary NSCS score 4 3 7 4 3 7 4 3 7 0.716 
 
(*) denotes significance level of 0.05 or less 
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Variable 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1. Birth gestational age (gr) -- 
.010 
2. Birth weight (grams)     .716 -- 
3. Current weight during CPAP (gr)
.140 .311 --- 
4. PMA during CPAP (weeks)
-.555 -.560 .523 
-- 
5. Mean FIO2 administered (%)
-.467 -.369 -.080 .151 
-- 
6. Time to NCPAP (weeks)
-.555 -.560 -.523 1.00 .155 
-- 
7. Number of CPAP days
.000 .000 .051 .255 -.068 .255 
-- 
8. CPAP temperature (C)
.085 -.084 .025 .067 .045 .067 -.002 
-- 
9. CPAP flow rate in LPM
.054 .012 -.011 .154 .126 .192 .126 
-.250 -- 
10. Incubator humidity (%)
.165 .383 .366 -.325 .727 .253 .727 .310 -.047 
-- 
11. Developmental positioning
.099 .037 .026 -.033 -.089 -.033 .039 .037 .001 .042 
-- 
12. Nasal suctioning
-.037 -.029 -.061 .031 .074 .031 .024 .058 -.012 -.062 .008 
-- 
13. Use of Normal Saline w/suctioning
.085 .091 -.003 -.040 -.023 -.040 -.100 -.010 -.023 .047 .014 .269 
-- 
14. NSCS score (erythma)
-.107 -.054 -.093 -.053 -.004 -.053 .207 .046 -.021 .061 .003 .009 .035 
-- 
15. NSCS score (dryness)
-.284 -.292 -.167 .394 .128 .394 .301 .022 -.191 -.461 .032 .039 .093 .034 
-- 
16. NSCS score (excoriation)
.057 .071 -.073 -.041 -.008 -.041 .216 .038 -.002 .040 0.63 .022 .088 .571 .055 
-- 
17. Summary NSCS score
.290 -.282 .015 .176 .065 .176 .360 .051 -.060 -.210 .045 .007 .105 .747 .594 
.727 
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Table 5a: Independent variables entered into the multiple regression model 
Independent Variables β t - statistic  p value 
Birth weight -0.070 -0.534 0.595 
Number of CPAP days 0.031 2.808 0.006 
CPAP flow rate  in LPM -0.049 -0.433 0.667 
Mean incubator temp -0.170 -1.097 0.276 
Mean post menstrual age at time of nasal CPAP 0.030 2.414 <0.001 
Percent nasal suctioning 0.073 0.680 0.499 
Percent oral suctioning -0.052 -0.473 0.637 
Percent nasal/oral suctioning 0.014 0.131 0.896 
Developmental position utilized -0.004 0.033 0.974 
Dependent variable: Mean NSCS sum score 
 
 
 
 
 
Table 5b: Predictors of skin breakdown risk factors during nasal CPAP use in the neonate <1500 grams 
 
Model R R square  Standard 
error 
Df1  Df2 F p-
value 
Model 1 - Mean post menstrual age at 
time of nasal CPAP (constant) 
0.399 0.159 0.48 1  73  13.82 <0.001 
Model 2 - Mean post menstrual age at 
time of nasal CPAP; number of CPAP 
days (constant) 
0.492 0.221 0.46 1  72 11.51   0.006 
Dependent variable: Mean NSCS sum score 
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Total admissions to the NICU  
Each patient screened for inclusion criteria 
N = 377 
NO 
N = 2 
(excluded) 
YES 
N = 78 
YES 
N = 90 
YES 
N = 138 
YES 
N = 140 
Screened for airway exclusion criteria 
NO 
N = 237  
(excluded) 
Parental consent 
NO 
Refused N = 2 
Missed/pending N= 
32 
Patient expired N =14 
N = 48 
(excluded)
To NASAL CPAP 
NO 
N = 12 
(excluded) 
EExclude
d
Rotation CPAP 
N = 22 
Mask CPAP 
N = 35 
Prong CPAP 
N = 21 
Weight 
criteria 
500-1500
NO  
N = 237 
(excluded)
grams
 Weight criteria 500-1500 grams 
Figure 1: Consort table for study screening and enrollment 
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VCU IRB 
FULL and EXPEDITED STUDY INITIAL REVIEW SUBMISSION FORM 
IRB NUMBER:   
DO NOT DELETE SECTIONS OF THIS FORM 
SECTION 1: PRINCIPAL INVESTIGATOR AND OTHER VCU PROJECT PERSONNEL 
1. PRINCIPAL INVESTIGATOR:   LIST NAME AS IT EXISTS IN THE HUMAN RESOURCE SYSTEM (HRS)
NOTE: See guidance on who can serve as PI at HTTP://WWW.RESEARCH.VCU.EDU/IRB/WPP/FLASH/IX-1.HTM) 
Name (Last, First, MI): McGrath, Jacqueline M. 
     PI Title and Degrees:     Associate Professor of Nursing, PhD, RN, NNP, FNAP 
VCU Department: School of Nursing 
   VCU P.O. Box #  
(must provide 6-digit box #): 
PO Box 980567 
Phone/Pager/Fax #’s: (804) 828-1930 
 VCU Email: MCGRATHJM@VCU.EDU 
2. PROJECT PERSONNEL TO BE
INCLUDED IN CORRESPONDENCE:
These persons may be copied on correspondence from the IRB.  
(ALL project personnel are to be listed on a separate VCU IRB Study Personnel Roster) 
  RESEARCH COORDINATOR (if applicable): 
Name (Last, First, MI), Degrees: Email: 
  TRAINEE (Postdoctoral Scholar, Fellow or Resident) (if trainee project): 
Name (Last, First, MI), Degrees: Email: 
  STUDENT (if student project): 
Name (Last, First, MI), Degrees: Newnam, Katherine M., PhD (c), RN, NNP, 
CPNP 
Email: NEWMANKM2@VCU.EDU 
SECTION 2: PROJECT INFORMATION 
1. PROJECT TYPE (check one):
 BIOMEDICAL Research involving medical interventions and/or FDA-regulated products 
 SOCIAL-BEHAVIORAL (check one): Social or behavioral research that does NOT involve medical 
interventions or FDA-regulated products 
 SOCIAL-BEHAVIORAL QUALITATIVE 
 SOCIAL-BEHAVIORAL QUANTITATIVE 
 SOCIAL-BEHAVIORAL QUALITATIVE     
  & QUANTITATIVE  
2. TITLE OF PROTOCOL SUBMISSION:
A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) Related Skin Breakdown when using 
Different Nasal Interfaces in the Extremely Low Birth Weight (ELBW) Neonate. 
3. Are there any IRB-APPROVED PROTOCOLS ASSOCIATED with this submission?  YES  NO 
If YES, please list the associated VCU IRB Protocol #’s: 
Note:  If this submission is associated with other new projects submitted to the IRB (but not yet approved), please attach a 
cover memo to your submission noting related projects.  
4. Is this a TRAINEE OR STUDENT PROJECT in which activities will be carried out by that
individual under your supervision?      
 YES  NO 
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SECTION 3: TYPE OF SUBMISSION 
Please check all categories that apply to the study being submitted for IRB review. 
 RESEARCH PROJECT 
 FDA REGULATED RESEARCH* 
* FDA regulated research includes:
a) any research involving a drug or biologic intended for human use (other than the use of an approved drug in the course of
medical practice); 
b) any research designed to test the safety and effectiveness of a device; or
c) research involving ANY FDA regulated product where the intent is to submit data to the FDA in support of a research or
marketing application.  Regulated products include foods & dietary supplements, infant formulas, food & color additives, and 
electronic products.    
  CLINICAL TRIAL 
See definition of clinical trial at http://www.cto.vcu.edu/about/index.html#ClinicalTrialDefinitition 
   HUMANITARIAN USE DEVICE 
See guidance at http://www.research.vcu.edu/irb/wpp/flash/XVI-2.htm 
   TREATMENT USE OF INVESTIGATIONAL DRUG/DEVICE  
See guidance at http://www.research.vcu.edu/irb/wpp/flash/XVI-5.htm 
SECTION 4: TYPE OF REVIEW 
REVIEW TYPE REQUESTED (check one): 
 FULL BOARD REVIEW NOTE: Industry-sponsored research MUST be submitted to Western IRB (WIRB) for 
review. See instructions available at http://www.research.vcu.edu/forms/wirb.htm 
 EXPEDITED REVIEW * EXPEDITED CATEGORIES:  Type 1
* Identify the expedited category or categories in which your research falls (See Expedited Review Guidance at
http://www.research.vcu.edu/irb/reviewtypes.htm) 
NOTE: For projects requesting exempt review determination, use the exempt review submission form, available at 
http://www.research.vcu.edu/forms/vcuirb.htm. 
SECTION 5:  SPONSOR DATA 
1. Does the research project involve a DIRECT FEDERAL AWARD made to VCU (or a research
funding proposal for such)?     
 YES  NO 
2. Have you submitted a related research funding proposal(s) to the VCU Office of Sponsored
Programs (OSP)? 
 YES  NO 
If YES, you must provide (a) NAME OF THE FUNDING SOURCE AND (b) PT/PD # for each related proposal (regardless of 
the funding source): 
(1)          (2)        (3)     
NOTE: Federal regulations require IRB approval of NEW, RESUBMISSION, or COMPETING CONTINUATION FEDERAL RESEARCH FUNDING
PROPOSALS. If there is a new, resubmission, or competing continuation VCU federal research funding proposal associated with this 
research project, you must include a copy of your ENTIRE proposal (exclusive of appendices) and OSP Internal Approval Form with this 
submission. Failure to do so may delay your research award start date. Other sponsors also may require IRB approval of research 
proposals. It is the investigator’s responsibility to determine whether this review is needed. If the sponsor does not require IRB approval 
of research proposals, DO NOT submit them to the IRB for review. If you have questions about whether your sponsor requires IRB 
approval of your research funding proposal, please contact OSP. 
   Page 2 of 11 
 75
Rev. Date: 6-1-11 
IRB Use – Do not Delete 
SECTION 6: STATEMENTS OF COMPLIANCE 
PRINCIPAL INVESTIGATOR STATEMENT OF COMPLIANCE: 
I understand and accept responsibility for ensuring the safety and welfare of all human subjects who participate in the 
proposed research project. I certify that all key project personnel, including myself, sub/co-investigators, research 
coordinators, trainees, and students have completed the VCU required training on human subjects protection. I agree to a 
continuing exchange of information with the VCU IRB including the requirements to (i) obtain IRB approval before making 
non-emergency changes/revisions to the project, except where necessary to eliminate apparent immediate hazards to subjects 
or others, (ii) provide progress reports to the VCU IRB at their request (and at least annually), and (iii) report promptly to the 
IRB all unanticipated problems and serious adverse events involving risk to human subjects (in accordance with required 
reporting timelines by the IRB). 
SIGNATURE OF INVESTIGATOR: DATE OF SIGNATURE: 
TRAINEE OR STUDENT INVESTIGATOR STATEMENT OF COMPLIANCE (IF APPLICABLE): 
This is a student or trainee project, which will potentially be presented outside the classroom and/or published. I understand 
that I may not proceed with the research without first receiving a formal written letter of approval from the VCU IRB. I 
certify that I have completed the VCU required training on human subjects protection.  
SIGNATURE OF TRAINEE OR 
STUDENT: 
DATE OF SIGNATURE: 
DEPARTMENT/DIVISION CHAIRPERSON OR DEAN STATEMENT OF COMPLIANCE*see NOTE: 
I certify that the research project referenced in this document (check one of the following): 
 Has been subjected to scrutiny within a VCU Committee (i.e., Massey Cancer Center Protocol Review, Clinical Research 
Center [CRC]) or sponsor study group (i.e., NIH or other agency with appropriate scientific expertise) and found to be 
scientifically acceptable. 
 Has been subjected to scrutiny by my designee or me according to criteria that include the following, as applicable: 
appropriate power and sample size, currency of literature review, and relevance of hypothesis or research question and found 
to be scientifically acceptable.   
PRINT NAME, DEGREES, TITLE OF
DEPARTMENT/DIVISION CHAIRPERSON OR DEAN: 
SIGNATURE OF DEPARTMENT/ DIVISION 
CHAIRPERSON OR DEAN: 
DATE OF 
SIGNATURE: 
*NOTE: Department/Division Chairperson cannot sign if he/she is a co-investigator on the project. In these instances, a Dean’s signature
is required.  If a designee is signing the Statement of Compliance, his/her name, degrees, and title should be listed. 
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SECTION 7:  PROJECT DETAIL 
ANSWER ALL OF THE FOLLOWING QUESTIONS (by marking the appropriate box to the right): 
1. Will DRUG(S), BIOLOGIC(S), OR DEVICE(S) be utilized for this project?
If NO, skip to Question 7. 
 YES  NO* 
2. Will DRUG(S) be administered in this project? If YES, supply the following information
(attach a separate sheet if necessary): 
 YES  NO 
DRUG NAME(S): 
2-A.  If drug is INVESTIGATIONAL or involves an IND, please complete the following: 
IND #:       HELD BY (check one):  SPONSOR  INVESTIGATOR  N/A 
   If IND is held by the SPONSOR, provide copy of the INVESTIGATOR’S BROCHURE and the SPONSOR’S PROTOCOL 
   If IND is held by the INVESTIGATOR, provide copy of the IND APPLICATION submitted to the FDA and safety information 
   Attach copy of FDA FORM 1572 
3. Will BIOLOGIC AGENTS be used in this project?  If YES, supply the following information:  YES  NO 
BIOLOGIC NAME(S): 
4. Will the VCU/VCUHS INVESTIGATIONAL DRUG SERVICE PHARMACY
(IDS) be utilized? (required for all inpatient projects)           
  N/A** 
  NO*     
*If NO, you must submit a descriptive plan regarding appropriate drug storage and dispensing for an investigational drugs or
biologic agents/drugs used in the research to the Investigational Drug Service (IDS) Pharmacy.  Guidance and the form for 
describing the management plan is located at http://www.investigationaldrugs.vcu.edu.  Submit the form to the IDS.  Upon 
IDS’s receipt of the plan, an email response containing the plan is generated.  Include the IDS confirmation or receipt with 
this submission.  For assistance, please call the Investigational Drug Pharmacy at 828-7901.        
**Submitting a plan to the IDS is not required if: 1) no drugs are used in the study, 2) the drug used in the study is FDA-
approved, considered standard of care and is a patient-charge item, 3) off-label use of such a drug is not being studied and 4) 
there is no protocol requirement for specific management of the drug.     
5. Are you evaluating MARKETED MEDICAL DEVICE(S) (including 510k devices) in this
project?  If YES, supply the following information: 
 YES  NO 
DEVICE NAME(S):   
NAME OF MANUFACTURER: 
NOTE: In addition, provide any supporting documentation regarding LEVEL OF RISK (SIGNIFICANT vs. NON-SIGNIFICANT 
RISK) 
6. Are you evaluating INVESTIGATIONAL MEDICAL DEVICE(S) or a NEW USE FOR MARKETED
MEDICAL DEVICE(S) in this project?  If YES, supply the following information: 
 YES  NO 
DEVICE NAME(S): 
NAME OF MANUFACTURER: 
IDE #:       HELD BY (check one):  SPONSOR  INVESTIGATOR  N/A 
   If IDE is held by the SPONSOR, provide a copy of the INVESTIGATOR’S BROCHURE and the SPONSOR’S PROTOCOL 
   If IDE is held by the INVESTIGATOR, provide a copy of the IDE APPLICATION submitted to the FDA 
NOTE: In addition, provide any supporting documentation regarding LEVEL OF RISK (SIGNIFICANT vs. NON-SIGNIFICANT 
risk) 
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7-A. Does this project involve the use of any procedure(s) that will expose the research subject to IONIZING 
RADIATION? 
 YES (Proceed to 7-B)  NO (Proceed to Question 8) 
7-B. If all of these procedures are for the direct clinical benefit of the research subject/patient, check YES.  If any of 
these procedures are of research interest only and will not affect the clinical management of the research subject, 
check NO. 
 YES (no further information required)  NO (Proceed to 7-C) 
7-C. RADIATION SAFETY COMMITTEE (RSC) approval is required if you answered NO to item 7-B. Do you have RSC 
approval for this project? 
 YES (Attach copy of RSC Approval Letter)  NO (Contact the Radiation Safety Section at 828-9131 for approval 
information) 
NOTE: See also http://www.vcu.edu/oehs/radiation/humanuseguide.pdf 
8-A. Does this project involve the use of RECOMBINANT DNA, BIO-HAZARDOUS SUBSTANCES including pathogenic or 
potentially pathogenic viruses and bacteria (e.g., Adenovirus, HIV, Hepatitis B), CARCINOGENS OR ACUTE 
CARCINOGENS, MUTAGENS, TERATOGENS, ACUTE TOXINS, OR SELECT AGENT MATERIALS? 
 YES (Proceed to 8-B)  NO (Proceed to Question 9) 
8-B. INSTITUTIONAL BIOSAFETY COMMITTEE (IBC) approval is required if you answered YES to this question.  Do you 
have IBC approval for this project? 
 YES (Attach copy of IBC Approval Letter)  NO (Contact CHEMICAL AND BIOLOGICAL SAFETY OFFICE 
at 828-4866 for approval information) 
NOTE: See also http://www.vcu.edu/oehs/chemical/ 
9. Does this project involve GENE THERAPY?  YES  NO 
10-A. Does this study involve cancer patients, their families, or their health care providers? 
10-B.  Is this a Cancer Prevention Study? 
 YES * 
 YES * 
 NO 
 NO 
* If YES TO 10-A OR 10-B, the research project must be reviewed and approved by the MASSEY CANCER CENTER PROTOCOL
REVIEW AND MONITORING COMMITTEE before IRB Review, and a copy of the approval letter provided. For information, see 
http://www.massey.vcu.edu/research/?pid=2013 or call the PRMC Coordinator at 628-1924. 
11. Will this project be conducted in the CLINICAL RESEARCH CENTER (CRC)?
* If YES, please review information for investigators available at http://www.vcuhealth.org/crc/
 YES *  NO 
12. Is your project: (1) involving human subject activities conducted by Navy and Marine
Corps personnel; (2) involving naval military personnel and Department of Navy (DoN) 
employees as research subjects; (3) supported by naval activities through any agreement 
(e.g., contract, grant cooperative agreement, development agreement [CRADSs], or other 
arrangement), regardless of the source of funding, funding appropriation, nature of support, 
performance site, or security classification; or (4) using DoN property, facilities or assets? 
* If YES, you must ensure that your project meets the additional Department of Defense (DoD)-
Department of the Navy (DoN) requirements for human subject protection.  Guidance on 
additional requirements can be found at [http://www.research.vcu.edu/irb/wpp/flash/XVII-12.htm] 
 YES *  NO 
13. Will this project be conducted in a VCUHS patient care area or involve VCUHS
patients? 
 YES*  NO 
*If YES, I have reviewed and agree to comply with the CONDUCT OF CLINICAL RESEARCH IN VCU HEALTH
SYSTEM PATIENT CARE AREAS policy on this page: http://www.research.vcu.edu/irb/guidance.htm. 
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14. HIPAA Regulatory Compliance
14-A. Will this study use or access protected health information (PHI)?*  YES  NO** 
*See Decision Tree 1:  Determining when HIPAA Applies to Research at http://www.research.vcu.edu/irb/hipaa-
guidance.htm 
**If no, go to Question 15 
14-B. Select all of the ways PHI will be used for this study. 
 Determine study feasibility [COMPLETE REVIEW PREPARATORY TO RESEARCH FORM] 
 Identify and recruit potential study participants from within the VCUHS system or other covered entity[COMPLETE 
APPENDIX A:  HIPAA FOR RESEARCH] 
 Collected and maintained in medical record or research records (prospective collection) [COMPLETE APPENDIX A:  
HIPAA FOR RESEARCH] 
 Collected from medical records within the VCUHS system or other covered entity (retrospective collection) 
[COMPLETE APPENDIX A:  HIPAA FOR RESEARCH] 
Access HIPAA guidance information here:  http://www.research.vcu.edu/irb/hipaa-guidance.htm 
15. Does this project involve the creation of or contribution to a Research Registry? (A
registry is an organized collection of retrievable, identifiable information (pertaining to living 
humans) that is intentionally maintained for use as a prospective instrument for the conduct of 
research.  
* If YES, you must follow guidance at http://www.research.vcu.edu/irb/wpp/flash/XVII-4.htm
and answer 15-A and 15-B. 
**If NO, skip to Question 16 
 YES*  NO** 
15-A.  Will the registry be maintained at VCU?  YES  NO 
15-B.  Does the registry include any identifiers? 
See list of 18 identifiers here:  http://www.research.vcu.edu/irb/hipaa-guidance.htm 
 YES  NO 
16. Do you plan to involve NON-VCU INSTITUTIONS (i.e., institutions [or employees or agents
of the institutions] that are not under the authority of VCU or VCU Health Systems and are 
located within the United States or a United States territory) in your research project?  
 YES *  NO 
* If YES, you must follow guidance at http://www.research.vcu.edu/irb/wpp/flash/XVII-6.htm
17. Do you plan to involve FOREIGN RESEARCH SITES (i.e., institution or non-institutional
setting)? 
 YES *  NO 
* If YES, you must follow guidance at http://www.research.vcu.edu/irb/wpp/flash/XVII-11.htm
18. Do you plan to involve INDEPENDENT INVESTIGATORS (i.e., individuals who are not
representatives of VCU or any other institution or facility) in your research project? 
 YES *  NO 
* If YES, you must follow guidance at http://www.research.vcu.edu/irb/wpp/flash/XVII-15.htm
19. Does this project involve GENETIC TESTING, that is, testing human tissue samples for
heritable characteristics or storing human tissue samples for possible future such testing? 
 YES *  NO 
* If YES, you must follow guidance at http://www.research.vcu.edu/irb/wpp/flash/XVII-5.htm
SECTION 8: RESEARCH SUBJECT INFORMATION 
VULNERABLE SUBJECTS: 
1. Do you plan to allow for the inclusion of data on subjects who are children?  YES *  NO 
* If YES, include the VCU IRB CHILDREN-SUBJECT FORM with your submission. The form is available at
http://www.research.vcu.edu/forms/vcuirb.htm 
NOTE: In Virginia, children are those under the age of 18 and not emancipated. 
2. Do you plan to allow for the inclusion of data on subjects who are PREGNANT WOMEN,
HUMAN FETUSES, or NEONATES?
 YES *  NO 
* If YES, include the VCU IRB PREGNANT WOMEN, FETUSES, NEONATES-SUBJECT FORM with your submission.  The form
is available at http://www.research.vcu.edu/forms/vcuirb.htm 
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3. Do you plan to allow for the inclusion of data on subjects who are, or may become a
PRISONER?
 YES *  NO 
* If YES, you must follow the VCU IRB PRISONER-SUBJECT GUIDANCE and include the VCU IRB PRISONER-SUBJECT
FORM with your submission.  The guidance and form are available at http://www.research.vcu.edu/forms/vcuirb.htm 
SUBJECT ENROLLMENT PLAN: 
Anticipated # OF SUBJECTS (if this is a multi-center project, list only subjects under this IRB approval): 72 
Is this a MULTI-CENTER PROJECT?  YES  NO 
If YES, please provide: 
(1) # OF SITES:       (2) # OF SUBJECTS ACROSS ALL SITES:   
CONSENT DOCUMENTATION: (Mark the type of consent process/documentation planned): 
STANDARD CONSENT FORM: A copy of the proposed consent form(s) is attached to this submission. 
CONSENT FORM FOR PRISONER SUBJECTS: A copy of the proposed consent form for prisoners is attached to this 
submission. 
WAIVER OF SOME OR ALL ELEMENTS OF CONSENT OR PARENTAL PERMISSION: NOTE: Waiver is not allowed for 
FDA-regulated research unless it meets FDA requirements for Waiver of Consent for Emergency Research (see 
below). A request is being made to waive the requirement to obtain prospective informed consent from subjects or 
permission from parents. Your research synopsis should explain why: (1) the research involves no more than minimal 
risk to the subjects, (2) the waiver or alteration will not adversely affect the rights and welfare of the subjects, (3) the 
research could not practicably be carried out without the waiver or alteration; AND (4) whether or not subjects will be 
debriefed after their participation.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XI-1.htm. 
WAIVER OF DOCUMENTATION OF CONSENT, PARENTAL PERMISSION:    
A request is being made to waive documentation of consent.  The IRB may waive this requirement if it finds either: 
(1) that the only record linking the subject and the research would be the consent document and the principal risk 
would be potential harm resulting from a breach of confidentiality. Subjects will be asked whether they want 
documentation linking them with the research, and each subject’s wishes will govern; or (2) that the research presents 
no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally 
required outside of the research context. Your research synopsis should include a justification for waiver based on one 
of these two elements and include a description of the information that will be provided to participants.  If you are 
proposing to use a verbal consent statement, the proposed consent script should be attached to this submission.  
Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XI-2.htm  
ASSENT FORM: A copy of the assent form for children or decisionally-impaired persons is attached to this 
submission.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm. and 
http://www.research.vcu.edu/irb/wpp/flash/XVII-7.htm. 
WAIVER OF ASSENT: A request is being made to waive the requirement to obtain prospective assent from children 
age 7 or higher, or decisionally-impaired persons. Your research synopsis should explain (1) why some or all of the 
individuals  age 7 or higher, or decisionally-impaired will not be capable of providing assent based on their 
developmental status or impact of illness; (2) the research holds out a prospect of direct benefit not available outside 
of the research; AND/OR (3) [a] the research involves no more than minimal risk to the subjects, [b] the waiver or 
alteration will not adversely affect the rights and welfare of the subjects, [c] the research could not practicably be 
carried out without the waiver or alteration; AND [d] whether or not subjects will be debriefed after their participation.  
Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm. 
WAIVER OF CONSENT FOR EMERGENCY RESEARCH:  Guidance is available at 
http://www.research.vcu.edu/irb/wpp/flash/XVII-16.htm. 
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SECTION 9: VCU RESEARCH PLAN 
You must use the VCU Research Plan Template that can be found at http://www.research.vcu.edu/forms/vcuirb.htm, 
Use of this template is required to provide your VCU Research Plan to the IRB. Your responses should be written in terms 
for the non-scientist to understand.  If a detailed research protocol (e.g., sponsor’s protocol) exists, you may reference that 
protocol by including the specific location (section # or small page range) within the protocol where the requested 
information can be found.   
NOTE: If that protocol does not address all of the issues outlined in each Section Heading, you must address the 
remaining issues in this Plan.  It is NOT acceptable to reference a research funding proposal.  
NOTE:  A roster of all study personnel is to be provided utilizing a VCU IRB Study Personnel Roster. Information regarding 
each study personnel is to be submitted using the VCU IRB Study Personnel Information and Change Form. These forms can 
be found at http://www.research.vcu.edu/forms/vcuirb.htm.     
SECTION 10: SUBMISSION CHECKLIST 
The following elements are reminders of steps and documentation that must be included with your submission packet. 
NOTE:  If required documents are missing and multi-page documents are not individually stapled or clipped, your 
review may be delayed. 
This checklist must be included as the last page of the IRB INITIAL REVIEW SUBMISSION FORM 
If not applicable, indicate “N/A.” 
1. VCU IRB INITIAL REVIEW SUBMISSION FORM
2. VCU RESEARCH PLAN
Required with ALL submissions and MUST follow the template and include version number or date, and page 
numbers [see SECTION 9 of this form]. Review of your protocol will be delayed if the template is not followed. 
NOTE: A research funding proposal cannot substitute for the VCU Research Plan 
3. VCU  IRB STUDY PERSONNEL INFORMATION AND CHANGE FORM
Required with ALL submissions and MUST be completed for each project personnel [see SECTION 9 of this form]. 
4. VCU IRB STUDY PERSONNEL ROSTER
Required with ALL submissions and MUST follow the template and include version number or date, and page 
numbers [see SECTION 9 of this form].  
5. MEASURES (e.g., surveys, questionnaires, instruments, appendices)
Measures MUST include title, version number or date, and page numbers 
 N/A 6. SPONSOR’S PROTOCOL 
If a sponsor’s protocol exists, it must be submitted with the VCU Research Synopsis. 
NOTE: A research funding proposal is not considered a Sponsor’s protocol 
 N/A 7. ADVERTISEMENTS/SUBJECT RECRUITMENT MATERIALS 
If approval is sought for advertisement/subject recruitment materials at this time.  Materials MUST include 
version number or date 
8. INFORMED CONSENT/ASSENT DOCUMENT(S)
Informed consent document(s) should follow a version of the VCU IRB CONSENT TEMPLATE and MUST include 
version number or date, and page numbers 
 N/A 9.  VCU IRB CHILDREN-SUBJECT FORM  
10. VCU IRB PREGNANT WOMEN, FETUSES, AND NEONATES-SUBJECT FORM
 N/A 11.  VCU IRB PRISONER-SUBJECT FORM 
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 N/A 12.  FDA FORM 1572 
If investigational drugs are involved in the research 
 N/A 13.  INVESTIGATIONAL DRUG PHARMACY PLAN
If a drug or biologic agent/drug will be used in the research and IDS will not be used, confirmation from IDS that 
a plan has been received is required with this submission [see SECTION 7(4) of this form] 
 N/A 14.  IND OR IDE APPLICATION 
If a drug or device is used in the project and IND or IDE is held by the investigator [see SECTION 7(2) or 7(6) of 
this form] 
 N/A 15.  INVESTIGATOR’S BROCHURE 
If a drug or device is used in the project and the IND or IDE is held by the sponsor [see SECTION 7(2) or 7(6) of 
this form] 
 N/A 16. DOCUMENTATION REGARDING LEVEL OF RISK (when evaluating a device) 
If an investigational medical device or a new use for marketed medical device is being evaluated [see SECTION 
7(5) or 7(6) of this form] 
 N/A 17.  RADIATION SAFETY COMMITTEE APPROVAL If required [see SECTION 7(7) of this form] 
 N/A 18.  INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW If required [see SECTION 7(8) of this form] 
 N/A 19.  MASSEY CANCER CENTER PROTOCOL REVIEW AND MONITORING SYSTEM APPROVAL 
If required, [see SECTION 7(10) of this form] 
20. CONFLICT OF INTEREST DISCLOSURE STATEMENT
This form and explanatory supplement (if applicable) is required for the PI and all others who have responsibility 
for the design, conduct, or reporting of the research. 
 N/A 21.  RESEARCH FUNDING PROPOSAL 
If required [see SECTION 5 of this form] The entire proposal (exclusive of appendices) and VCU Office of 
Sponsored Programs (OSP) Internal Approval Form must be included.   
22. PRINCIPAL INVESTIGATOR CV (not to exceed 5-6 pages) or a BIOSKETCH (2-3 pages)
If submitting a biosketch, the NIH biosketch form (398) must be used. The biosketch form is available at 
http://grants.nih.gov/grants/funding/phs398/biosketch.pdf. Additional instructions are available at 
http://grants1.nih.gov/grants/funding/phs398/phs398.html.  
23. CV OF DOCTORAL STUDENT, POSTDOCTORAL SCHOLAR, FELLOW, OR RESIDENT (not to exceed 5-6
pages) or a BIOSKETCH (2-3 pages)  
 N/A 24. MEDICALLY RESPONSIBLE INVESTIGATOR CV (not to exceed 5-6 pages) or a BIOSKETCH (2-3 pages) 
 N/A 25. REVIEW PREPARATORY TO RESEARCH FORM If required [see SECTION 7(14) of this form] 
26. APPENDIX A:  HIPAA FOR RESEARCH  If required [see SECTION 7(14) of this form]
27. OTHER:
In addition, please ensure the following: 
• All key project personnel, including the principal investigator, sub/co-investigators, project coordinators, and 
students have completed VCU REQUIRED TRAINING ON HUMAN SUBJECTS PROTECTION. The exam can be 
accessed from the following website http://www.research.vcu.edu/irb/education.htm 
• Principal Investigator, Trainee or Student (if applicable) and Department/Division Chairperson or Dean have 
SIGNED THE APPROPRIATE STATEMENTS OF COMPLIANCE [see SECTION 6 of this form] 
• The REVIEW TYPE REQUESTED [see SECTION 4 of this form] has been checked 
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NUMBER OF COPIES REQUIRED 
NOTE:  If required documents are missing, multi-page documents are not individually stapled or clipped, or the 
documents are not provided in the order noted below, your review may be delayed.  
Double-sided documents are encouraged; but it is recommended that one (original) copy of consent/assent forms and 
recruitment documents  be submitted as single sided to ensure that documents returned to the PI with an IRB approval stamp 
are legible. 
I.  If review type requested is EXPEDITED, submit (4) COLLATED SETS containing the following documents in the order 
noted.   
1) VCU IRB Initial Review Submission Form
2) VCU Research Plan
3) Appendix A:  HIPAA for Research
4) VCU IRB Study Personnel Information and Change Form(s)
5) VCU IRB Study Personnel Roster
6) Sponsor’s Protocol (if applicable)
7) Advertisements/Subject Recruitment Materials (if applicable)
8) Informed Consent/Assent Documents(s) (if applicable) (NOTE: If this is a DHHS protocol, you MUST include the
DHHS-approved consent/assent documents)
9) VCU IRB Children-Subject Form (if applicable)
10) VCU IRB Pregnant Women, Fetuses, Neonates-Subject Form (if applicable)
11) VCU IRB Prisoner-Subject Form (if applicable)
12) Confirmation of receipt of management plan from Investigational Drug Pharmacy (if applicable)
13) FDA Form 1572 (if applicable)
14) IND or IDE Application (if applicable)
15) Investigator’s Brochure (if applicable)
16) Radiation Safety Committee Approval Letter (if applicable)
17) Massey Cancer Center Protocol Review and Monitoring System Approval Letter (if applicable)
18) Conflict of Interest Disclosure Statement (s) and supplement(s) if applicable
19) Research Funding Proposal (if applicable)
20) Principal Investigator CV or Biosketch
21) CV of Doctoral Student, Postdoctoral Scholar, Fellow, or Resident (if applicable)
II. If review type requested is FULL BOARD, follow the instructions below:
A) All Full Board Initial Review submissions will undergo a pre-review process - Submit 1 COLLATED SET containing
the following documents for the pre-review process:
1) VCU IRB Initial Review Submission Form (signatures are not required for pre-review)
2) VCU Research Plan
3) Appendix A:  HIPAA for Research
4) VCU IRB Study Personnel Information and Change Form(s)
5) VCU IRB Study Personnel Roster
6) Sponsor’s Protocol (if applicable)
7) Advertisements/Subject Recruitment Materials (if applicable)
8) Informed Consent/Assent Document(s) (if applicable) (NOTE: If this is a DHHS protocol, you MUST include the
DHHS-approved consent /assent documents)
9) VCU IRB Children-Subject Form (if applicable)
10) VCU IRB Pregnant Women, Fetuses, Neonates-Subject Form (if applicable)
11) VCU IRB Prisoner-Subject Form (if applicable)
12) Conflict of Interest Disclosure Statement. Submit Conflict of Interest Disclosure Statement AND Disclosure Supplement
Form(s) IF any of the investigators answered YES to one of the questions.  Signatures are required.
13) Principal Investigator CV or Biosketch
14) FDA Form 1572 (if applicable)
15) IND or IDE Application (if applicable)
16) Investigator’s Brochure (if applicable)
17) Documentation of Level of Risk (if applicable)
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18) Radiation Safety Committee Approval Letter (if applicable)
19) Massey Cancer Center Protocol Review and Monitoring System Approval Letter (if applicable)
20) Confirmation of receipt of management plan from Investigational Drug Pharmacy (if applicable)
21) Research Funding Proposal (if applicable)
22) Medically Responsible Investigator CV or Biosketch (if applicable)
23) CV of Doctoral Student, Postdoctoral Scholar, Fellow, or Resident (if applicable)
AND 
B) Once all outstanding items are addressed through the pre-review process and you have received confirmation that
the submission is considered complete - Submit 25 COLLATED SETS containing the following documents (only 4 of the 25 
sets need to include the documents noted in items 11-22 below): 
1) VCU IRB Initial Review Submission Form (signatures are required - 25 copies)
2) VCU Research Plan (25 copies)
3) VCU IRB Study Personnel Information and Change Form(s) (25 copies)
4) VCU IRB Study Personnel Roster (25 copies)
5) Sponsor’s Protocol (if applicable – 25 copies)
6) Advertisements/Subject Recruitment Materials (if applicable – 25 copies)
7) Informed Consent/Assent Document(s) (if applicable – 25 copies) (NOTE: If this is a DHHS protocol, you MUST
include the DHHS-approved consent/assent documents)
8) VCU IRB Children-Subject Form (if applicable – 25 copies)
9) VCU IRB Pregnant Women, Fetuses, Neonates-Subject Form (if applicable – 25 copies)
10) VCU IRB Prisoner-Subject Form (if applicable – 25 copies)
11) Conflict of Interest Disclosure Statement. Submit Conflict of Interest Disclosure Statement AND Disclosure Supplement
Form(s) IF any of the investigators answered YES to one of the questions.  (signatures are required - 25 copies)
12) Principal Investigator CV or Biosketch (4 copies)
13) FDA Form 1572 (if applicable – 4 copies)
14) IND or IDE Application (if applicable – 4 copies)
15) Investigator’s Brochure (if applicable – 4 copies)
16) Documentation of Level of Risk (if applicable – 4 copies)
17) Radiation Safety Committee Approval Letter (if applicable – 4 copies)
18) Massey Cancer Center Protocol Review and Monitoring System Approval Letter (if applicable – 4 copies)
19) Confirmation of receipt of management plan from Investigational Drug Pharmacy (if applicable – 4 copies)
20) Research Funding Proposal (if applicable – 4 copies)
21) Medically Responsible Investigator CV or Biosketch (if applicable – 4 copies)
22) CV of Doctoral Student, Postdoctoral Scholar, Fellow, or Resident (if applicable – 4 copies)
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VCU RESEARCH PLAN TEMPLATE 
Use of this template is required to provide your VCU Research Plan to the IRB.  Your responses should be written in terms 
for the non-scientist to understand.  If a detailed research protocol (e.g., sponsor’s protocol) exists, you may reference 
specific sections of that protocol.  NOTE: If that protocol does not address all of the issues outlined in each Section 
Heading, you must address the remaining issues in this Plan.  It is NOT acceptable to reference a research funding 
proposal.       
ALL Sections of the Human Subjects Instructions must be completed with the exception of the Section entitled 
“Special Consent Provisions.”  Complete that Section if applicable.  When other Sections are not applicable, list the Section 
Heading and indicate “N/A.” 
NOTE: The Research Plan is required with ALL Expedited and Full review submissions and MUST follow the 
template, and include version number or date, and page numbers.   
DO NOT DELETE SECTION HEADINGS OR THE INSTRUCTIONS. 
I. TITLE   
A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) Related Skin Breakdown 
when using Different Nasal Interfaces in the Extremely Low Birth Weight (ELBW) Neonate 
II. RESEARCH PERSONNEL
A. PRINCIPAL INVESTIGATOR 
List the name of the VCU Principal Investigator 
Jacqueline M. McGrath, PhD, RN, NNP, FNAP 
B.  STUDY PERSONNEL 
NOTE:   
1. Information pertaining to each project personnel, including their role, responsibilities, and qualifications, is to
be submitted utilizing a VCU IRB Study Personnel Information and Changes Form. This form is available at
http://www.research.vcu.edu/forms/vcuirb.htm.
2. A roster of all project personnel, including the principal investigator, medically responsible investigator, and
non-VCU personnel, is to be maintained as a separate study document which is retained with the Research
Plan, and is to be updated as necessary. This template document, entitled VCU IRB Study Personnel Roster, is
available at http://www.research.vcu.edu/forms/vcuirb.htm.
C.  Describe the process that you will use to ensure that all persons assisting with the research are adequately 
informed about the protocol and their research-related duties and functions. 
NICU personnel including the bedside registered nurses and respiratory care therapist will be informed of the research 
study including study aims, recruitment and planned research protocol using both group and individual in-service format 
before the study enrollment is initiated.  The Core Research team (see VCU IRB Study Personnel Information and 
Changes Form and Personnel Roster) will be updated weekly using a written report to include number of participant’s 
recruited, current number of participants and potential study participants pending informed consents.   
III. CONFLICT OF INTEREST
Describe how the principal investigator and sub/co-investigators might benefit from the subject’s participation in this 
project or completion of the project in general. Do not describe (1) academic recognition such as publications or (2) 
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grant or contract based support of VCU salary commensurate with the professional effort required for the conduct of 
the project 
Conflict of Interest: 
There is no identified conflict of interest on the part of the Principal Investigator (PI) or the student investigator. 
IV. RESOURCES
Briefly describe the resources committed to this project including: (1) time available to conduct and complete the 
research, (2) facilities where you will conduct the research, (3) availability of medical or psychological resources that 
participants might require as a consequence of the research (if applicable), and (4) financial support. 
1) Available time:
The student investigator will maintain an on- site presence as needed for participant recruitment, consenting
and data collection.  The PI for the project is a full time VCU faculty member whose position supports ongoing 
nursing research as well as the support of mentored PhD student projects. 
2) Study Site:
The neonatal Intensive care unit at the Children’s Hospital of the King’s Daughters (CHKD) in Norfolk
Virginia will be utilized as the study site for this project.  This is a 62 bed level III NICU that serves a large 
geographic territory from Northern North Carolina to Williamsburg, Virginia.  Based on unit statistics from 
January through June, 2011 (see appendix 2) there were 58 patients admitted to the CHKD NICU who required 
nasal CPAP and who met the inclusion criteria for birth weight 500-1500 grams. The range of CPAP days based 
on these statistics show that these patients used nasal CPAP from 1-16 days for a total of over 900 CPAP days.  
The average patient’s birth weight was 833.6 grams.  This data was collected as a feasibility projection for the 
planned study sample of ELBW infants less than 1500 grams.   
3) N/A
4) N/A
V. HYPOTHESIS 
Briefly state the problem, background, importance of the research, and goals of the proposed project. 
Introduction: 
     The use of nasal CPAP has become widely accepted by health care providers who care for preterm infants in 
the treatment of respiratory distress syndrome (RDS), yet few studies have used comparative effectiveness 
research to examine the performance of various nasal interfaces within this group to determine differences in 
either the incidence or severity of nasal skin breakdown, a well described side effect of this useful treatment.  
     Following a systematic literature review of 111 articles related to the use of nasal CPAP on the preterm 
infant, only a single study was reviewed which included the study aim of comparing nasal interfaces to 
determine the frequency of skin breakdown (Rego and Martinez 2002).  This research study, conducted in Sao 
Paulo, Brazil evaluated the performance of two types of nasal prongs, Argyle and Hudson, to deliver nasal 
CPAP to preterm infants.  The conclusion of the study was the prongs were found to be equally effective in the 
delivery of CPAP, the Argyle prong was more difficult to maintain in the infant’s nares and had a higher 
incidence of nasal hyperemia, the first sign of skin breakdown when compared to the Hudson prong.  No 
comparison studies were reviewed between prongs, mask or a rotation of devices that have been described 
antidotally as a strategy to reduce pressure on nasal skin during the use of nasal CPAP (Robertson, McCarthy et 
al. 1996; McCoskey 2008; Squires and Hyndman 2009).  Additionally, there is universal agreement that nasal 
injury is a potential risk factor when using the nasal interfaces with CPAP delivery with clear directives for 
attention to skin assessment and increased nursing care and expertise which was mentioned in 44 of the 111 
reviewed articles.  
Study Goals: 
     The primary aim of this study will be to determine differences in the frequency, severity and specific types of 
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nasal injuries described when comparing different nasal CPAP interfaces (prongs/mask) used to treat respiratory 
distress syndrome. These outcome measures will be calculated based on nurses recording information included 
in the skin condition score (NSCS), a three parameter tool that evaluates skin breakdown, erythma and dryness. 
A secondary aim of the study will be to identify those risk those factors associated with nasal injury and skin 
breakdown during nasal CPAP administration. Lastly an exploratory aim will be to identify and describe nursing 
strategies that can support the reduction of nasal injuries in this vulnerable population during nasal CPAP 
administration.  Additional data will be collected during the study which will include the agitation levels of the 
infants during nasal CPAP administration and the respiratory stability of the patients as measured by blood 
gases. These measures will be used to explore other potential factors associated with nasal injury and skin 
breakdown. 
VI. SPECIFIC AIMS
For this Comparative Effectiveness Study the Hypotheses are: 
1) Is there a difference in the incidence and/or severity of skin breakdown of the ELBW preterm neonate
(less than 1500 grams) when nasal CPAP is administered using three types of nasal interfaces: 1)
continuous nasal prongs, 2) continuous nasal mask or 3) alternating the nasal mask and prongs every 4
hours?
2) Are the differences in the incidence and/or severity of skin breakdown related to other predisposing risk
factors such as gestational age, birth weight, length of therapy, environmental humidity level, amount of
CPAP flow administered and/or nursing interventions that include positioning techniques, nasal
suctioning devices and the use of nasal saline during suctioning?
3) Will the frequency and severity of nasal injury be accurately measured with the NSCS?
4) Is there a correlation between agitation scores as measured by the N-PASS and the incidence and/or
severity of nasal injury during the use of nasal CPAP in the ELBW preterm neonate?
5) Is there a correlation between blood gas results, specifically respiratory acidosis reflected in the pH, CO2
and base excess levels and the incidence of nasal injury in the ELBW preterm neonate?
VII. BACKGROUND AND SIGNIFICANCE
Include information regarding pre-clinical and early human studies.  Attach appropriate citations. 
Background and Significance: 
     The dynamic approach to respiratory care of the preterm neonate has progressed following scientific evidence 
which clearly demonstrates advantages to early nasal continuous positive airway pressure (CPAP) or early 
extubation to nasal CPAP  in this population.  It is now well understood that reduced mechanical ventilation in 
high-risk preterm infants has many advantages which includes; decreased chronic lung disease, decreased 
incidence of ventilator associated pneumonia as well as overall reduction in blood stream infections, reduction in 
the incidence of periventricular luekomalacia (PVL) previously associated with long term ventilation, improved 
neurodevelopmental outcomes and shortened hospital length of stay (De Paoli, Davis et al. 2008; Squires and 
Hyndman 2009).  These small infants however require some adjunct to maintain functional residual capacity 
(FRC) as well as improve the symptoms of respiratory distress syndrome (Buettiker, Hug et al. 2004).  Nasal 
continuous positive airway pressure (CPAP) is often used to support this need.   
     Nasal CPAP is a non invasive method for providing a constant distending pressure during both the inhalation 
and exhalation phase of respiration.  Used in the spontaneously breathing preterm infant it provides stability of 
the infant’s FRC, improves oxygenation, conserves surfactant, aids in the prevention of atelectasis, improves gas 
exchange and aids in the prevention of obstructive and central apnea (Davis, Jankov et al. 1998; Diblasi 2009; 
Squires and Hyndman 2009).  First described in 1914 in a German textbook about the diseases of the newborn, a 
system of hoses placed into a water filled receptacle, a face mask with a gas source was used on a newborn who 
had symptoms of respiratory distress to provide continuous airway pressure (Diblasi 2009). Ventilator delivered 
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CPAP first was reported in the late 1970’s and 1980’s that  were adapted from adult models (Gregory, Kitterman 
et al. 1971); then in the 90’s free standing nasal CPAP delivery systems were designed and widely adapted into 
routine practice (Verder 2007; Diblasi 2009). 
     Three major types of nasal CPAP are used in the neonatal population, traditionally classified by the technique 
used to control the gas flow to the patient (Gupta, Sinha et al. 2009).  These include constant flow or bubble 
CPAP, variable flow which are devices that have fluidic control to maintain the CPAP pressure and finally 
ventilator delivered CPAP generally delivered through an endotracheal tube (ETT) or a long single nasal 
pharyngeal tube.  All devices share in four components, 1) a heated/humidified blended gas source, 2) a nasal 
interface, 3) a patient circuit and 4) a pressure-generating apparatus (Diblasi 2009).   
     Risks attributed to the use of nasal CPAP in this population have also been described.  These include 
abdominal distension, inability to provide enteral nutrition secondary to gut disturbance, slightly increased 
incidence of necrotizing enterocolitis (NEC), pneumothorax and nasal injury or nasal mucosal damage (Verder 
2007; Squires and Hyndman 2009)  The current CPAP devices are effective in maintaining needed positive end 
expiratory pressure (PEEP) but also place constant pressure on the nares, nasal septum and forehead leading to 
decreased skin integrity and injury (De Paoli, Davis et al. 2008).  Research is needed to 1) compare nasal CPAP 
interfaces commonly used to determine differences in frequency and severity of skin break down and 2) to 
identify strategies to reduce skin breakdown during nasal CPAP use in extremely low birth weight (ELBW) 
infants.   
          The overall clinical management of preterm infants whose respiratory status is supported through the use 
of nasal CPAP is based on anecdotal experience and unit standards rather than on scientific evidence.  Nursing 
skill level and experience with positioning, frequent assessment and intervention, all of which takes significant 
nursing time has been well described by nearly half of the 111 reviewed articles.  Practices vary widely from 
unit to unit making standardization of nursing care to protect vulnerable preterm infant skin during this therapy 
difficult.   
     We clearly understand the advantages of using nasal CPAP in this population which outweighs the observed 
risk to this therapy.  We must now examine the different delivery methods and nasal interface devices while 
providing non-invasive nasal CPAP to preterm infants to best manage the preterm infant’s respiratory distress 
syndrome using scientific evidence to create and test best clinical practices.  In a meta analysis completed on the 
devices and pressure sources for the administration of nasal CPAP,  implications for further research included 
determining which nasal interface device is the least traumatic to the infant nose, particularly the very low birth 
weight infant (De Paoli, Davis et al. 2008).  Additionally, a systematic review of non-invasive ventilation 
strategies described nasal prongs and newer nasal masks for use in the neonate.  The masks were described to 
require less pressure to remain in place but “will need empiric testing to determine safety in this population” 
(Courtney and Barrington 2007). 
     Empiric evidence based on current scientific literature is needed to support nursing interventions to reduce 
iatrogenic skin injury of the nose, face and head during nasal CPAP administration to provide improved long 
term outcomes. Specific attention to those details of nursing care to this patient population to addresses 
strategies for optimal outcomes are clearly needed. 
VIII. PRELIMINARY PROGRESS/DATA REPORT
If available. 
N/A 
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IX. RESEARCH METHOD AND DESIGN
Include a brief description of the project design including the setting in which the research will be conducted and 
procedures.  If applicable, include a description of procedures being performed already for diagnostic or treatment 
purposes. 
Research Method and Design: 
     A three group prospective randomized experimental study design is currently planned. This would include 
recruitment into the study following admission to the neonatal intensive care unit (NICU) when infants are 
typically intubated during the mechanical ventilation phase of treatment. Upon extubation to nasal CPAP (the 
typical care for these infants) the participants would be randomized into three groups to include, 1) a continuous 
nasal prong group,  2) a continuous nasal mask group or 3) an alternating mask/prongs every 4 hours group. All 
infants will be managed with the same type of nasal CPAP delivery system.  Infants transported from the 
delivery room or outlying hospital that are initially treated with nasal CPAP would be considered for enrollment 
if consent was obtained and randomization could occur within 8hours.       
     Following parental consent, infants would be clearly identified by a star placed at the infant’s bedside to 
remind caregivers to enroll participants as the medical condition of the patient was appropriate for transition 
from current therapy to nasal CPAP following physician or neonatal nurse practitioner (NNP) order to extubate 
the patient.  Infants who meet study inclusion criteria and who have been consented and self extubate will also 
be randomized for nasal CPAP trial if medically appropriate as dictated by physician or nurse practitioner order.  
No infants will be placed on nasal CPAP unless medically warranted; therefore patients who are extubated to 
high flow or regular nasal cannula will be excluded unless nasal CPAP is used in those patients at a later time as 
medically indicated.  
     Following parental consent the infants recruited for the study will be block stratified according to weight into 
four categories according to birth weight: < 750 grams, 750-1000 grams, 1001-1250 grams and > 1251-1500 
grams. Known differences in the skin integrity have been demonstrated with the lowest birth weights proven the 
most vulnerable. Stratification according to infant’s birth weight will keep the groups more homogeneous as it is 
expected that the smallest group will have the least patients.  After stratified the subjects will be randomly 
allocated into the three groups, 1) a continuous nasal prong group, 2) a continuous nasal mask group or 3) an 
alternating mask/prongs every 4 hours group.   Randomization will accomplished using serially numbered 
opaque sealed envelopes developed by the researcher which will be located close to the storage area which 
houses the CPAP equipment within the NICU. 
     A flow diagram (algorithm) will be placed beside the aforementioned sealed envelopes to provide a quick 
reference to the respiratory team collecting the necessary equipment for the infants ordered transition to nasal 
CPAP (see appendix 1). This diagram will visually describe the information required (birth weight) in order for 
the respiratory therapist to determine from which group of envelops they should select from which will 
determine group assignment.  This diagram will be located on the respiratory care clipboard, not visible to 
patient’s families or visitors. The equipment would then be collected by the respiratory staff to place the infant 
on nasal CPAP with continuous nasal prongs, continuous nasal mask or alternating each device every four hours 
based on randomization. 
     Routine skin assessments will be completed every 3-4 hours which is consistent with current care practice.  
This skin assessment is primarily a nursing responsibility but collaboration between the bedside nurse and 
respiratory therapist will be encouraged. A small group of skin experts, described as the Core Research Team, 
which includes seven senior staff RN’s and advance practice nurses will be responsible for twice a day skin care 
evaluations on enrolled participants.  These skin evaluations will be scheduled during the infant’s routine 
nursing care.  This will be accomplished through communication with the bedside nursing staff to coordinate 
assessment times in an effort to protect the infant’s quiet environment. 
 
X.  PLAN FOR CONTROL OF INVESTIGATIONAL DRUGS,  BIOLOGICS, AND DEVICES.  
Investigational drugs and biologics:  IF Investigational Drug Pharmacy Service (IDS) is not being used, attach the IDS 
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confirmation of receipt of the management plan.  
Investigational and humanitarian use devices (HUDs): Describe your plans for the control of investigational devices 
and HUDs including:  
(1) how you will maintain records of the product’s delivery to the trial site, the inventory at the site, the use by each 
subject, and the return to the sponsor or alternative disposition of unused product(s);  
(2) plan for storing the investigational product(s)/ HUD as specified by the sponsor (if any) and in accordance with 
applicable regulatory requirements;  
(3) plan for ensuring that the investigational product(s)/HUDs are used only in accordance with the approved 
protocol; and  
(4) how you will ensure that each subject understands the correct use of the investigational product(s)/HUDs (if 
applicable) and check that each subject is following the instructions properly (on an ongoing basis). 
N/A 
XI. DATA ANALYSIS PLAN
For investigator–initiated studies. 
Data Analysis Plan 
    Demographic information from each participant will be collected for descriptive purposes and the means of 
each group will be compared using a one way analysis of variance (ANOVA) to identify group differences.  
Data analysis will be performed at both the individual and group levels for descriptive and comparison purposes. 
Specific intended study analysis will be discussed according to study aim: 
1) The primary aim of this study will be to determine differences in the frequency, severity and specific types
of nasal injuries described when comparing different nasal CPAP interfaces (prongs, mask or alternating 
prong/mask) used to treat respiratory distress syndrome. Analysis will be conducted using the previously 
described NSCS scores every 10-12 hours with an incidence of skin breakdown classified as mild, moderate or 
severe.  Incidence of breakdown per group will be calculated for all three groups and one-way ANOVA will be 
used to analyze continuous variables.  The frequency of nasal breakdown per group will be determined by the 
number of cased of nasal breakdown divided by the total number within the group. 
2) A secondary aim of the study will be to identify those risk those factors associated with nasal injury and skin
breakdown during nasal CPAP administration. This descriptive analysis will examine those factors such as 
gestational age, birth weight, nutritional support, liter per minute of CPAP flow, length of CPAP therapy, 
environmental humidity and nursing factors such as infant positioning, suctioning practices and suctioning 
frequency in each group.  Inferential statistics will be used to examine individual factors using ANOVA for 
continuous variables and logistic regression for dichotomous variables.  
3) Will the frequency and severity of nasal injury be accurately measured with the NSCS?  The Core research
team will be scoring the NSCS every 10-12 hours who have expertise in use and scoring guidelines of the tool 
(see Appendix 4 and 5). At least 10% of the study sample will be tested by multiple core researchers to provide 
inter rater reliability data. This data will be collected weekly (see Appendix 6).Analysis will be on both tool and 
interrater reliability using Cohen's Kappa and chronbach’s alpha.   
4) Is there a correlation between agitation scores as measured by the N-PASS and the incidence and/or severity
of nasal injury during the use of nasal CPAP in the ELBW preterm neonate? The Neonatal Pain, Agitation and 
Sedation Scale  (N-Pass) was developed as a clinically relevant tool to assess primarily acute or chronic pain as 
well as sedation level in preterm infants who are not capable of self report (Hummel, Puchalski et al. 2008).  
This scale (see appendix 7) has been well validated in the preterm population and is currently used as a measure 
of agitation at the proposed research site; therefore information will be extrapolated from the medical record. 
5) Is there a correlation between respiratory acidosis as defined by blood gas results and the incidence of nasal
injury in the ELBW preterm neonate? The presence of respiratory acidosis will be defined as pH < 7.25 with 
CO2 reading >55 in the preterm population and when these conditions are present the participant will be 
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classified as respiratory acidosis.  Cases which have been identified as breakdown present will be filtered for 
inclusion for analysis.  ANOVA will be completed to establish correlation between groups 1, 2 or 3 with 
identified breakdown and the presence of respiratory acidosis.  
XII. DATA AND SAFETY MONITORING
• If the research involves greater than minimal risk and there is no provision made for data and safety monitoring
by any sponsor, include a data and safety-monitoring plan that is suitable for the level of risk to be faced by
subjects and the nature of the research involved.
• If the research involves greater than minimal risk, and there is a provision made for data and safety monitoring
by any sponsor, describe the sponsor’s plan.
• If you are serving as a Sponsor-Investigator, identify the Contract Research Organization (CRO) that you will be
using and describe the provisions made for data and safety monitoring by the CRO.  Guidance on additional
requirements for Sponsor-Investigators is available at http://www.research.vcu.edu/irb/wpp/flash/X-2.htm
No greater than minimal risk without current provision for data and safety monitoring. 
XIII. MULTI-CENTER STUDIES
If VCU is the lead site in a multi-center project or the VCU PI is the lead investigator in a multi-center project, 
describe the plan for management of information that may be relevant to the protection of subjects, such as reporting 
of unexpected problems, project modifications, and interim results. 
N/A 
XIV. INVOLVEMENT OF NON-VCU INSTITUTIONS/SITES (DOMESTIC AND FOREIGN)
1. Provide the following information for each non-VCU institution/site (domestic and foreign) that has agreed to
participate:
• Name of institution/site
• Contact information for institution/site
• Engaged in Research or not (if YES AND the research involves a DIRECT FEDERAL AWARD made to
VCU, include FWA #).  See OHRP’s guidance on “Engagement of Institutions in Research” at
http://www.hhs.gov/ohrp/policy/engage08.html.
• Request for the VCU IRB to review on behalf of the Non-VCU institution? See requirements found at
http://www.research.vcu.edu/irb/wpp/flash/XVII-6.htm.
• See VCU WPPs:
http://www.research.vcu.edu/irb/wpp/flash/XVII-6.htm and 
http://www.research.vcu.edu/irb/wpp/flash/XVII-11.htm. 
Name of Institution Contact Information for 
Site 
Engaged (Y/N)  
and  
FWA # if applicable 
Request for VCU IRB to 
review on behalf of the 
non-VCU institution 
(Y/N)* 
Children’s Hospital of the 
King’s Daughters, Norfolk, 
Virginia  
Katherine Newnam  PhD 
(c), RN, NNP-BC at (757) 
668-7452 (NICU) or (757) 
567-5334 (cell number) 
Engages--Yes 
FWA—N/A 
No-IRB application will be 
submitted to the Eastern 
Virginia Medical School. 
*NOTE:  If a Non-VCU site is engaged in the research, the site is obligated to obtain IRB review or request that the VCU
IRB review on its behalf. 
2. Provide a description of each institution’s role (whether engaged or not) in the research, adequacy of the facility
(in order to ensure participant safety in the case of an unanticipated emergency), responsibilities of its 
agents/employees, and oversight that you will be providing in order to ensure adequate and ongoing protection of the 
Version: 11.20.11 
Page 7 of 15  91
Rev. Date: 6-1-11 
IRB USE - Do Not Delete 
human subjects.  You should only identify institutions that have agreed to participate.  If additional institutions agree 
to participate at a later time, they must be added by amendment to the protocol.   
The primary site for the proposed research study is a large Neonatal Intensive Care Unit located within a teaching hospital, 
The Children’s Hospital of the Kings Daughters.   
XV. HUMAN SUBJECTS INSTRUCTIONS
ALL sections of the Human Subjects Instructions must be completed with the exception of the section entitled 
“Special Consent Provisions.”  Complete that section if applicable. 
A.  DESCRIPTION 
Provide a detailed description of the proposed involvement of human subjects or their private identifiable data. 
Privacy of Participants: 
     The privacy of the participants will be supported through the use of participant identifier as described in 
section “Confidentiality of Data”.  The group that each patient is randomized which dictates the type of nasal 
interface utilized to deliver nasal CPAP will be recorded as part of the health care record which is standard care 
for patients receiving nasal CPAP.  All research records with all patient identifiers removed will be removed 
from the patient’s bedside daily and placed into a secure location on the unit for later analysis. 
Confidentiality of Data: 
     All information will be de-identified by assignment of research assigned patient number which will be used 
on all study records. The process of assignment will start with the number (N) 001 through (N) 024 for the first 
patient in the continuous nasal prong group; (M) 101 through (M) 123 for the continuous nasal mask group, and 
(R) 201 through (R) 224 for the rotation group.  This patient identifier will be recorded on all maintained study 
records. The consent which will contain patient names and medical record number will be related to assigned 
patient identifier as described above using a key which will be available to the PI and student investigator only.  
This information will be kept under lock and key in the Virginia Commonwealth University School of Nursing 
and will be destroyed following the data analysis phase of the research project. De-identified data will be 
maintained for an undetermined length of time. 
 
B.  SUBJECT POPULATION 
Describe the subject population in terms of sex, race, ethnicity, age, etc., and your access to the population that will 
allow recruitment of the necessary number of participants.  Identify the criteria for inclusion or exclusion of all 
targeted populations and include a justification for any exclusion.  Explain the rationale for the involvement of special 
cases of subjects, such as children, pregnant women, human fetuses, neonates, prisoners or others who are likely to be 
vulnerable.  If you plan to allow for the enrollment of Wards of the State (or any other agency, institution, or entity), 
you must specifically request their inclusion and follow guidance in VCU IRB WPP XV-3: Wards and Emancipated 
Minors available at http://www.research.vcu.edu/irb/wpp/flash/XV-3.htm.  
Human Subjects: 
Inclusion criteria:  Infants who are initially treated with or weaned from mechanical ventilation to nasal 
CPAP and who are birth weight 500 grams to 1500 grams.  Infants with a birth weight under 500 grams 
will not be considered based on documented overall concerns with skin integrity in this group (Sardesai, 
Kornacka et al. 2011) which could influence study results. 
Exclusion criteria:  Infants who have been diagnosed with major cardiac disease or congenital 
malformation which could impair the nasal CPAP performance would be excluded.  Patients who are not 
consented within 8 hours of nasal CPAP initiation or who had nasal skin breakdown at enrollment would 
be excluded and patients outside of the weight inclusion would not be included.   
Mothers less than 18 years of age:  Mothers who are under the age of 18 that have infants that meet 
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inclusion criteria for this research project will be excluded secondary to informed consent limitations. 
Recruitment Plan: 
      Parents or guardians of those patients who are admitted to the NICU and who meet the study inclusion 
criteria will be approached by a member of the Core Research Team following admission to the unit. All 
members of this Research Team are employed as staff within the study site. The research study will be explained 
to each family providing adequate time to answer questions related to the proposed research plan. Those parents 
who are unable to visit the NICU because of geographic or other barriers will be contacted by phone to explain 
the research study and invite participation. 
     A power analysis using a significance level of p < 0.05 was performed (see appendix 8) to meet the described 
primary aim of the study which was to determine differences in the frequency, severity and specific types of 
nasal injuries described when comparing different nasal CPAP interfaces (prongs/mask) used to treat respiratory 
distress syndrome in the preterm infant less than 1500 grams.  The analysis was focused on the frequency 
parameter of this aim and a total sample size of 72 with 24 in each of the three groups (continuous nasal prongs, 
continuous nasal mask or alternating nasal mask and prongs every 4 hours) was adequate to determine 
significant differences between groups. 
C.  RESEARCH MATERIAL 
Identify the sources of research material obtained from individually identifiable living human subjects in the form of 
specimens, records, or data.  Indicate whether the material or data will be obtained specifically for research purposes 
or whether use will be made of existing specimens, records, or data. 
1) Data Collection Form; Enrollment/Daily and Weekly (Appendix 4/5 and 6) which will include the following
information which is extrapolated from the medical record.  Each of these items were shown through the 
literature review to be factors related to skin breakdown in the preterm infant during nasal CPAP use. 
a) Patient’s birth weight
b) Patient’s current weight
c) Patient’s gestational age at birth
d) Patients current age
e) Length of CPAP use
f) CPAP flow rate
g) Amount of FIO2 required
h) Incubator humidity
i) Type of nasal interface
j) Suctioning  requirements
k) Saline use during suctioning
l) Bleeding with suctioning
m) Blood gas results
n) Skin injury location
o) Skin injury reported to the medical team
p) Intervention provided for skin injury
q) Additional clinical issues/concerns
r) Care strategies per standard of care complied with (pectin barrier, developmental position and CPAP hat
  placement) 
2) Neonatal Skin Condition Scale (NSCS) which will be collected by the Core Research team every 10-12 hours
in coordination with routine infant care/assessment performed every 3-4 hours (see Appendix 3).  This 
information will be collected for research purposes. 
3) Neonatal Pain, Agitation and Sedation Scale (N-PASS) is a scale (see appendix 7) has been well validated in
the preterm population and is currently used as a measure of agitation at the proposed research site; therefore 
information will be extrapolated from the medical record. 
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D.  RECRUITMENT PLAN 
Describe in detail your plans for the recruitment of subjects including:  
(1) how potential subjects will be identified (e.g., school personnel, health care professionals, etc),  
(2) how you will get the names and contact information for potential subjects, and  
(3) who will make initial contact with these individuals (if relevant) and how that contact will be done.   
If you plan to involve special cases of subjects, such as children, pregnant women, human fetuses, neonates, prisoners 
or others who are likely to be vulnerable, describe any special recruitment procedures for these populations. 
Recruitment Plan: 
1) Subjects will be identified based on current respiratory management (mechanical ventilation or nasal CPAP)
and birth weight 500-1500 grams.  
2) Parents or guardians of those patients who are admitted to the NICU and who meet the study inclusion
criteria will be approached following admission to the unit. The research study will be explained to each family 
providing adequate time to answer questions related to the proposed research plan. Those parents who are unable 
to visit the NICU because of geographic or other barriers will be contacted by phone to explain the research 
study and invite participation. 
3) The initial contact with the parent will be made by the Core Research Team if the neonate meets inclusion criteria.
E.  PRIVACY OF PARTICIPANTS  
NOTE:  Privacy refers to individuals and their interests in controlling access to their identities, their physical person, 
and how and what kind of information is obtained about them. Privacy also encompasses the interests of defined 
communities (e.g. those with a certain diagnosis or social circumstance) in controlling access to the group identity and 
information about the group or individuals as part of the group. 
Describe how the privacy interests of subjects (and communities, if appropriate) will be protected including: 
 (1) in the research setting (e.g., in the identification, recruitment, and intervention settings) and  
(2) with the information being sought and the way it is sought.  For example, providing drapes or barriers, 
interviewing in a private room, and collecting only the amount of sensitive information needed for identification, 
recruitment, or the conduct of the study.   
Privacy of Participants: 
     The privacy of the participants will be supported through the use of participant identifier as described in section 
“Confidentiality of Data”.  The group that each patient is randomized which dictates the type of nasal interface 
utilized to deliver nasal CPAP will be recorded as part of the health care record which is standard care for patients 
receiving nasal CPAP.  All research records with all patient identifiers removed will be removed from the patient’s 
bedside daily and placed into a secure location on the unit for later analysis. 
Confidentiality of Data: 
     All information will be de-identified by assignment of research assigned patient number which will be used on 
all study records. The process of assignment will start with the number (N) 001 through (N) 024 for the first patient 
in the continuous nasal prong group; (M) 101 through (M) 123 for the continuous nasal mask group, and (R) 201 
through (R) 224 for the rotation group.  This patient identifier will be recorded on all maintained study records. 
The consent which will contain patient names and medical record number will be related to assigned patient 
identifier as described above using a key which will be available to the PI and student investigator only.  This 
information will be kept under lock and key in the Virginia Commonwealth University School of Nursing and will 
be destroyed following the data analysis phase of the research project. De-identified data will be maintained for an 
undetermined length of time. 
F.  CONFIDENTIALITY OF DATA 
NOTE:  Confidentiality refers to the way private, identifiable information about a subject or defined community is 
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maintained and shared. 
Check all of the following precautions that will be used to maintain the confidentiality of identifiable information: 
X Paper-based records will be kept in secure location and only accessed by authorized study personnel 
X Electronic records will be made available only to those personnel in the study through the use of access controls and 
encryption 
X  Identifiers will be removed from study-related data (data is coded with a key stored in a separate secure location) 
 For research involving web-based surveys, data is secured via passwords and encryption 
 Audio or video recordings of subjects will be transcribed and then destroyed to prevent audio or visual identification.  
Note the date of destruction (e.g., 3 months from close of study; after transcription is determined to be error free).  
 Obtaining a Certificate of Confidentiality 
 Other precautions:       
G.  POTENTIAL RISKS 
Describe potential risks (physical, psychological, social, legal, or other) and assess their likelihood and seriousness.  
Where appropriate, describe alternative treatments and procedures that might be advantageous to the subjects. 
Potential Risks: 
    There are no anticipated risks or discomforts associated with participation in this research study.   Individual 
risk to individual patients are considered minimal and consistent with the risk experienced with current standard 
nasal CPAP care for the identified population within the NICU. 
H.  RISK REDUCTION 
Describe procedures for protecting against or minimizing potential risk.  Where appropriate, discuss provisions for 
ensuring necessary medical or professional intervention in the event of adverse events to the subjects.  Describe the 
provisions for monitoring the data collected to ensure the safety of subjects, if any. 
Risk Reduction: 
     Frequent patient skin assessment (at least every 4 hours) by the bedside registered nurse and/or respiratory 
care therapist is required by both unit and research protocol.  Signs of hyperemia, erythma or excoriation will be 
reported to the health care team and treatment ordered as necessary which is consistent with current medical 
care.  Intolerance to nasal CPAP treatment will be addressed in the usual manner with increased medical care to 
include escalating respiratory support up to and including endotrachael intubation. All three described nasal 
interfaces are currently in use within the NICU research setting.  No changes in the standard unit care are 
anticipated based on the use of the type of nasal interface during the administration of nasal CPAP in the preterm 
infant.  
I.  ADDITIONAL SAFEGUARDS FOR VULNERABLE PARTICIPANTS  
Describe any additional safeguards to protect the rights and welfare of participants if you plan to involve special cases 
of subjects such as children, pregnant women, human fetuses, neonates, prisoners or others who are likely to be 
vulnerable.   
Safeguards to protect the rights and welfare of participants might relate to Inclusion/Exclusion Criteria: (“Adults 
with moderate to severe cognitive impairment will be excluded.”  “Children must have diabetes.  No normal controls 
who are children will be used.”)  Consent: (“Participants must have an adult care giver who agrees to the participant 
taking part in the research and will make sure the participant complies with research procedures.”  “Adults must be 
able to assent.  Any dissent by the participant will end the research procedures.”)  Benefit: (“Individuals who have not 
shown benefit to this type of drug in the past will be excluded.”).   
Neonates who meet inclusion criteria will be considered eligible for the research study if the adult care giver 
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(parent) agrees to the participant taking part in the study which consist of the neonate being randomized into a 
specific nasal interface group and data collection from pertinent items from the medical record as well as serial 
skin assessments during the nasal CPAP use.  Clear discussion with the adult care giver regarding the consent 
not pertaining to the use of nasal CPAP with nasal prongs, nasal masks and alternating devices as this is standard 
of care within the NICU as part of respiratory management of the preterm infant. 
J.  RISK/BENEFIT 
Discuss why the risks to participants are reasonable in relation to the anticipated benefits to subjects and in relation 
to the importance of the knowledge that may reasonably be expected to result.  If a test article (investigational new 
drug, device, or biologic) is involved, name the test article and supply the FDA approval letter. 
Risk/Benefit: 
     There are no direct benefits to the study participants at present; however, changes in how nasal CPAP is 
administered to this patient population may provide benefits in future neonatal care. 
K. COMPENSATION PLAN 
Compensation for participants (if applicable) should be described, including possible total compensation, pro-rating, 
any proposed bonus, and any proposed reductions or penalties for not completing the project. 
Compensation Plan for Study Participants: 
     No compensation is planned for study participants or their families. 
L.  CONSENT ISSUES 
1. CONSENT PROCESS
Indicate who will be asked to provide consent/assent, who will obtain consent/assent, what language (e.g., English, 
Spanish) will be used by those obtaining consent/assent, where and when will consent/assent be obtained, what steps 
will be taken to minimize the possibility of coercion or undue influence, and how much time will subjects be afforded 
to make a decision to participate. 
Consent Process: 
     Informed consent will be obtained by the researcher or his/her designees (identified as the Core Research 
Team) which are advanced practice nurses or physicians experienced in obtaining informed consent. Each parent 
or guardian of the qualifying patients will be asked to sign a consent form which will describe the study aim, the 
study design and various steps to be employed during the study (see appendix 4). Parents of the participants will 
be encouraged to discuss any items or words that are unclear or that they do not understand during the consent 
process. The parents of the participants will be provided a copy of the signed consent with contact information 
including the primary investigator (PI) as well as student researcher.  The Internal Review Board (IRB) contact 
information will be included for parental questions not answered by the PI or research team.  Languages other 
than English will be translated using the translation language line currently used as the standard method in 
which to communicate with Non-English speaking parents of NICU patients.  This method will provide a full 
reading of the consent in the parent’s native language with the ability to answer questions, raise and concerns 
regarding the study. 
2. SPECIAL CONSENT PROVISIONS
If some or all subjects will be cognitively impaired, or have language/hearing difficulties, describe how capacity for 
consent will be determined. Consider using the VCU Informed Consent Evaluation Instrument available at 
http://www.research.vcu.edu/irb/guidance.htm.  If you anticipate the need to obtain informed consent from legally 
authorized representatives (LARs), please describe how you will identify an appropriate representative and ensure 
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that their consent is obtained.  Guidance on LAR is available at http://www.research.vcu.edu/irb/wpp/flash/XI-3.htm. 
N/A 
3. ASSENT PROCESS
If applicable, explain the Assent Process for children or decisionally impaired subjects.  Describe the procedures, if 
any, for re-consenting children upon attainment of adulthood. Describe procedures, if any, for consenting subjects 
who are no longer decisionally impaired.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XV-
2.htm and http://www.research.vcu.edu/irb/wpp/flash/XVII-7.htm.
N/A 
4. REQUESTS FOR WAIVERS OF CONSENT  (COMPLETE IF REQUESTING ANY TYPE OF WAIVER OF CONSENT OR ASSENT)
Not requesting waiver of consent 
4-A.  REQUEST TO WAIVE SOME OR ALL ELEMENTS OF INFORMED CONSENT FROM SUBJECTS OR PERMISSION FROM 
PARENTS: A waiver of informed consent means that the IRB is not requiring the investigator to obtain informed consent OR 
the IRB approves a consent form that does not include or alters some/all of the required elements of consent.  Guidance is 
available at http://www.research.vcu.edu/irb/wpp/flash/XI-1.htm.  NOTE: Waiver is not allowed for FDA-regulated 
research unless it meets FDA requirements for Waiver of Consent for Emergency Research (see below). 
4-A.1.  Explain why a waiver or alteration of informed consent is being requested. 
4-A.2.  Describe how this study meets ALL FOUR of the following conditions for a waiver or alteration: 
• The research involves no more than minimal risk to the participants.  Explain how your study meets this
criteria:  
• The waiver or alteration will not adversely affect the rights and welfare of participants.  Explain how your
study meets this criteria:
• The research could not practicably be carried out without the waiver or alteration.  Explain how your study
meets this criteria:
• Will participants be provided with additional pertinent information after participation?
  Yes  
  No  Explain why not: 
4-B.  REQUEST TO WAIVE DOCUMENTATION OF CONSENT:  A waiver of documentation occurs when the consent process 
occurs but participants are not required to sign the consent form.  Guidance is available at 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XI-2.htm.  One of the following two conditions must be 
met to allow for consenting without signed documentation. Choose which condition is applicable and explain why 
(explanation required): 
 The only record linking the participant and the research would be the informed consent form. The principal risk to the 
participant is the potential harm resulting from a breach of confidentiality. Each participant will be asked whether he/she 
wants documentation linking the participant with the research and the participants wishes will govern.  Explain how 
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your study fits into the category:  
 The research presents no more than minimal risk of harm to participants & involves no procedures for which signed 
consent is normally required outside of the research context.  Explain how your study fits into the category:     
4-C.  REQUEST TO WAIVE SOME OR ALL ELEMENTS OF ASSENT FROM CHILDREN ≥ AGE 7 OR FROM DECISIONALLY 
IMPAIRED INDIVIDUALS: A waiver of assent means that the IRB is not requiring the investigator to obtain assent OR 
the IRB approves an assent form that does not include some/all of the required elements.  Guidance is available at 
http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm.   
4-C.1.  Explain why a waiver or alteration of informed consent is being requested. 
In order for the IRB to approve a request for waiver of assent, the conditions for 4-C.2, 4-C.3, OR 4-C.4 must be met. 
Check which ONE applies and explain all required justifications. 
4-C.2.  Some or all of the individual’s age 7 or higher will not be capable of providing assent based on their 
developmental status or impact of illness.   Explain how your study meets this criteria:  
4-C.3.   The research holds out a prospect of direct benefit not available outside of the research.   Explain how 
your study meets this criteria:  
4-C.4.   Describe how this study meets ALL FOUR of the following conditions: 
• The research involves no more than minimal risk to the participants.  Explain how your study meets this
criteria:  
• The waiver or alteration will not adversely affect the rights and welfare of participants.  Explain how your
study meets this criteria:  
• The research could not practicably be carried out without the waiver or alteration.  Explain how your study
meets this criteria:  
• Will participants be provided with additional pertinent information after participation?
  Yes  
  No  Explain why not: 
4-D.  REQUEST TO WAIVE CONSENT FOR EMERGENCY RESEARCH:  Describe how the study meets the criteria for 
emergency research and the process for obtaining LAR consent is appropriate.  See guidance at 
http://www.research.vcu.edu/irb/wpp/flash/XVII-16.htm. 
N/A 
5. GENETIC TESTING
If applicable, address the following issues related to Genetic Testing.
5-A. FUTURE CONTACT CONCERNING FURTHER GENETIC TESTING RESEARCH 
Describe the circumstances under which the subject might be contacted in the future concerning further participation 
in this or related genetic testing research. 
N/A 
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5-B. FUTURE CONTACT CONCERNING GENETIC TESTING RESULTS 
If planned or possible future genetic testing results are unlikely to have clinical implications, then a statement that the 
results will not be made available to subjects may be appropriate. If results might be of clinical significance, then 
describe the circumstances and procedures by which subjects would receive results. Describe how subjects might 
access genetic counseling for assistance in understanding the implications of genetic testing results, and whether this 
might involve costs to subjects. Investigators should be aware that federal regulations, in general, require that testing 
results used in clinical management must have been obtained in a CLIA-certified laboratory. 
N/A 
5-C. WITHDRAWAL OF GENETIC TESTING CONSENT 
Describe whether and how subjects might, in the future, request to have test results and/or samples withdrawn in 
order to prevent further analysis, reporting, and/or testing. 
N/A 
5-D. GENETIC TESTING INVOLVING CHILDREN OR DECISIONALLY IMPAIRED PARTICIPANTS 
Describe procedures, if any, for consenting children upon the attainment of adulthood. Describe procedures, if any, 
for consenting participants who are no longer decisionally impaired. 
N/A 
5-E. CONFIDENTIALITY OF GENETIC INFORMATION 
Describe the extent to which genetic testing results will remain confidential and special precautions, if any, to protect 
confidentiality. 
N/A 
Version: 11.20.11 
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VCU IRB STUDY PERSONNEL ROSTER 
(for Expedited and Full Board Research) 
PRINCIPAL INVESTIGATOR: Jacqueline M. McGrath, PhD, RN, 
NNP, FNAP 
VCU EMAIL: mcgrathjm@vcu.edu 
RESEARCH COORDINATOR: VCU EMAIL: 
VCU IRB #: 
TITLE OF PROJECT:  A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) Related 
Skin Breakdown when using Different Nasal Interfaces in the Extremely Low Birth Weight 
(ELBW) Neonate 
General Instructions – List all project personnel*, including Principal Investigator, individuals from other institutions, and independent investigators. (Add rows as 
necessary). This roster is to be kept current throughout the approval period with the IRB, and is to be retained within the investigator’s study documentation. This 
roster is intended to serve as an ongoing list of all personnel who  are currently engaged in the project, as well as those who have been, but are no longer, involved. 
Individual Personnel Information and Change Forms are also required for each project personnel.  
Submission Instructions - See Submission Instructions on next page 
*Project Personnel includes anyone ‘engaged’ in the research (VCU & non-VCU personnel), including independent investigators. Engaged means interacting or
intervening with research participants and/or having access to identifiable private information about participants. See OHRP’s guidance on “Engagement of
Institutions in Research” at http://www.hhs.gov/ohrp/humansubjects/guidance/engage08/html.
STUDY PERSONNEL ROSTER 
FIRST NAME LAST NAME ROLE IN STUDY -  (entry should match information on Study Personnel Information and Change Form)
DATE ADDITION 
PROPOSED TO
IRB: 
DATE REMOVAL
PROPOSED TO
IRB: 
1) Jacqueline McGrath Principal Investigator If Other, list: 11/21/11 
2) Katherine Newnam Student If Other, list: 11/21/11 
3) Thape Jan Research Assistant If Other, list: 11/21/11 
4) Deborah Quast Research Assistant If Other, list: 11/21/11 
5) Lynetta Cox Research Assistant If Other, list: 11/21/11 
6) Melinda Bissett Research Assistant If Other, list: 11/21/11 
7) Yvette Conyers Research Assistant If Other, list: 11/21/11 
8) Morit Leonardo Research Assistant If Other, list: 11/21/11 
9) Ortiz Angela Research Assistant If Other, list: 11/21/11 
10) (Choose an Item) If Other, list: 
11) (Choose an Item) If Other, list: 
12) (Choose an Item) If Other, list: 
13) (Choose an Item) If Other, list: 
14) (Choose an Item) If Other, list: 
15) (Choose an Item) If Other, list: 
16) (Choose an Item) If Other, list: 
17) (Choose an Item) If Other, list: 
18) (Choose an Item)     If Other, list: 
19) (Choose an Item) If Other, list: 
20) (Choose an Item) If Other, list: 
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Roster Version Date:  11.21.11  (Insert updated version date) 
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STUDY PERSONNEL ROSTER INSTRUCTIONS 
THE FOLLOWING INSTRUCTIONS DO NOT NEED TO BE SUBMITTED TO THE IRB 
SUBMISSION INSTRUCTIONS 
Initial Review Submission: 
• List all personnel currently ‘engaged’ in this study. This includes the Principal Investigator, Medically Responsible Investigator, and non-VCU personnel (if
applicable). 
• At the time of Initial Review, submit 4 copies of the following to ORSP, attached to the Initial Review Submission Form and accompanying documents:
o VCU IRB Study Personnel Roster listing all project personnel (insert version date in footer)
o VCU IRB Study Personnel Information and Change Forms for all project personnel
Existing Studies Only (during the phase-in of this new process): 
• NOTE: For existing studies, implementation of this process will be required upon submission of the next continuing review. This continuing
review will not be approved until a VCU IRB Study Personnel Roster is on file for the existing study. 
o Following IRB approval of the roster, the investigator is requested (upon submission of the next amendment to the Research Plan) to update
section II. Research Personnel of the Research Plan to list only the Principal Investigator.
• List all personnel currently involved in this study. This includes the Principal Investigator, Medically Responsible Investigator, and non-VCU personnel (if
applicable). 
• If list of personnel varies from the previously approved protocol/research plan (adding or removing personnel), also follow instructions below under To
Add or Remove Personnel from a Study. 
• For existing studies only (during the phase-in process) - The IRB is not requiring that the initial roster include personnel who are no longer involved in
the study; list only those currently involved (including the Principal Investigator and the Medically Responsible Investigator, if applicable). 
• For existing studies only (during the phase-in process) - Investigators are not required to submit the VCU IRB Study Personnel Information and
Change Forms for currently approved personnel. All project personnel must be listed on the VCU IRB Study Personnel Roster, however. 
• At the time of Continuing Review (during phase-in and subsequent continuing reviews), submit 4 copies of the following to ORSP, attached to the
Continuing Review Submission Form and accompanying documents: 
o VCU IRB Study Personnel Roster listing all project personnel (insert version date in footer)
Add or Remove Personnel from a Study: 
• All changes in research personnel must first be submitted to, and approved by, the IRB.
• To add or remove personnel (including a change to the Principal Investigator and/or Medically Responsible Investigator), revise the VCU IRB Study
Personnel Roster to note personnel who are being added and/or removed. Include updated version date in footer. NOTE: When removing personnel 
from a study, do not delete name(s) from this roster, but enter the date of removal in the appropriate column. When updating the roster to add or 
remove personnel, also submit the appropriate VCU IRB Study Personnel Information and Change Form(s). 
• A change to the Principal Investigator also requires (in addition to the Personnel documents noted above) submission of a Change in Research
Submission Form and applicable amended documents (i.e. Protocol/Research Plan, ICF, etc). 
• For changes that involve Non-VCU sites – In addition to the VCU IRB Study Personnel Roster and VCU IRB Study Personnel Information and Change
Form, personnel changes that involve non-VCU sites must also be addressed within the protocol/research plan (Section XIV. Involvement of Non-VCU 
Institutions/Sites). Changes to the protocol/research plan are to be submitted via a Change in Research Submission Form, along with  any other 
applicable document(s).  
• If adding Independent Investigators, follow instructions for the addition of Independent Investigators available at
http://www.research.vcu.edu/forms/vcuirb.htm. . 
• To make changes to study personnel, submit 4 copies of the following to ORSP:
o Revised VCU IRB Study Personnel Roster, noting personnel who are being added and/or removed (update version date in footer). Also
provide the most recent IRB-approved Roster.
o VCU IRB Study Personnel Information and Change Form(s), noting personnel who are being added and/or removed.
o Conflict of Interest Disclosure Statement(s) for all personnel being added.
o Curriculum Vitae for addition of  Principal Investigator and/or Medically Responsible Investigator
o Additional applicable documents, as noted above, and per instructions.
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IRB Use – Do Not Revise or Delete 
VCU IRB STUDY PERSONNEL INFORMATION AND CHANGE FORM 
(for Expedited and Full Board Research)  
PRINCIPAL INVESTIGATOR: Jacqueline M. McGrath, PhD, RN, NNP,
FNAP 
VCU EMAIL: mcgrathjm@vcu.edu
RESEARCH COORDINATOR: VCU EMAIL: 
VCU IRB #:
TITLE OF PROJECT:   A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) Related Skin Breakdown
when using Different Nasal Interfaces in the Extremely Low Birth Weight (ELBW) Neonate.     
1. Does this change involve a change to the Principal Investigator? Yes* No 
*If YES, submit this form along with an updated Personnel Roster and the Change in Research Submission Form. Also see #2 below.
2. Does this change require additional changes to the research plan, consent, or other study documents?
*If YES, also submit Change in Research Submission Form and appropriate documents for changes to study documents
Yes* No 
3. STUDY PERSONNEL TO BE REMOVED   - - IF MORE SPACE IS NEEDED, PLEASE  ATTACH ADDITIONAL FORM AND CHECK HERE
A) 1. First Name: Last Name: 
2. First Name: Last Name: 
3. First Name: Last Name: 
B) Does the Principal Investigator confirm that the personnel remaining on this study have the
expertise needed to conduct this study?
Yes No 
4. STUDY PERSONNEL TO BE ADDED – - IF SPACE IS NEEDED FOR ADDITIONAL PERSONNEL, PLEASE USE CONTINUATION PAGE AND CHECK HERE- ENTER TOTAL NUMBER OF PERSONNEL ADDITIONS INCLUDED WITH THIS SUBMISSION:      
A) First Name: Jacqueline Last Name: McGrath Degrees: PhD, RN, NNP, FNAP 
Email Address: mcgrathjm@vcu.edu Phone: (804) 828-1930 VCU eID: 
Mailing Address/VCU PO Box: 1100 East Leigh Street, Richmond, VA 23298 
PO BOX 980567 
Affiliate 
Status: 
VCU Affiliate School/Department: School of Nursing 
Non-VCU Affiliate – 
Affiliated with a non-
VCU institution/site 
Name of Institution/Site: 
* NOTE: Personnel changes that involve non-VCU sites must also be addressed within the research plan
(Section XIV). Changes to the research plan are to be submitted to the ORSP, via a Change in Research 
Submission Form, along with an amended research plan and any other applicable document(s). 
Independent 
Investigator –  
Not affiliated with VCU 
or any other institution 
* NOTE: If an independent investigator is “engaged,” and the research involves a DIRECT FEDERAL award made
to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU 
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must 
directly supervise all of the research activities, (2) agreement must follow the ORSP template, (3) IRB must 
agree to the involvement of the independent investigator, AND (4) agreement must be in effect prior to final 
IRB approval. 
Role in the Study:  Principal Investigator 
 If Other, list:   
Responsibilities in the Study: Describe the duties of the individual (i.e. consenting, interviewing, data analysis, data collection) 
Qualifications: Describe how the individual is qualified to carry out study related responsibilities. 
B) Does the Principal Investigator confirm this individual has current CITI training in Human
Participant Protections.*
*Non-VCU research personnel may provide proof of training from their home institution.
Yes No 
Signature of Principal Investigator 
or Designee: 
Date: 
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IRB Use – Do Not Revise or Delete 
Continuation Page for Addition of Personnel 
4. A) First Name: Katherine Last Name: Newnam Degrees: PhD c), RN, NNP-BC, 
CPNP 
Email Address: 
newmankm2@vcu.edu 
Phone: (757) 546-7497 VCU eID: V004-1830 
Mailing Address/VCU PO Box: 1104 Hillston Court, Chesapeake Virginia 23322 
PO Box 980567 
Affiliate 
Status: 
VCU Affiliate School/Department: School of Nursing 
Non-VCU Affiliate – 
Affiliated with a non-
VCU institution/site 
Name of Institution/Site: 
* NOTE: Personnel changes that involve non-VCU sites must also be addressed within the research plan
(Section XIV). Changes to the research plan are to be submitted to the ORSP, via a Change in Research 
Submission Form, along with an amended research plan and any other applicable document(s). 
Independent 
Investigator –  
Not affiliated with VCU 
or any other institution 
* NOTE: If an independent investigator is “engaged,” and the research involves a DIRECT FEDERAL award made
to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU 
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must 
directly supervise all of the research activities, (2) agreement must follow the ORSP template, (3) IRB must 
agree to the involvement of the independent investigator, AND (4) agreement must be in effect prior to final 
IRB approval. 
Role in the Study:  Student 
 If Other, list:   
Responsibilities in the Study: Describe the duties of the individual (i.e. consenting, interviewing, data analysis, data collection)  On site 
responsibility to include participant identification, obtaining informed consent from parent, participant enrollment and data collection, weekly 
reports to the Core Research Team and data analysis. 
Qualifications: Describe how the individual is qualified to carry out study related responsibilities.  NNP currently employed at the Study 
site as an advanced practice nurse, enrolled in PhD program at VCU with knowlegde of conducting research.
B) Does the Principal Investigator confirm this individual has current CITI training in Human
Participant Protections.*
*Non-VCU research personnel may provide proof of training from their home institution.
Yes No 
4. A) First Name: Thape Last Name: Jan Degrees: MS, RN 
Email Address: Jan.Thape@chkd.org Phone: (757) 668-7448 VCU eID: N/A 
Mailing Address/VCU PO Box: 601 Childrens Lane,  Norfolk, Virginia 23507 
Affiliate 
Status: 
VCU Affiliate School/Department: 
Non-VCU Affiliate – 
Affiliated with a non-
VCU institution/site 
Name of Institution/Site: Children's Hospital of the King's Daughters 
* NOTE: Personnel changes that involve non-VCU sites must also be addressed within the research plan
(Section XIV). Changes to the research plan are to be submitted to the ORSP, via a Change in Research 
Submission Form, along with an amended research plan and any other applicable document(s). 
Independent 
Investigator –  
Not affiliated with VCU 
or any other institution 
* NOTE: If an independent investigator is “engaged,” and the research involves a DIRECT FEDERAL award made
to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU 
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must 
directly supervise all of the research activities, (2) agreement must follow the ORSP template, (3) IRB must 
agree to the involvement of the independent investigator, AND (4) agreement must be in effect prior to final 
IRB approval. 
Role in the Study:  Research Assistant 
 If Other, list:   
Responsibilities in the Study: Describe the duties of the individual (i.e. consenting, interviewing, data analysis, data collection)  Data 
collection
Qualifications: Describe how the individual is qualified to carry out study related responsibilities.  Advanced Practice nurse who has 
completed previous research and has expertise using the skin assessment tool (NSCS) planned for the study.
B) Does the Principal Investigator confirm this individual has current CITI training in Human
Participant Protections.*
*Non-VCU research personnel may provide proof of training from their home institution.
Yes No 
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STUDY PERSONNEL INFORMATION AND CHANGE FORM 
(The following instructions do not need to be submitted to the IRB) 
SUBMISSION INSTRUCTIONS: 
The VCU IRB Study Personnel Information and Change Form is to be used to add and remove project personnel* from the study, and is used in conjunction with the 
Study Personnel Roster, which is intended to serve as an ongoing list of all personnel who are currently involved in the project, as well as those who have been, but are 
no longer, involved.  
*Project Personnel includes anyone ‘engaged’ in the research (VCU & non-VCU personnel), including independent investigators. ‘Engaged’ means interacting or
intervening with research participants and/or having access to identifiable private information about participants. See OHRP’s guidance on ‘Engagement of Institutions in
Research’ at http://www.hhs.gov/ohrp/humansubjects/guidance/engage08/html.
Initial Review Submission – For submission at the time of Initial Review of a new study
• Complete the VCU IRB Study Personnel Information and Change Form for each project personnel, including Principal Investigator, Medically Responsible
Investigator, and non-VCU personnel (if applicable). Use the Continuation Page for additional personnel, if needed.
• Note:
o Study personnel are required to complete the CITI human research protection training before involvement in the research project.  For information about
mandatory training requirements for study personnel, read WPP V-1 or Required Education. 
o Study personnel are required to submit a signed Conflict of Interest Disclosure Statement.
• At the time of Initial Review, submit 4 copies of the following to ORSP, attached to the Initial Review Submission Form and accompanying documents:
o VCU IRB Study Personnel Information and Change Forms for all project personnel
o VCU IRB Study Personnel Roster listing all project personnel (insert version date in footer).
Existing Studies Only (during phase-in of this new process) – For first time submission of the VCU IRB Study Personnel Roster for previously approved studies. 
• NOTE: For existing studies, implementation of this process will be required upon submission of the next continuing review. This continuing review
will not be approved until the VCU IRB Study Personnel Roster is on file for the existing study. 
• For existing studies only (during the phase-in process) -  Investigators are not required to submit VCU IRB Study Personnel Information and Change
Forms for currently approved personnel. All personnel must be listed on the VCU IRB Study Personnel Roster, however. 
• If the personnel on the VCU IRB Study Personnel Roster vary from the previously approved protocol/research plan (adding or removing personnel), also follow
instructions below under To Add or Remove Personnel from a Study. 
To Add or Remove Personnel from a Study – For personnel changes following initial VCU IRB Study Personnel Roster review 
• All changes in research personnel must first be submitted to, and approved by, the IRB.
• To add or remove personnel (including a change to the Principal Investigator and/or Medically Responsible Investigator), submit the appropriate VCU IRB
Study Personnel Information and Change Form(s), accompanied by an updated VCU IRB Study Personnel Roster. Use the Continuation Page of the VCU IRB
Study Personnel Information and Change Form if needed for additional personnel.
• A change to the Principal Investigator also requires (in addition to the Personnel documents noted above) submission of a Change in Research Submission
Form and applicable amended documents (i.e. Protocol/Research Plan, ICF, etc).
• Note: Study personnel are required to complete the CITI human research protection training before involvement in the research project.  For information about
mandatory training requirements for study personnel, read WPP V-1 or Required Education.
• Study personnel are required to submit a signed Conflict of Interest Disclosure Statement.
• For changes that involve Non-VCU sites – In addition to the VCU IRB Study Personnel Information and Change Form and VCU IRB Study Personnel Roster,
personnel changes that involve non-VCU sites must also be addressed within the protocol/research plan (Section XIV. Involvement of Non-VCU
Institutions/Sites). Changes to the protocol/research plan are to be submitted via a Change in Research Submission Form, along with any other applicable
document(s).
• If adding Independent Investigators, follow instructions for the addition of Independent Investigators available at http://www.research.vcu.edu/forms/vcuirb.htm.
• To make changes to study personnel, submit 4 copies of the following to ORSP:
o VCU IRB Study Personnel Information and Change Form(s), noting personnel who are being added and/or removed
o Revised VCU IRB Study Personnel Roster, noting personnel who are being added and/or removed (update version date in footer). Also provide the most
recent IRB-approved roster. 
o Conflict of Interest Disclosure Statement(s) for all personnel being added.
o Curriculum Vitae or NIH Biosketch for new Principal Investigator and/or Medically Responsible Investigator, if applicable- (CV  should not to exceed 5-6
pages; BIOSKETCH should be 2-3 pages. If submitting BIOSKETCH, the NIH BIOSKETCH form 398 must be used. 
o Additional applicable documents, as noted above, and per instructions.
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VCU IRB STUDY PERSONNEL INFORMATION AND CHANGE FORM 
(for Expedited and Full Board Research)  
PRINCIPAL INVESTIGATOR: Jacqueline M. McGrath, PhD, RN, NNP,
FNAP 
VCU EMAIL: mcgrathjm@vcu.edu
RESEARCH COORDINATOR: VCU EMAIL: 
VCU IRB #:
TITLE OF PROJECT:  A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) Related Skin Breakdown when
using Different Nasal Interfaces in the Extremely Low Birth Weight (ELBW) Neonate.       
1. Does this change involve a change to the Principal Investigator? Yes* No 
*If YES, submit this form along with an updated Personnel Roster and the Change in Research Submission Form. Also see #2 below.
2. Does this change require additional changes to the research plan, consent, or other study documents?
*If YES, also submit Change in Research Submission Form and appropriate documents for changes to study documents
Yes* No 
3. STUDY PERSONNEL TO BE REMOVED   - - IF MORE SPACE IS NEEDED, PLEASE  ATTACH ADDITIONAL FORM AND CHECK HERE
A) 1. First Name: Last Name: 
2. First Name: Last Name: 
3. First Name: Last Name: 
B) Does the Principal Investigator confirm that the personnel remaining on this study have the
expertise needed to conduct this study?
Yes No 
4. STUDY PERSONNEL TO BE ADDED – - IF SPACE IS NEEDED FOR ADDITIONAL PERSONNEL, PLEASE USE CONTINUATION PAGE AND CHECK HERE- ENTER TOTAL NUMBER OF PERSONNEL ADDITIONS INCLUDED WITH THIS SUBMISSION:      
A) First Name: Deborah Last Name: Quast Degrees: RN 
Email Address: 
Deborah.Quast@chkd.org 
Phone: 757) 668-7448 VCU eID: N/A 
Mailing Address/VCU PO Box: 601 Childrens Lane,  Norfolk, Virginia 23507 
Affiliate 
Status: 
VCU Affiliate School/Department: 
Non-VCU Affiliate – 
Affiliated with a non-
VCU institution/site 
Name of Institution/Site: Children's Hospital of the King's Daughters 
* NOTE: Personnel changes that involve non-VCU sites must also be addressed within the research plan
(Section XIV). Changes to the research plan are to be submitted to the ORSP, via a Change in Research 
Submission Form, along with an amended research plan and any other applicable document(s). 
Independent 
Investigator –  
Not affiliated with VCU 
or any other institution 
* NOTE: If an independent investigator is “engaged,” and the research involves a DIRECT FEDERAL award made
to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU 
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must 
directly supervise all of the research activities, (2) agreement must follow the ORSP template, (3) IRB must 
agree to the involvement of the independent investigator, AND (4) agreement must be in effect prior to final 
IRB approval. 
Role in the Study:  Research Assistant 
 If Other, list:   
Responsibilities in the Study: Describe the duties of the individual (i.e. consenting, interviewing, data analysis, data collection)  Data 
Collection
Qualifications: Describe how the individual is qualified to carry out study related responsibilities.  Full time Research nurse within the NICU 
B) Does the Principal Investigator confirm this individual has current CITI training in Human
Participant Protections.*
*Non-VCU research personnel may provide proof of training from their home institution.
Yes No 
Signature of Principal Investigator 
or Designee: 
Date: 
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Continuation Page for Addition of Personnel 
4. A) First Name:  Lynetta Last Name: Cox Degrees: MS, RN, NNP-BC 
Email Address: Lynetta.Cox@chkd.org Phone: (757)668-7452 VCU eID: N/A 
Mailing Address/VCU PO Box: 601 Childrens Lane,  Norfolk, Virginia 23507 
Affiliate 
Status: 
VCU Affiliate School/Department: 
Non-VCU Affiliate – 
Affiliated with a non-
VCU institution/site 
Name of Institution/Site: 
* NOTE: Personnel changes that involve non-VCU sites must also be addressed within the research plan
(Section XIV). Changes to the research plan are to be submitted to the ORSP, via a Change in Research 
Submission Form, along with an amended research plan and any other applicable document(s). 
Independent 
Investigator –  
Not affiliated with VCU 
or any other institution 
* NOTE: If an independent investigator is “engaged,” and the research involves a DIRECT FEDERAL award made
to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU 
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must 
directly supervise all of the research activities, (2) agreement must follow the ORSP template, (3) IRB must 
agree to the involvement of the independent investigator, AND (4) agreement must be in effect prior to final 
IRB approval. 
Role in the Study:  Research Assistant 
 If Other, list:   
Responsibilities in the Study: Describe the duties of the individual (i.e. consenting, interviewing, data analysis, data collection) 
Obtaining informed consent from parents of eligible participants and data collection 
Qualifications: Describe how the individual is qualified to carry out study related responsibilities.  Advanced practice nurse who is 
knowledgable with informed consent and expert in neonatal assessment including skin.
B) Does the Principal Investigator confirm this individual has current CITI training in Human
Participant Protections.*
*Non-VCU research personnel may provide proof of training from their home institution.
Yes No 
4. A) First Name: Melinda Last Name: Bissett Degrees: MS, RN, NNP-BC 
Email Address: Melinda.Bissett Phone: 757) 668-7452 VCU eID: N/A 
Mailing Address/VCU PO Box: 601 Childrens Lane,  Norfolk, Virginia 23507 
Affiliate 
Status: 
VCU Affiliate School/Department: 
Non-VCU Affiliate – 
Affiliated with a non-
VCU institution/site 
Name of Institution/Site: Children's Hospital of the King's Daughters 
* NOTE: Personnel changes that involve non-VCU sites must also be addressed within the research plan
(Section XIV). Changes to the research plan are to be submitted to the ORSP, via a Change in Research 
Submission Form, along with an amended research plan and any other applicable document(s). 
Independent 
Investigator –  
Not affiliated with VCU 
or any other institution 
* NOTE: If an independent investigator is “engaged,” and the research involves a DIRECT FEDERAL award made
to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU 
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must 
directly supervise all of the research activities, (2) agreement must follow the ORSP template, (3) IRB must 
agree to the involvement of the independent investigator, AND (4) agreement must be in effect prior to final 
IRB approval. 
Role in the Study:  Research Assistant 
 If Other, list:   
Responsibilities in the Study: Describe the duties of the individual (i.e. consenting, interviewing, data analysis, data collection) 
Obtaining informed consent from parents of eligible participants and data collection  
Qualifications: Describe how the individual is qualified to carry out study related responsibilities.  Advanced practice nurse who is 
knowledgable with informed consent and expert in neonatal assessment including skin.
B) Does the Principal Investigator confirm this individual has current CITI training in Human
Participant Protections.*
*Non-VCU research personnel may provide proof of training from their home institution.
Yes No 
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STUDY PERSONNEL INFORMATION AND CHANGE FORM 
(The following instructions do not need to be submitted to the IRB) 
SUBMISSION INSTRUCTIONS: 
The VCU IRB Study Personnel Information and Change Form is to be used to add and remove project personnel* from the study, and is used in conjunction with the 
Study Personnel Roster, which is intended to serve as an ongoing list of all personnel who are currently involved in the project, as well as those who have been, but are 
no longer, involved.  
*Project Personnel includes anyone ‘engaged’ in the research (VCU & non-VCU personnel), including independent investigators. ‘Engaged’ means interacting or
intervening with research participants and/or having access to identifiable private information about participants. See OHRP’s guidance on ‘Engagement of Institutions in
Research’ at http://www.hhs.gov/ohrp/humansubjects/guidance/engage08/html.
Initial Review Submission – For submission at the time of Initial Review of a new study
• Complete the VCU IRB Study Personnel Information and Change Form for each project personnel, including Principal Investigator, Medically Responsible
Investigator, and non-VCU personnel (if applicable). Use the Continuation Page for additional personnel, if needed.
• Note:
o Study personnel are required to complete the CITI human research protection training before involvement in the research project.  For information about
mandatory training requirements for study personnel, read WPP V-1 or Required Education. 
o Study personnel are required to submit a signed Conflict of Interest Disclosure Statement.
• At the time of Initial Review, submit 4 copies of the following to ORSP, attached to the Initial Review Submission Form and accompanying documents:
o VCU IRB Study Personnel Information and Change Forms for all project personnel
o VCU IRB Study Personnel Roster listing all project personnel (insert version date in footer).
Existing Studies Only (during phase-in of this new process) – For first time submission of the VCU IRB Study Personnel Roster for previously approved studies. 
• NOTE: For existing studies, implementation of this process will be required upon submission of the next continuing review. This continuing review
will not be approved until the VCU IRB Study Personnel Roster is on file for the existing study. 
• For existing studies only (during the phase-in process) -  Investigators are not required to submit VCU IRB Study Personnel Information and Change
Forms for currently approved personnel. All personnel must be listed on the VCU IRB Study Personnel Roster, however. 
• If the personnel on the VCU IRB Study Personnel Roster vary from the previously approved protocol/research plan (adding or removing personnel), also follow
instructions below under To Add or Remove Personnel from a Study. 
To Add or Remove Personnel from a Study – For personnel changes following initial VCU IRB Study Personnel Roster review 
• All changes in research personnel must first be submitted to, and approved by, the IRB.
• To add or remove personnel (including a change to the Principal Investigator and/or Medically Responsible Investigator), submit the appropriate VCU IRB
Study Personnel Information and Change Form(s), accompanied by an updated VCU IRB Study Personnel Roster. Use the Continuation Page of the VCU IRB
Study Personnel Information and Change Form if needed for additional personnel.
• A change to the Principal Investigator also requires (in addition to the Personnel documents noted above) submission of a Change in Research Submission
Form and applicable amended documents (i.e. Protocol/Research Plan, ICF, etc).
• Note: Study personnel are required to complete the CITI human research protection training before involvement in the research project.  For information about
mandatory training requirements for study personnel, read WPP V-1 or Required Education.
• Study personnel are required to submit a signed Conflict of Interest Disclosure Statement.
• For changes that involve Non-VCU sites – In addition to the VCU IRB Study Personnel Information and Change Form and VCU IRB Study Personnel Roster,
personnel changes that involve non-VCU sites must also be addressed within the protocol/research plan (Section XIV. Involvement of Non-VCU
Institutions/Sites). Changes to the protocol/research plan are to be submitted via a Change in Research Submission Form, along with any other applicable
document(s).
• If adding Independent Investigators, follow instructions for the addition of Independent Investigators available at http://www.research.vcu.edu/forms/vcuirb.htm.
• To make changes to study personnel, submit 4 copies of the following to ORSP:
o VCU IRB Study Personnel Information and Change Form(s), noting personnel who are being added and/or removed
o Revised VCU IRB Study Personnel Roster, noting personnel who are being added and/or removed (update version date in footer). Also provide the most
recent IRB-approved roster. 
o Conflict of Interest Disclosure Statement(s) for all personnel being added.
o Curriculum Vitae or NIH Biosketch for new Principal Investigator and/or Medically Responsible Investigator, if applicable- (CV  should not to exceed 5-6
pages; BIOSKETCH should be 2-3 pages. If submitting BIOSKETCH, the NIH BIOSKETCH form 398 must be used. 
o Additional applicable documents, as noted above, and per instructions.
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IRB Use – Do Not Revise or Delete 
VCU IRB STUDY PERSONNEL INFORMATION AND CHANGE FORM 
(for Expedited and Full Board Research)  
PRINCIPAL INVESTIGATOR: Jacqueline M. McGrath, PhD, RN, NNP,
FNAP 
VCU EMAIL: mcgrathjm@vcu.edu
RESEARCH COORDINATOR: VCU EMAIL: 
VCU IRB #:
TITLE OF PROJECT:  A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) Related Skin Breakdown when
using Different Nasal Interfaces in the Extremely Low Birth Weight (ELBW) Neonate.       
1. Does this change involve a change to the Principal Investigator? Yes* No 
*If YES, submit this form along with an updated Personnel Roster and the Change in Research Submission Form. Also see #2 below.
2. Does this change require additional changes to the research plan, consent, or other study documents?
*If YES, also submit Change in Research Submission Form and appropriate documents for changes to study documents
Yes* No 
3. STUDY PERSONNEL TO BE REMOVED   - - IF MORE SPACE IS NEEDED, PLEASE  ATTACH ADDITIONAL FORM AND CHECK HERE
A) 1. First Name: Last Name: 
2. First Name: Last Name: 
3. First Name: Last Name: 
B) Does the Principal Investigator confirm that the personnel remaining on this study have the
expertise needed to conduct this study?
Yes No 
4. STUDY PERSONNEL TO BE ADDED – - IF SPACE IS NEEDED FOR ADDITIONAL PERSONNEL, PLEASE USE CONTINUATION PAGE AND CHECK HERE- ENTER TOTAL NUMBER OF PERSONNEL ADDITIONS INCLUDED WITH THIS SUBMISSION:      
A) First Name: Yvette Last Name: Conyers Degrees: MS, RN 
Email Address: 
Yvette.Conyers@chkd.org 
Phone: 757) 668-7448 VCU eID: N/A 
Mailing Address/VCU PO Box: 601 Childrens Lane,  Norfolk, Virginia 23507 
Affiliate 
Status: 
VCU Affiliate School/Department: 
Non-VCU Affiliate – 
Affiliated with a non-
VCU institution/site 
Name of Institution/Site: Children's Hospital of the King's Daughters 
* NOTE: Personnel changes that involve non-VCU sites must also be addressed within the research plan
(Section XIV). Changes to the research plan are to be submitted to the ORSP, via a Change in Research 
Submission Form, along with an amended research plan and any other applicable document(s). 
Independent 
Investigator –  
Not affiliated with VCU 
or any other institution 
* NOTE: If an independent investigator is “engaged,” and the research involves a DIRECT FEDERAL award made
to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU 
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must 
directly supervise all of the research activities, (2) agreement must follow the ORSP template, (3) IRB must 
agree to the involvement of the independent investigator, AND (4) agreement must be in effect prior to final 
IRB approval. 
Role in the Study:  Research Assistant 
 If Other, list:   
Responsibilities in the Study: Describe the duties of the individual (i.e. consenting, interviewing, data analysis, data collection)  Data 
Collection
Qualifications: Describe how the individual is qualified to carry out study related responsibilities.  Advanced practice nurse who serves 
the NICU as a clinical specialist, knowledgable regarding neonatal skin assessment and conducting research.
B) Does the Principal Investigator confirm this individual has current CITI training in Human
Participant Protections.*
*Non-VCU research personnel may provide proof of training from their home institution.
Yes No 
Signature of Principal Investigator 
or Designee: 
Date: 
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Continuation Page for Addition of Personnel 
4. A) First Name: Leonardo Last Name: Morit Degrees: BS, RN 
Email Address: 
Leonardo.Morit@chkd.org 
Phone: (757)668-7448 VCU eID: N/A 
Mailing Address/VCU PO Box: 601 Childrens Lane,  Norfolk, Virginia 23507 
Affiliate 
Status: 
VCU Affiliate School/Department: 
Non-VCU Affiliate – 
Affiliated with a non-
VCU institution/site 
Name of Institution/Site: 
* NOTE: Personnel changes that involve non-VCU sites must also be addressed within the research plan
(Section XIV). Changes to the research plan are to be submitted to the ORSP, via a Change in Research 
Submission Form, along with an amended research plan and any other applicable document(s). 
Independent 
Investigator –  
Not affiliated with VCU 
or any other institution 
* NOTE: If an independent investigator is “engaged,” and the research involves a DIRECT FEDERAL award made
to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU 
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must 
directly supervise all of the research activities, (2) agreement must follow the ORSP template, (3) IRB must 
agree to the involvement of the independent investigator, AND (4) agreement must be in effect prior to final 
IRB approval. 
Role in the Study:  Research Assistant 
 If Other, list:   
Responsibilities in the Study: Describe the duties of the individual (i.e. consenting, interviewing, data analysis, data collection)  Data 
Collection
Qualifications: Describe how the individual is qualified to carry out study related responsibilities.  Staff nurse in the NICU who is 
qualified to perform serial skin assessments on preterm neonates and currently serves on the hospital research committee.
B) Does the Principal Investigator confirm this individual has current CITI training in Human
Participant Protections.*
*Non-VCU research personnel may provide proof of training from their home institution.
Yes No 
4. A) First Name: Angela Last Name: Ortiz Degrees: BS, RN 
Email Address: Angela.Ortiz Phone: 757) 668-7448 VCU eID: N/A 
Mailing Address/VCU PO Box: 601 Childrens Lane,  Norfolk, Virginia 23507 
Affiliate 
Status: 
VCU Affiliate School/Department: 
Non-VCU Affiliate – 
Affiliated with a non-
VCU institution/site 
Name of Institution/Site: Children's Hospital of the King's Daughters 
* NOTE: Personnel changes that involve non-VCU sites must also be addressed within the research plan
(Section XIV). Changes to the research plan are to be submitted to the ORSP, via a Change in Research 
Submission Form, along with an amended research plan and any other applicable document(s). 
Independent 
Investigator –  
Not affiliated with VCU 
or any other institution 
* NOTE: If an independent investigator is “engaged,” and the research involves a DIRECT FEDERAL award made
to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU 
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must 
directly supervise all of the research activities, (2) agreement must follow the ORSP template, (3) IRB must 
agree to the involvement of the independent investigator, AND (4) agreement must be in effect prior to final 
IRB approval. 
Role in the Study:  Research Assistant 
 If Other, list:   
Responsibilities in the Study: Describe the duties of the individual (i.e. consenting, interviewing, data analysis, data collection)  Data 
Collection
Qualifications: Describe how the individual is qualified to carry out study related responsibilities.  Staff nurse in the NICU who is 
qualified to perform serial skin assessments on preterm neonates and currently serves on the hospital research committee.
B) Does the Principal Investigator confirm this individual has current CITI training in Human
Participant Protections.*
*Non-VCU research personnel may provide proof of training from their home institution.
Yes No 
Page 2 of 3   110
Form Creation Date:  6-1-11 
IRB Use – Do Not Revise or Delete 
STUDY PERSONNEL INFORMATION AND CHANGE FORM 
(The following instructions do not need to be submitted to the IRB) 
SUBMISSION INSTRUCTIONS: 
The VCU IRB Study Personnel Information and Change Form is to be used to add and remove project personnel* from the study, and is used in conjunction with the 
Study Personnel Roster, which is intended to serve as an ongoing list of all personnel who are currently involved in the project, as well as those who have been, but are 
no longer, involved.  
*Project Personnel includes anyone ‘engaged’ in the research (VCU & non-VCU personnel), including independent investigators. ‘Engaged’ means interacting or
intervening with research participants and/or having access to identifiable private information about participants. See OHRP’s guidance on ‘Engagement of Institutions in
Research’ at http://www.hhs.gov/ohrp/humansubjects/guidance/engage08/html.
Initial Review Submission – For submission at the time of Initial Review of a new study
• Complete the VCU IRB Study Personnel Information and Change Form for each project personnel, including Principal Investigator, Medically Responsible
Investigator, and non-VCU personnel (if applicable). Use the Continuation Page for additional personnel, if needed.
• Note:
o Study personnel are required to complete the CITI human research protection training before involvement in the research project.  For information about
mandatory training requirements for study personnel, read WPP V-1 or Required Education. 
o Study personnel are required to submit a signed Conflict of Interest Disclosure Statement.
• At the time of Initial Review, submit 4 copies of the following to ORSP, attached to the Initial Review Submission Form and accompanying documents:
o VCU IRB Study Personnel Information and Change Forms for all project personnel
o VCU IRB Study Personnel Roster listing all project personnel (insert version date in footer).
Existing Studies Only (during phase-in of this new process) – For first time submission of the VCU IRB Study Personnel Roster for previously approved studies. 
• NOTE: For existing studies, implementation of this process will be required upon submission of the next continuing review. This continuing review
will not be approved until the VCU IRB Study Personnel Roster is on file for the existing study. 
• For existing studies only (during the phase-in process) -  Investigators are not required to submit VCU IRB Study Personnel Information and Change
Forms for currently approved personnel. All personnel must be listed on the VCU IRB Study Personnel Roster, however. 
• If the personnel on the VCU IRB Study Personnel Roster vary from the previously approved protocol/research plan (adding or removing personnel), also follow
instructions below under To Add or Remove Personnel from a Study. 
To Add or Remove Personnel from a Study – For personnel changes following initial VCU IRB Study Personnel Roster review 
• All changes in research personnel must first be submitted to, and approved by, the IRB.
• To add or remove personnel (including a change to the Principal Investigator and/or Medically Responsible Investigator), submit the appropriate VCU IRB
Study Personnel Information and Change Form(s), accompanied by an updated VCU IRB Study Personnel Roster. Use the Continuation Page of the VCU IRB
Study Personnel Information and Change Form if needed for additional personnel.
• A change to the Principal Investigator also requires (in addition to the Personnel documents noted above) submission of a Change in Research Submission
Form and applicable amended documents (i.e. Protocol/Research Plan, ICF, etc).
• Note: Study personnel are required to complete the CITI human research protection training before involvement in the research project.  For information about
mandatory training requirements for study personnel, read WPP V-1 or Required Education.
• Study personnel are required to submit a signed Conflict of Interest Disclosure Statement.
• For changes that involve Non-VCU sites – In addition to the VCU IRB Study Personnel Information and Change Form and VCU IRB Study Personnel Roster,
personnel changes that involve non-VCU sites must also be addressed within the protocol/research plan (Section XIV. Involvement of Non-VCU
Institutions/Sites). Changes to the protocol/research plan are to be submitted via a Change in Research Submission Form, along with any other applicable
document(s).
• If adding Independent Investigators, follow instructions for the addition of Independent Investigators available at http://www.research.vcu.edu/forms/vcuirb.htm.
• To make changes to study personnel, submit 4 copies of the following to ORSP:
o VCU IRB Study Personnel Information and Change Form(s), noting personnel who are being added and/or removed
o Revised VCU IRB Study Personnel Roster, noting personnel who are being added and/or removed (update version date in footer). Also provide the most
recent IRB-approved roster. 
o Conflict of Interest Disclosure Statement(s) for all personnel being added.
o Curriculum Vitae or NIH Biosketch for new Principal Investigator and/or Medically Responsible Investigator, if applicable- (CV  should not to exceed 5-6
pages; BIOSKETCH should be 2-3 pages. If submitting BIOSKETCH, the NIH BIOSKETCH form 398 must be used. 
o Additional applicable documents, as noted above, and per instructions.
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RESEARCH SUBJECT INFORMATION AND CONSENT FORM 
TITLE:  A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) 
Related Skin Breakdown when using Different Nasal Interfaces in the Extremely Low Birth 
Weight (ELBW) Neonate. 
VCU IRB NO.: 
This consent form may contain words that you do not understand. Please ask the study staff to 
explain any words that you do not clearly understand. You may take home an unsigned copy of 
this consent form to think about or discuss with family or friends before making your decision. 
PURPOSE OF THE STUDY: 
To provide breathing assistance to your preterm baby, nasal CPAP is often used 
immediately after delivery or when your baby is taken off the ventilator.  Nasal CPAP is a 
respiratory machine that is secured to your babies’ nose through the use of either short soft nasal 
prongs, a soft nasal mask or a rotation between the mask and prongs in order to provide constant 
air flow or air pressure into the baby’s nose and airways to help the baby breath more effectively.  
Although both the nasal prongs and mask are effective in providing respiratory support to your 
baby and is routinely used in our Neonatal Intensive Care Unit (NICU) we would like to know if 
one device is more comfortable for your baby or may cause less skin irritation where the skin 
comes in contact with the respiratory machine.     
You are being asked to participate in this study because you have a preterm infant 
between the birth weight of 500 and 1500 grams who is currently treated with nasal CPAP or 
may be treated with nasal CPAP after your baby is taken off the ventilator.  
DESCRIPTION OF THE STUDY AND YOUR (YOUR CHILD’S) INVOLVEMENT: 
RISKS AND DISCOMFORTS: 
There are no anticipated risks or discomforts above what is currently associated with 
nasal CPAP use therefore no additional risks or discomforts are expected with the participation 
in this research study.  All study team members will maintain confidentiality of completed skin 
assessments and medical record information collected.   Skin assessments will be performed in 
conjunction with nursing care therefore no additional interruption of infant rest or additional 
handing is anticipated. Other data collection will be extrapolated from the infant’s medical 
record without interruption of bedside care. 
BENEFITS TO YOU AND OTHERS 
There are no direct benefits to you or your infant at the present time; however the 
information collected will be used to improve nasal CPAP care in our NICU and therefore might 
benefit other infants who have nasal CPAP therapy.   
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COSTS: 
There are no financial costs associated with participation in this research study. 
PAYMENT FOR PARTICIPATION: 
There is no payment for participation in this research study. 
ALTERNATIVES 
The alternative is to not participate in this research study. 
CONFIDENTIALITY 
Potentially identifiable information about your infant will consist of this consent form. 
Skin assessment data will be collected on a data collection form by the research team which will 
be associated with an enrollment number and not your babies name. This data is being collected 
for research purposes only. All consent forms will be kept in a secure area and electronic data 
files will be kept in a password-protected computer. All personal identifying information will be 
deleted in accordance with state and federal regulations and guidelines.  Data will be kept 
indefinitely.  Access to all study materials will be limited to study personnel. 
****We will not tell anyone the answers you give us; however, information from the 
study and information from your medical record and the consent form signed by you may be 
looked at or copied for research or legal purposes by Virginia Commonwealth University.  What 
we find from this study may be presented at meetings or published in papers, but your name will 
never be used in these presentations or papers. 
IF AN INJURY HAPPENS 
This study is minimal risk and no more than currently expected during the current 
standard of care during the administration of nasal CPAP.   
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
You do not have to participate in this study. If you choose to participate, you may stop at 
any time without any penalty. Your decision to participate or not participate in this research 
study will involve no penalty or loss of care, service or benefits to which you are otherwise 
entitled from this agency/service provider. 
QUESTIONS 
In the future, you may have questions about your participation in this study. If you have 
any questions, complaints, or concerns about the research, contact: 
Jacqueline M. McGrath, PhD, RN, NNP, FNAP 
Associate Professor of Nursing 
School of Nursing 
Viriginia Commonwealth Univeristy 
11100 East Leigh Street 
Richmond, VA 23298 
(804) 828-1930 
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Mailing Address: 
PO Box 980567 
Richmond, VA 23298-0567 
Katherine Newnam RN, MS, NNP-BC 
Children’s Hospital of the Kings Daughters 
601 Children’s Lane 
Norfolk, Virginia 23507 
(757)668-7452 
If you have any questions about your rights as a participant in this study, you may contact: 
Office for Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 113 
P.O. Box 980568 
Richmond, VA  23298 
Telephone:  804-827-2157 
You may also contact this number for general questions, concerns or complaints about 
the research.  Please call this number if you cannot reach the research team or wish to talk to 
someone else.  Additional information about participation in research studies can be found at 
http://www.research.vcu.edu/irb/volunteers.htm. 
CONSENT 
I have been given the chance to read this consent form. I understand the information 
about this research study. Questions that I wanted to ask about the research study have been 
answered. My signature says that I am willing to participate in this research study. I will receive 
a copy of the consent form once I have agreed to participate. 
Participant name printed Participant signature Date 
________________________________________________ 
Name of Person Conducting Informed Consent  
Discussion / Witness  
(Printed) 
________________________________________________ ________________ 
Signature of Person Conducting Informed Consent   Date 
Discussion / Witness 
________________________________________________ ________________ 
Investigator Signature (if different from above)    Date 
11.12.11  
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VCU IRB 
APPENDIX A:  HIPAA FOR RESEARCH 
PRINCIPAL INVESTIGATOR: McGrath, Jacqueline M. 
EMAIL: McGrathJM@vcu.edu 
RESEARCH COORDINATOR: 
EMAIL: 
P.O. BOX #: PO Box 980567 
STUDY TITLE: A COMPARATIVE EFFECTIVENESS STUDY OF CONTINUOUS POSITIVE AIRWAY
PRESSURE (CPAP) RELATED SKIN BREAKDOWN WHEN USING DIFFERENT NASAL
INTERFACES IN THE EXTREMELY LOW BIRTH WEIGHT (ELBW) NEONATE. 
SECTION A:  GENERAL INFORMATION 
1. Describe the health information that will be obtained or used in this research.
1) Data Collection Form; Enrollment/Daily and Weekly (Appendix 4/5 and 6) which will include the following
information which is extrapolated from the medical record.  
a) Patient’s birth weight
b) Patient’s current weight
c) Patient’s gestational age at birth
d) Patients current age
e) Length of CPAP use
f) CPAP flow rate
g) Amount of FIO2 required
h) Incubator humidity
i) Type of nasal interface
j) Suctioning  requirements
k) Saline use during suctioning
l) Bleeding with suctioning
m) Blood gas results
n) Skin injury location
o) Skin injury reported to the medical team
p) Intervention provided for skin injury
q) Additional clinical issues/concerns
r) Care strategies per standard of care complied with (pectin barrier, developmental position and CPAP hat
             placement) 
2) Neonatal Skin Condition Scale (NSCS) which will be collected by the Core Research team every 10-12 hours
in coordination with routine infant care/assessment performed every 3-4 hours (see Appendix 3).  This information 
will be collected for research purposes following skin assessment. 
3) Neonatal Pain, Agitation and Sedation Scale (N-PASS) is a scale (see appendix 7) has been well validated in
the preterm population and is currently used as a measure of agitation at the proposed research site; therefore 
information will be extrapolated from the medical record 
2. Indicate the source(s) of the health information.  (check all that apply)
  VCUHS medical records  
 X  Non-VCUHS health care provider medical records 
  PHI held by a component of the VCU ACE (other than VCUHS) 
X   Directly from the research participant (e.g., physical exams, diagnostic results, interviews and questionnaires) 
  Records open to the public 
  Other (please specify):     
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3. Explain how the PHI collected or used in this research is the minimum necessary to accomplish the research.
The data included on the Data Collection Form (Enrollment/Daily and Weekly--Appendix 4/5 and 6) include items 
were shown through the literature review to be factors related to skin breakdown in the preterm infant during nasal 
CPAP use and are critical to examination of this identified side effect of nasal CPAP use in this population.  
4. Select all of the identifiers that will be used in this research.
X Names  Social security numbers  IP addresses 
XDates (e.g., birth, admission, death)  Medical record numbers  License numbers 
 Phone numbers  Health plan beneficiary numbers  Internet URLs 
 Fax numbers  Device identifiers & serial numbers  Vehicle ID & serial numbers 
X Ages ≥ 89  Full-face photos or comparable X Biometric identifiers 
 Geographic subdivisions smaller than 
state (e.g., city, county, zip) 
 Account numbers (e.g., bank, 
invoice#, credit card #) 
X Other unique identifying #, code, or 
characteristic 
 None of the above 
5. Select all pathways this research will employ or use to access PHI.
De-identified data [FINISHED WITH THIS FORM AFTER THIS QUESTION] 
X All identifiers removed (safe harbor) 
 Statistical analysis verifying no possibility of re-identification [SUBMIT ATTESTATION FROM 
STATISTICIAN WITH THIS FORM] 
 Limited Data Set (may ONLY include city, state, zip code, dates, and ages) [COMPLETE DATA USE 
AGREEMENT] 
 Waiver of Authorization [COMPLETE SECTION B] 
 Partial Waiver of Authorization for Recruitment (allows access to PHI to contact potential participants who 
will sign consent and authorization upon enrollment) [COMPLETE SECTION C] 
 Signed Authorization from participants in a combined Informed Consent and Authorization form [FINISHED 
WITH THIS FORM] 
 Signed Authorization from participants in a separate Authorization form [FINISHED WITH THIS FORM] 
SECTION B:  WAIVER OF AUTHORIZATION 
1. Describe how the use of PHI in this study poses no greater than minimal risk to participants’ privacy.
2. When will identifiers be destroyed? (Identifiers must be destroyed at earliest opportunity)
  End of the study 
    years after the end of the study (enter # of years) 
 Other (please specify):     
3. Other than the PI and research personnel, who else will have access to the health information?
4. Explain why this research cannot practicably be conducted without the use of PHI.
5. Explain why this research cannot practicably be conducted without a waiver of authorization.
Assurances 
In applying for a waiver of authorization, I agree to the following: 
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A) The identifiers used for this research study will not be used for any other purpose or disclosed to any other
person or entity (aside from members of the research team identified in the research application), except as
required by law.
B) If at any time I want to reuse this information for other purposes or disclose the information to other
individuals, I will seek approval from the IRB.
C) I will comply with VCU HIPAA policies and procedures and with the use and disclosure restrictions
described above.
D) I assume responsibility for all uses and disclosures of the PHI by members of the study team.
SIGNATURE OF PRINCIPAL 
INVESTIGATOR OR DESIGNEE: 
DATE OF 
SIGNATURE: 
SECTION C:  PARTIAL WAIVER OF AUTHORIZATION 
1. Describe how the use of PHI for recruitment poses no greater than minimal risk to participants’ privacy.
2. When will identifiers be destroyed? (Identifiers must be destroyed at earliest opportunity)
  Following participant contact 
Following participant enrollment
Upon reaching study accrual objectives
Other (please specify):
3. Other than the PI and research personnel, who else will have access to the health information?
4. Explain why this recruitment cannot practicably be conducted without the use of PHI.
5. Explain why the recruitment cannot practicably be conducted without the partial waiver of
authorization.
Assurances 
In applying for a partial waiver of authorization, I agree to the following: 
A) The identifiers used for this research study will not be used for any other purpose or disclosed to any other
person or entity (aside from members of the research team identified in the research application), except as 
required by law. 
B) If at any time I want to reuse this information for other purposes or disclose the information to other
individuals, I will seek approval from the IRB. 
C) I will comply with VCU HIPAA policies and procedures and with the use and disclosure restrictions described
above. 
D) I assume responsibility for all uses and disclosures of the PHI by members of the study team.
SIGNATURE OF PRINCIPAL 
INVESTIGATOR: 
DATE OF 
SIGNATURE: 
  118
VCU IRB SUBMISSION FORM ADDENDUM 
REQUIRED FOR RESEARCH INVOLVING 
CHILDREN 
PRINCIPAL INVESTIGATOR: 
Name (Last, First, MI): McGrath, Jacqueline M. 
Department: Nursing 
   VCU Box # (must 
provide 6-digit #): 
PO Box 980567 
Study Title: A Comparative Effectiveness Study of Continuous Positive 
Airway Pressure (CPAP) Related Skin Breakdown when using 
Different Nasal Interfaces in the Extremely Low Birth Weight 
(ELBW) Neonate. 
VCU IRB #: 
CHILDREN:  AGE 
RANGE 
Preterm infants from birth to 8 weeks of age. 
The purpose of this VCU IRB form addendum is to assist the principal investigator in complying 
with the regulations unique to Children and to guide the reviewer in the review documentation.   
An overview of special considerations to review prior to completing this form: 
 In Virginia, children (those under the legal age of 18 and not emancipated) are also termed
minors.  Children are a special class of research participants and classified as vulnerable
populations, with unique protections under DHHS regulations at 45 CFR 46 Subpart D and
21CFR50 Subpart D.
 Use this submission form addendum to ensure that the requirements of Subpart D are met if
research will involve children, as defined in the Virginia Code or according to the law of the
jurisdiction where the research will be conducted.
 Definitions:  See Section B Definitions, in WPP XV-1 for federal definitions of child, parent,
guardian, assent and permission.  In contrast to federal law, Virginia Code does not
specifically define ‘assent’, ‘permission’ or ‘parent’ or ‘guardian.’
 Legally Authorized Representatives for Children:  For purposes of research with
unemancipated minors, individuals who may serve as ‘LARs” for children/ unemancipated
minors are:  1) “the parent or parents having custody of a prospective subject who is a minor,
2) ‘the legal guardian of a prospective subject,’ or 3) ‘any person or judicial or other body
authorized by law or regulation to consent on behalf of a prospective subject to such subject’s 
participation in the particular human research’ (for children in state- or court-appointed 
custody). 
 Court-appointed and State Custody:  Due to the specific requirements related to the
involvement in human subjects research of children in court-appointed and state custody,
such children ARE EXCLUDED from VCU IRB consideration, unless a specific request has
been made to include children in court-appointed or state custody. Section V on this form
specifically addresses the inclusion of such children.  To request the research participation of
children in court-appointed or state custody, Section V MUST be completed.  See alsoIRB
WPP XV-3 “Children in Court-Appointed or State Custody and Emancipated Minors.”
 Legally-Emancipated Minors:  Note that in Virginia, an individual below the age of 18 years
of age who is legally emancipated (with legal documentation to verify such status) is
permitted to make all decisions concerning research participation as would someone 18 and
older who is also decisionally capable.  Such an individual is no longer considered a ‘child’
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under Virginia law or federal definitions.  Consequently, the individual’s consent, not 
assent, is obtained and parental or guardian permission is not relevant to the research.   
I.  PERMITTED RESEARCH CATEGORIES: 
Guidance for this section:
 Check one or more of the following categories of research that best describe your research study (404,
405, 406 or 407) and answer the questions in that section. 
 NOTE:  Subsequent sections of this form will refer to the category you select, below (be careful to
fully consider ALL aspects of your research protocol). 
Complete the following, Section I: 
X [404] NO GREATER THAN MINIMAL RISK:  Research involving no greater than 
minimal risk to children with adequate provisions for soliciting the assent of the children 
and permission of their parents or guardians (as set forth in Sec 46.408) [46.404]. 
NEXT:  Go to Section II – Assent of Children 
 [405] GREATER THAN MINIMAL RISK with Direct Benefit:  Research involving 
greater than minimal risk but presenting the prospect of direct benefit to the individual 
subjects. [46.405]. 
The principal investigator should provide brief protocol-specific information in support of 
each of the following 3 required conditions: 
1. Explain how the risk is justified by the anticipated benefit to subjects:
2. Explain how the relation of the anticipated benefit to the risk is at least as favorable
to the subjects as that presented by available alternative approaches.
3. Briefly explain how you plan to ensure that provisions are made for soliciting the
assent of the children and permission of their parents or guardians, as set forth in Sec.
46.408. 
NEXT:  Go to Section II – Assent of Children 
 [406] GREATER THAN MINIMAL RISK with No Direct Benefit:  Research 
involving greater than minimal risk and no prospect of direct benefit to individual 
subjects, but likely to yield generalizable knowledge about the subject’s disorder or 
condition [46.406]. 
The principal investigator should provide brief protocol-specific information in support of 
each of the following 4 required conditions: 
1. Explain how the risk represents only a minor increase over minimal risk.
2. Explain how the intervention or procedure presents experiences to subjects that are
reasonably commensurate with those inherent in their actual or expected medical,
dental, psychological, social, or educational situations.
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3. Explain how the intervention or procedure is likely to yield generalizable knowledge
about the subjects’ disorder or condition, which is of vital importance for the
understanding or amelioration of the subjects’ disorder, or condition.
4. Briefly explain how you plan to ensure that provisions are made for soliciting the
assent of the children and permission of their parents or guardians, as set forth in Sec.
46.408. 
NEXT:  Go to Section II – Assent of Children 
 [407] NOT OTHERWISE APPROVABLE:  Research not otherwise approvable, which 
presents an opportunity to understand, prevent, or alleviate a serious problem affecting 
the health or welfare of children [46.407]. 
The principal investigator should provide brief protocol-specific information in support 
of each of the following 2 required conditions [NOTE:  if the research is not HHS 
funded, then only the first condition must be met]: 
1. Explain how the research presents a reasonable opportunity to further the
understanding, prevention, or alleviation of a serious problem affecting the health or
welfare of children.  (Note: The IRB will also have to make this finding, so be clear
and include protocol-specific information).
2. (For HHS Supported Research ONLY): The Secretary, after consultation with a
panel of experts in pertinent disciplines and following opportunity for public review
and comment has made its required determinations under Sec. 46.407.  The OHRP
Guidance Document:  Special Protections for Children as Research Subjects (45
CFR 46.407 Process) will be followed by the VCU IRB.  Not until the Secretary has
issued determinations in writing back to the IRB (as documented in the official
record) will the IRB be able to fully review the research and consider it approval
status.
Has the Secretary issued a written determination?   YES      NO 
NEXT:  Go to Section II – Assent of Children or Waiver of Assent (Request) 
II. ASSENT OF CHILDREN OR WAIVER OF ASSENT (REQUEST):
Guidance for this section:
 The principal investigator should provide briefly describe the assent plan (including any request for
waiver of assent (for certain ages or situations) below. 
 Protocol specific information must be provided in support of each item below (page numbers are
helpful, but should not be provided in lieu of specific information) [see VCU IRB WPP#: XV-2 for 
detailed guidance].   
 Unless age-specific waiver of assent is requested and approved, children of age 7 and higher are
expected to be part of the discussion about the research.  To request a waiver of assent for some or all 
participants, due to age or anticipated condition, the PI must provide a sufficient justification. Child 
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participants not meeting the age or condition specified must give assent.  An IRB approved waiver of 
assent for children below age 7 is not required.   
Complete the following, Section II: 
1. Completely describe the provisions in place for soliciting the assent of children (when the
IRB determines capability to do so).  Please note that the IRB may consider waiver of
assent for certain age groups (if requested and justified by the PI here).  Generally, the
VCU IRB anticipates assent appropriate for children 7 and older.
N/A.
1(a). Exactly how do the provisions for assent take into account, ages, maturity, and 
psychological state for decisions made on behalf of all children or each child 
(IRB will review and determine if this is appropriate).   
1(b). For research which holds a prospect for direct benefit (available only through 
the research), indicate if assent be required for the research to proceed. 
NOTE:  Assent of children to participate in research may be waived by the IRB 
for children above the age of 7 (in agreement with PI justification) in cases 
where the research holds out the prospect of direct benefit to the health or 
well-being of the children, and is available to them only in the context of the 
research. In such circumstances, children should be informed about the 
research, but should be told that their assent will not be solicited.  Indicate if 
the waiver of assent will apply to all children regardless of age or condition.  If 
the waiver will only apply to some children, give examples and explain why 
their assent is to be waived. 
2. Indicate if the waiver of assent will apply to all children or some children.  If the waiver
will only apply to some children, give examples and explain why their assent is to be
waived, eg. a) some/all children will not be capable of providing assent based on their
age, maturity, psychological, or physical state, the capability of some or all children may
be so limited that they could not reasonably be consulted, c) the research holds out the
prospect of direct benefit that is important to the health or well-being of some or all
children and is only available in the context of the research, and/or d) the criteria for
waiver of consent apply to the waiver of assent ((45CFR46.116.d)  See WPP XI-1
Consent Process, Elements, Waiver of Element(s), and Modification).
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III. WAIVER OF PARENTAL/GUARDIAN PERMISSION:
Guidance for this section:
 Parental/guardian permission may not be waived for FDA-regulated research except for emergent
or life-threatening situations, either individually or as a group (see 21CFR 50.23 and 24,
respectively).
 For non-FDA regulated research all of the requirements of 45CFR46.116 concerning informed
consent apply to parental permission, including the general and required elements.
 See WPP XI-1 CONSENT PROCESS, ELEMENTS, WAIVER OF ELEMENT(S), AND
MODIFICATION. The elements of informed parental permission can be modified or waived
entirely in accord with 45CFR46.116 (d).
Complete the following, Section III: 
A.    Is a waiver of parental or guardian permission requested? 
  YES – Continue to “B” 
X  NO – Skip the remainder of this section, Continue at Section IV. 
B. The principal investigator should provide brief protocol-specific information in support of 
each of the following ONLY IF WAIVER OF CONSENT/permission IS REQUESTED: 
1. The PI/IRB must find/document that the requirement for parental permission is not
reasonable in order to protect the subjects (e.g., abused, neglected children).
2. The IRB/PI must ensure that an appropriate mechanism for protection of the children
is substituted.
3. Consideration must be given to the nature of the research, risks and benefits, and the
subject’s age, maturity, status, and condition.
4. Indicate that the 4 elements for waiver of some or all elements of parental
permission/informed consent are addressed (45CFR46.116.d) See WPP XI-1
CONSENT PROCESS, ELEMENTS, WAIVER OF ELEMENT(S), AND MODIFICATION.
IV. DOCUMENTATION OF PARENTAL/GUARDIAN PERMISSION AND ASSENT
Guidance for this section:
• Documentation of parental permission is determined according to 45CFR46.117, or 21 CFR50
Subparts B and D.  See WPP XI-2 Informed Consent Documentation, Waiver of Documentation,
and Required Signatures.
• For Categories 404 and 405:  If the Research involves categories 404 and 405, The IRB may find
that the permission of one or both parents is adequate/necessary.   For Categories 406 and 407:  If
the research involves categories 406 and 407, the IRB must find that the permission of BOTH
parents is necessary unless one parent is deceased, unknown, incompetent, not reasonable
available, or not a custodial parent.
• Consent forms should be drafted to allow for BOTH parents to provide permission for a child to
participate in research.  The inclusion of two consent signature lines will help to ensure that both
parents are encouraged to provide and document their permission in all cases, if so desired.
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Complete the following, Section IV: 
A. Parental/Guardian Permission:  Indicate your plan for obtaining parental signatures (see 
guidance, above): 
X We will require that ONE parent/guardian to sign permission (research under category 
404 or 405).  Justification:  Category 404—No greater than minimal risk to the infant 
as nasal CPAP with all three types of nasal interfaces are currently used at the study 
site (CHKD NICU) for the administration of nasal CPAP, which is a universally 
accepted method of respiratory support for the preterm infant.  The randomization 
into one of three groups for the research project for the purpose of correlation 
between nasal interface type and the incidence and severity of skin injury is the study 
purpose with skin assessment every 10-12 hours during the nasal CPAP use by a 
skilled nursing professional who is currently employed at the research site.  The skin 
assessments will be coordinated with routine infant care so that additional 
interruption of the infants sleep will be minimized.  Additionally collected data will 
be extrapolated from the medical record and will require no additional patient testing 
or manipulation. 
 We will require that TWO parents/guardians sign permission (research under 
category 404 or 405) when both parents/guardians are reasonably available.  
Justification:     
 We will require that TWO parents/guardians sign permission (research under 
category 406 and 407) unless one parent is deceased, unknown, incompetent, not 
reasonably available, or not a custodial parent.  Justification:     
B. Assent Signature:  Indicate your plan for obtaining assent of the child (provide a brief 
justification where required). 
1. Is a signature of assent required for ages 7 and older (standard practice)?
  YES 
  NO:   If assent signature is not required for all children, ages 7 and older, please 
answer the following: 
a. Indicate the age range for assent (e.g. ages 10 and older) and explain why
this age range was chosen:
b. Explain how the investigator will record assent (in the case where a signature
is not required)
c. If a signature of assent will be required on a case-by-case basis, explain how
it will be determined which children will be asked/required to sign an assent
document.
2. Indicate the type of assent document:
  Assent Form (Separate from Parental/Guardian Permission) 
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  Assent Combined with Parental/Guardian Permission Form (additional signature 
block on the parent/guardian document). 
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V. SPECIAL REQUEST/JUSTIFICATION FOR THE INVOLVEMENT OF
CHILDREN (OR AN INDIVIDUAL CHILD) IN COURT-APPOINTED OR STATE
CUSTODY 
Guidance for this section:
 Children in court-appointed or state custody (frequently termed ‘wards of the state’) are viewed as
highly vulnerable research subjects.  Plans for their involvement are to be considered accordingly. 
 Please see VCU IRB WPP #XV-3: Children in Court-Appointed or State Custody and
Emancipated Minors. 
Complete the following, Section V: 
X Check here to indicate that this research will EXCLUDE children in court-appointed or state 
custody (Skip this section V).  Form ends. 
OR 
 Check here to indicate that this research will INCLUDE children in court-appointed or state 
custody (Complete this section). 
Categories  [404] OR   [405] ONLY:  (Be sure to use the same category you selected in 
section I of this form!) 
Ensure that all 5 criteria are addressed (regulations require justification using protocol-
specific information): 
 (1) The research is submitted under category 404 or 405 and qualifies based upon the 
following brief information:  
Justification:    
 (2) The research is therapeutic with the prospect of direct benefit to the child or if non-
therapeutic, represents no more than minimal risk to the subject.   
Justification:    
 (3) For children in court-appointed or state custody (as vulnerable research subjects), the 
research does not pose additional risks to and/or could not reasonably be accomplished 
without their inclusion.    
Justification:    
 (4) For children in court-appointed or state custody (as vulnerable research subjects), the 
LAR does not over-ride known or reasonably known religious or value restrictions of the 
child in court-appointed or state custody (or parents or guardians) and otherwise acts in 
accordance with the laws of the Commonwealth.  
Justification:    
 (5) Assent is requested of the child, as appropriate given the age and maturity of the child. 
Justification:    
Categories  [406] OR   [407] ONLY:  (Be sure to use the same category you selected in 
section I of this form!) 
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Ensure that all 9 criteria are addressed (regulations require justification using protocol-
specific information): 
 (1) The research is submitted under category 406 or 407 and qualifies based upon the 
following brief information:  
Justification:    
 (2) The research is a study focused on evaluating the status of wards OR conducted in a 
setting where the majority of children involved as subjects are NOT in court-appointed or 
state custody.  
Justification:    
 (3) The research is therapeutic with the prospect of direct benefit to the child or if non-
therapeutic, represents no more than minimal risk to the subject. 
Justification:    
 (4) The research does not pose additional risks to children in court-appointed custody (as 
vulnerable research subjects) and/or could not reasonably be accomplished without their 
inclusion. 
Justification:    
 (5) The LAR does not over-ride known or reasonably know religious or value restrictions 
of the child in state custody and otherwise acts in accordance with the laws of the 
Commonwealth. 
Justification:    
 (6) An advocate is appointed for each child who is in court-appointed or state custody 
(the advocate may serve on behalf of more than one child at a time and must be prepared 
to document appropriate background and experience to act in the best interests of the 
child for the duration of the research, document their willingness accept the role of 
advocate for the child, document that they have no other association with the 
research/investigator(s)/guardian organization, except as the role of advocate or member 
of the IRB.   
Justification:    
 (7) Explain whether the parents of a child in court-appointed custody are to be informed 
of the child's possible involvement in research and whether parental refusal may be 
considered.   
Justification:    
 (8) Assent is requested of the child, as appropriate given the age and maturity of the 
child.   
Justification:    
 (9) If a child(ren) in court-appointed or state custody is/are eligible for enrollment, but the 
study was not approved by the IRB to involve children in court-appointed or state 
custody, include the rationale, and process to allow such children as participants in the 
research (attach the VCU IRB Change in Research form to mark the submission). 
Justification:    
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Katherine Newnam 1104 Hillston Court,  Chesapeake, VA  23322 
Employment/ 
Experience 
Jan. 2007 to present   Neonatal ICU         CHKD 
Neonatal Nurse Practitioner 
Assessment, diagnosis and treatment for the critical ill neonate within the 
ICU under the direct supervision of the neonatologist.   
1994-2001 and 2005-2007      Neonatal ICU        CHKD 
Staff Nurse 
Continual assessment and treatment of neonates under the direction of 
the neonatologist, resident staff and /or neonatal nurse practitioner. 
Assist with additional staffing when needed.  Participate in the family 
support committee to enhance family centered care within the NICU. 
2000-2005 Renaissance Pediatrics Chesapeake, VA 
Certified Pediatric Nurse Practitioner 
With the oversight of a supervising physician I assessed, diagnosed and 
treated patients including prescriptive authority.  Patient load was 
approximately 22 assigned pediatric patients daily from newborn to age 
21 years.  Focus on well and preventative care with a focus in lactation 
and asthma support and teaching.  Supervised office nursing and support 
persons while assigned to assist in my daily functions.  Phone triage at 
night as assigned; weekly and hospital visits as required.   
2001-2006 Hospital Lactation Support CHKD 
Lactation consultant 
Assist with any lactation issues throughout the inpatient units and the 
Emergency department.  Hands on participation with latch techniques 
and pumping equipment and support. 
1988-1994 Progressive Care Unit    CHKD 
Unit Director, Progressive Care Unit 
Twenty four hour accountability for the operation of the Progressive 
Care Nursing Unit.  This included staffing, patient care, education, budget 
analysis and development, policy development and departmental 
representation for the Progressive Care Unit.  Implemented 
departmental relocation to the third floor and unit expansion from 10-13 
beds.  Directly supervised and evaluated the performance of fifty 
professionals and paraprofessionals with the assistance of two assistant 
nurse managers. 
1986-1988    Assistant Unit Director NICU 
1983-1986    Staff Nurse Infant & Toddler Unit/NICU 
 134
Education 
May 1983    Old Dominion University        Norfolk, VA 
Bachelor of Science    Nursing 
August 1990        Old Dominion University  Norfolk, VA 
Master of Science  Nursing Administration 
December 1999                    Old Dominion University  Norfolk, VA 
Post Master’s Certification    Certified Pediatric Nurse Practitioner 
December 2006                     East Carolina University        Greenville, NC 
Post Master’s Certification    Neonatal Nurse Practitioner 
August 2008-Current  VA Commonwealth Univ.    Richmond, Va. 
(graduation 2/2013)    PhD in Nursing 
Professional NAPNAP   National and Local Chapter 
Affiliations NANN       National and Local Chapter   
Certifications Basic Life Support (BLS) 
Neonatal Advanced Life Support (NALS) 
Pediatric Advanced Life Support (PALS) 
Certified Pediatric Nurse Practitioner (CPNP) 
Certified Neonatal Nurse Practitioner (NNP) 
Lactation Consultant (IBCLC) 
Publications/  
Presentations   
Newnam, K.M. & Parrott, J. (2013). The NICU graduate; Implications for Pediatric Primary 
Care.  Newborn & Infant Nursing Reviews. Accepted for publication (June, 2013). 
Newnam, K. M., McGrath, J.M., Jallo, N., Sayler, J., Estes, T, & Bass, W.T. (2012). An Integrative 
Review of Skin Breakdown in the Preterm Infant Associated with Nasal Positive Airway 
Pressure.  Journal of Obstetric, Gynecologic & Neonatal Nursing. Accepted with revisions. 
Newnam, K. M. (2012).  Understanding the mystery of adrenal insufficiency in the preterm 
infant & Continuous Positive Airway Pressure (CPAP): What Do We Know in 2011?  28th 
National Association of Neonatal Nurses (NANN) 27th Annual Educational Conference, Palm 
Springs, Ca. Podium Presentations. 
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Newnam, K. M., McGrath, J.M., Jallo, N., Sayler, J., Estes, T, & Bass, W.T. (2012). Continuous 
Positive Airway Pressure (CPAP), State of the Science. Council of the Advancement of Nursing 
Science (CANS), 2012 SOS Congress-Nursing Research, Washington, DC. Poster Presentation. 
Newnam, K. M. (2012). Sharing Science as a method to increase breast feeding rates in the 
NICU. NANN Research Summit, Scottsdale, AZ. 
Newnam, K. M. (2012).  Strategies to Reduce Skin Injury related to Nasal Continuous Positive 
Airway Pressure (CPAP) in Preterm Infants. 26th Annual Conference of the Southern Nursing 
Research Society (SNRS), Podium presentation. 
Newnam, K. M. (2011). Prevention of Skin Injury Related to Nasal Continuous Positive Airway 
Pressure (CPAP) in Preterm Infants, An Evidence Based Approach. 25th Anniversary Research 
Symposium of the National Institute of Health/National Institute of Nursing Research (NINR), 
Washington DC, Poster Presentation. 
Newnam, K. M. (2011). Prevention of Skin Injury Related to Nasal Continuous Positive Airway 
Pressure (CPAP) in Preterm Infants.  6th Annual Research Summit of the National Association 
of Neonatal Nurses (NANN), Orlando, Fl.  Paper Presentation. 
Newnam, K. M. & DeLoach, D. L. (2011). Neonatal Hypothermia: A Method to Provide 
Neuroprotection After Hypoxic Ischemic Encephalopathy. Newborn and Infant Nursing 
Reviews. Vol. 11 (3), 113-124. 
Newnam, K. M. & McGrath, J. M. (2011). Following the Diagnosis of Neonatal Hypoxic 
Ischemic Encephalopathy: A Family-Centered Approach. Newborn and Infant Nursing Reviews. 
Vol 11 (3), 98-101. 
Newnam, K. M. (2011). Prevention of Skin Injury related to Continuous Positive Airway 
Pressure (CPAP) in Preterm Infants. NANN Research Summit, Scottsdale, AZ. 
Newnam, K. M. & McGrath, J. M. (2011). Integrated Review of findings related to  
Neonatal Skin Care. Southern Nursing Research Society (SNRS), Jacksonville, Fl., Poster 
Presentation. 
Newnam, K. M. & McGrath, J. M. (2010). Understanding the Inflammatory Response of the 
Neonate: Clinical Implications for Caregivers in the Neonatal Intensive Care Unit. Newborn 
and Infant Nursing Reviews. Vol. 10 (4), 165-176. 
Newnam, K. M. & McGrath, J. M. (2010). Families and the Sepsis Work-up: Considering their 
Fears. Newborn and Infant Nursing Reviews. Vol. 10 (4), 160-162. 
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Newnam, K. M. Improving Fluid Management and Decreasing PDA by improving the Neonatal 
Environment. Poster presentation for National Association of Neonatal Nurses (NANN), 
Annual conference 10/07. 
Newnam, K. M. Hyperbilirubinemia: Guidelines for Care in the Newborn. Presentation to 
Tidewater Area Lactation Consultant Association (TALCA) in 9/2005. 
Newnam, K. M. Hyperbilirubinemia: Guidelines for Care in the Newborn. Repeated 
presentation for NICU staff educational session, 10/2005. 
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Appendix B. 
 
 
 
 
The following published research plan was submitted to and approved by the  
Eastern Virginia Medical Center Institutional Review Board 
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OFFICE OF RESEARCH SUBJECTS' PROTECTIONS I WWW.EVMS .EDU ~ 
PO . Box 1980 [' Norfo lk, VA 2'3501-1980 I Phone 757.4 46.5854 l Fax 757 .624 .2275 ~ 
EVMS 
Eastern' irginia Medical School 
Kathy Newnam, RN, NNP-BC 
CHKD 
601 Children 's Lane 
Norfolk, VA 23507 
Dear Ms. Newnam: 
March 8, 2012 
IRB # 12-01 -EX-0013 
This form provides additional information to the Application for Approval of Research Involving Human Subjects form that accompanies this letter. 
The Application is the official document that confirms IRB review and type of approval and includes the IRB#, study title, and an appropriate chair, 
vice-chair or IR.B member signature. 
~ IRB Study Title: A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) Related Skin Breakdown when using 
Different Nasal Interfaces in the Extremely Low Birth Weight (ELBW) Neonate. 
• Protocol: A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) Related Skin Breakdown when using 
Different Nasal Interfaces in the Extremely Low Birth Weight (ELBW) Neonate Version Date: No version date 
~ No sponsor has been identified as providing funding for this study or project. 
Data Collection Consent Form: Version 1 Dated: 12/22/11 
Your consent form has been stamped with the approval date and is/are enclosed for your use until a different consent form supersedes it. 
Please remember that a signed written consent form is not considered a substitute for discussion, but an educational process including a 
full explanation of the protocol and consent form to the subject, while allowing time for questions prior to signing. The subject's signature is 
considered verification of the investigator's explanation of the research prior to, not after, initiation of the research. 
Waiver for the Use of PHI has been justified using the following criteria: 
• The use or disclosure of PHI involves no more than minimal risk to the individuals, based on, at least, the presence of the following 
elements: 
a. An adequate plan to protect the identifiers from improper use/disclosure 
b. An adequate plan to destroy the identifiers at the earliest opportunity consistent with the conduct of the research , unless there is a 
health or research justification for retaining identifiers or such retention is otherwise required by law 
c. Adequate written assurances that PHI will not be reused/disclosed to any other person or entity, except as required by law, for 
authorized oversight of research project, or for other research for which use/disclosure of PHI would be permitted by this subpart. 
• The research could not practicably be conducted without the alteration or waiver; 
• The, research could not practically be conducted without access to and use of the PHI . 
Data Collection Tools: 
Data Collection Form - Enrollment 
Data Collection Form - Daily 
Data Collection Form - Weekly 
This approval is a result of an Expedited Board action that specified the following category/categories under 63FR 60364 dated November 9, 1998: 
~ (4) Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical 
practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for 
marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, 
including studies of cleared medical devices for new indications.) Examples: (a) physical sensors that are applied either to the surface of 
the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject's privacy; 
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IRB# 12-01-EX-0013 
March 8, 2012 
Page 2 
(b) weighing or testing sensory acuity; (c) magnetic resonance imaging; (d) electrocardiography, electroencephalography, thermography, 
detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, doppler blood fiow, and 
echocardiography; (e) moderate exercise, muscular strength testing, body composition assessment, and fiexibility testing where 
appropriate given the age, weight, and health of the individual. 
I:8J (5) Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for 
non research purposes (such as medical treatment or diagnosis). 
I:8J This study was approved on January 25, 2012 and may be initiated now that you are in receipt of Final Approval documents. 
o IF YOU ARE CONDUCTING YOUR RESEARCH AT ONE OF THE LOCAL HOSPITALS, YOU MUST RECEIVE THE APPROPRIATE APPROVALS FROM THAT 
HOSPITAL BEFORE INITIATING YOUR STUDY. 
o IF YOU ARE CONDUCTING YOUR RESEARCH AT A SITE OTHER THAN EVMS, YOU ARE RESPONSIBLE FOR OBTAINING ANY LOCAL REVIEW 
NECESSARY FOR THE CONDUCT OF THIS RESEARCH. 
Child Risk Designated by the Board: 
The Board noted that this study using children does not involve greater than minimal risk and that adequate provisions have been made for 
soliciting the assent of the children , including permission of each subject's parent or guardian. [45CFR46.404] 
Your protocol expiration date is January 24, 2013. Please see the attached form for the due date of the next continuing review 
submission. 
Please remember that prompt reporting to the IRB of proposed changes in a research activity (e.g., changes to the protocol, consent 
form(s) , advertisements, or other study-related materials) is required. This includes information related to funding sources. In addition, the 
changes must be reviewed and approved by the EVMS IRB before the changes can be initiated except when it is necessary to eliminate 
apparent immediate hazards to the subject. 
Eastern Virginia Medical School (EVMS) has a Federalwide Assurance (FWA 00003956) from OHRP. The Institutional Review Boards 
(IRB 00000460 and IRB 00001345) are registered with OHRP and are in compliance with 45 CFR 46, 21 CFR 50, and 21 CFR 56. 
Please reference the IRB number, principal investigator and study title in any correspondence regard ing th is protocol. 
Thank you for your continued cooperation with the Institutional Review Board. 
BCC/dms 
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FWA #00003956 
July 2007 
APPLICATION FOR APPROVAL OF RESEARCH INVOLVING HUMAN SUBJECTS 
EVMS Institutional Review Board 
Instructions: Please submit this form to the IRB Office, attaching the IRB protocol, abstract, data collection instruments, consent forms 
andlor informational letters, letters of approval from agencies, hospital impact statement(s) and other supporting documents. 
HANDWRITIEN DOCUMENTS WILL NOT BE ACCEPTED BY THE IRB OFFICE. 
ALL DOCUMENTS INCLUDED IN THE SUBMISSION MUST BE PAGINATED. 
HELP: If you are unsure how to complete a field, press F1 while on the field and a help box will appear. 
IRB Number: 
(If ass~ned) ')-' - -'\ / . • •· .. -'>1 - "'.:.A·· c' ; . 
ADMINISTRATIVE INFORMATION 
A Comparative Effectiveness Study of Continuous Positive Airway Date Submitted: (IRB USE ONLY) 
Study Title: Pressure (CPAP) Related Skin Breakdown when using Different Nasal ~~~ . -.-, 
Inlerfaces in Ihe Extremely Low Birth Weight (ELBW) Neonate. rn u r; ~ 101 [1 i~il 
Principal Investigator: Katherine M. Newnam, PhD (c), RN, NNp·BC 
,,', , '., " i.::J 
Children's Hospital of the Kings Daughters, NICU 
PI Dept I Address 
601 Children's Lane In 
City I State I Zip Norfolk, Virginia 23507 ." -
Phone Number(s): (757) 668-7452 E·Mail: katherine.newnam@chkd.org 
Person Preparing This Submission 
Name: Katherine M. Newnam, PhD (c), RN, NNp·BC Role: Investigator 
Address: Children's Hospilal of the Kings Daughters, NICU, 601 Children's Lane, Norfolk, Virginia 23507 
Phone Number(s): (H) 757·546·7497 and (W) 757·668-7452 E·Mail : katherine.newnam@chkd.org 
INVESTIGATORS ANDIOR RESEARCH TEAM MEMBERS 
HIPAA for Human 
Name Department Address Status Research Subjects Protection Training Date Training Date 
Rebecca Tucker NeonatallCU, CHKD 601 Children's Lane, Research Team Member in process in process Norfolk, VirQinia 23507 
Melinda Bissett NeonatallCU, CHKD 601 Children's Lane, Research Team Member in process in process Norfolk, Virginia 23507 
Lynetta Cox NeonatallCU, CHKD 601 Children's Lane, Research Team Member in process in process Norfolk, Virginia 23507 
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-- Choose One --
-- Choose One --
-- Choose One --
-- Choose One --
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1
1
. 
TYPE OF REVIEW: Review the sub-categories and check the appropriate box (check only one) 
FULL BOARD REVIEW: (A $1 ,500 review fee is charged unless a "Wavier of IRB Fee" form is submitted with Ihis 
0 applicalion and approved by the Office of Research Subjects Protections.) 
CLICK HERE AND PRESS F1 FOR NUMBER OF COPIES TO SUBMIT: ~ 
~ EXPEDITED REVIEW: Insert the Category number below Ihat supports Ihe type of review: 4 & 5 CLICK HERE AND PRESS F1 FOR NUMBER OF COPIES TO SUBMIT: ~ 1 hard copy and electronic submission 
(1 ) Clinical Studies of drugs or devices when: [laJ Drugs: IND not required; [1bJ Devices: IDE not required. 
(2) Collection of blood samples. CLICK HERE AND PRESS F1 FOR GUIDANCE: ~ 
(3) Prospective collection of biological specimens for research purposes by noninvasive means. 
(4) Collection of data through noninvasive procedures roulinely employed in clinical practice. excluding procedures 
involving x-rays or microwaves. 
(5) Research involving materials that have been collecled. or will be collected solely for non-research purposes. 
(6) Colleclion of data from voice. video. digital. or image recordings made for research purposes. 
(7) Research on individual or group characteristics or behavior or research employing survey. interview, oral hislory, focus 
group. program evaluation human factors evaluation. or quality assurance methodologies. 
0 EXEMPT REVIEW: Insert the Calegory number below that supports the type of review: -- Choose One --CLICK HERE AND PRESS F1 FOR NUMBER OF COPIES TO SUBMIT: ~ 
(1) Research in Educational Setting involving normal educational praclices. 
(2) Educational Tests. Survey Procedures. Interview Procedures. or Observe Public Behavior unless subjects can be 
identified gruj disclosure place subjects at risk of criminal & civil liability. [Does not apply to those <18 years old. 
Therefore, defaults to expedited or Full Board review.J 
(3) Educational Tesls, Survey Procedures, Inlerview Procedures, or Observe Public Behavior unless subjects 
elected/appointed officials or candidates for public office gruj Federal stalule requires maintenance of confidentiality. 
[Does not apply to those <18 years old. Therefore, defaults to expedited or Full Board review.J 
(4) Collection/Study of Existing Dala, Documents, Records, PalhologicallDiagnostic Spec mens and Subjects Cannot Be 
Identified. CLICK HERE AND PRESS F1 FOR GUIDANCE: ~ 
(5) Federal Dept/Agency Research & Demonstration projects. 
(6) Taste & Food Quality Evaluation & Consumer Acceptance Studies. 
12. 1 REQUIRED TRAINING: 
It is necessary for all investigators, co-investigalors, and research team members to complete human subjecls proteclion training in 
order to receive IRB approval to proceed with research using human subjects, their data. or biological samples. Training opportunities 
and requirements can be found on Ihe Office of Research web sile at http://www.evms.edu/research/office/index.html. 
Contact the Office of Research at (757) 446-8480 for additional information on all research training requirements. 
Please note that Bloodborne Palhogen Training is mandated annually for EVMS faculty and staff wilh potential exposure to bloodlbody 
fluid by_lhe Occupational Safety and Heallh Administration (OSHA). 
Contact the Occupational Health Department at 446-5870 for additional information. 
3. 1 FINANCIAL STATEMENT: 
Have you, other family members or any other person responsible for the design, conduct, or reporting of this Choose one answer 
research received from the sponsor (or a subsidiary or parent company olthe sponsor): in each row below: 
Salary, olher paymenls for services (e.g. , consulting fees or honoraria), recruitment bonuses, trips. referral fees or ~No DYes 
other incentives that are NOT covered by an EVMS grant, contract, or clinical agreement? 
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Equity interests (e.g., stocks, stock options, or other ownership interests greater than 3% ownership or greater than IZ! No DYes $10,000 per annum of salary, fees, or other continuing payments)? 
Intellectual property rights (e.g., patents, copyrights and royalties from such rights)? IZ! No D Yes 
If "yes," to any ofthe above, please provide a written explanation of the situation in this box. You may also be required to submit 
information to the EVMS Conflict of Interest (COl) Committee through the Office of Research, 446-8480. Refer to Appendix C for Model 
Language to insert into the consent form. 
4, I THIS STUDY WILL BE ACTIVE AT THE FOLLOWING LOCAL SITES: (Be sure to list site for ALL phases of the research) 
o Bon Secours DePaul Medical Center o Bon Secours Maryview Hospital IZ! Children's Hospital of The King 's Daughters 
o Children's Specialty Group o Devine Tidewater Urology o Eastem Vi rginia Medical School 
o Sen tara Bayside Hospital o Sen tara CarePlex Hospital o Sentara Leigh Memorial Hospital 
o Sentara Norfolk General Hospital o Shore Health Services o Virginia Oncology Associates 
(41.) Other local or international site for this IRB application (specify nama and include the complete address): TYPE 
-- Choose One --
-- Choose One --
-- Choose One --
-- Choose One --
5. I OTHER SITES: 
In addition to the local sites listed above, is this study also conducted at any national or intemational sites? l IZ! No 0 Yes 
6. I TYPES OF PARTICIPANTS (CHECK ALL THAT APPLY): 
IZ! Children [specify age range(s)): Newborn to 2 o Adults [specify age range(s)): 
months of age. (NOTE: Adults 90 or older must be grouped into one category per HIPAA regulations. 
o Students/Employees o Healthy Volunteers o Critically III Patients 
o Cognitively Impaired Individuals o Subjects in Emergency Conditions o Economically Vulnerable Subjects 
o Pregnant Women o Fetus(es) o In vitro fertilization 
IZ! Medical Records o Specimens (blood, tissue) 
o Other: (specify): 
7. I SOURCE OF SUBJECTS: (CHECK ALL THAT APPLy): 
IZ! My Practice o Referral from Other Physicians o Medical Records 
o Outpatients/Clinics o Stored/Banked Human Specimens o Other, Explain in Protocol 
NOTE: Ail advertisements or other materials used to recruit subjects must be submitted for IRB approval. 
8. I CONSENT PROCEDURES: (CHECK ALL THA T APPLy): 
8a. CONSENTTO BE OBTAINED FROM: I 8b. CONSENT TO BE OBTAINED BY: 
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o PatienUSubject o Principal investigator 
[8] Parent(s)/Guardian [8] Co-investigator(s) 
o Legally authorized representative [8] Research Team Members not on protocol (list below) 
o Assent to be obtained from subjects age to 
Be_ List others not identified in the protocol who are qualified and authorized to obtain subject consent (e.g., study coordinators, 
clinical staff, etc.) Any individual listed in this section must meet all appropriate EVMS training requirements. 
NAME: RELATIONSHIP TO THE STUDY: LIST ALL SPECIFIC QUALIFICATIONS TO 
CONDUCT THE INFORMED CONSENT PROCESS: 
Rebecca Tucker Research Team Member Advanced nurse practitioner who has 
expertise in obtaining informed consent as 
part of her position in the management of the 
NICU patient. 
Melinda Bissett Research Team Member Advanced nurse practitioner who has 
expertise in obtaining informed consent as 
part of her position in the management of the 
NICU patient. 
Lynetta Cox Research Team Member Advanced nurse practitioner who has 
expertise in obtaining informed consent as 
part of her position in the management of the 
NICU patient. 
-- Choose One --
-- Choose One --
-- Choose One --
8d. WITNESS: In most cases, a witness signature is not required unless consent is obtained orally. If a witness signature is preferred by the 
investigator or sponsor, please explain below and indude the appropriate signature box on the subject consent form(s). 
9_ I WAIVER REQUESTS (CHECK ALL THAT APPLy): 
Are you requesting that the IRB waive the requirements for obtaining subject consent for this study? 
If yes, an "Application for Waiver of Consent" must be completed and attached to ALL copies of the submission. [8] No DYes 
ALL REQUESTS FOR WAIVER OF SUBJECT CONSENT ARE REVIEWED BY THE FULL BOARD. 
Are you requesting that the IRB allow access to or the use of Prolected Health Information (PHI) without obtaining 
subjects permission? 
oNo [8] Yes 
If yes, an "Application for Waiver of Authorization for the Use of Protected Health Information (PHI)" must be 
completed and attached to ALL copies of the submission 
10, SUBJECT PARTICIPATION: 'All items must be answered. If applying for a medical record review, length of active participation 
and follow-up should be answered as "Not Applicable". 
ITEM INSERT LENGTH OF TIME, NUMBER OR DATE 
The infant will be observed during nasal CPAP admistration which 
Length of time for active partiCipation (as defined in protocol) according to recent unit statistics (Jan-June, 2011) is between 1 and16 
days with a mean of 3.9 CPAP days. 
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Follow-up (long-term follow-up after study completion) None anticipated 
Number of local subjects or medical records or samples Anticipated enrollment of 72 patients 
Total number of subjects or records or samples across all sites Anticipated enrollement of 72 patients 
Duration of study at this local site Anticipated duration 7 months 
Anticipated Start Date the proposed study will begin (be sure to February, 2012 
allow time for IRB review and approval): Month /Year 
Anticipated End Date of the proposed study August, 2012 
Month /Year 
11. ARE THE FOLLOWING ASSOCIATED WITH THE RESEARCH STUDY? 
11a. SUPPlEMENTARY DOCUMENTS tNClUDED: 
0 Subject Diary ~ No DYes If Yes, insert identifier: 
0 Questionnaire or Psychologicallnslrument ~ No DYes If Yes, insert identifier: 
0 Federal NIH Grant Application ~ No DYes If Yes, insert identifier: 
0 Investigator Brochure ~ No DYes If Yes, insert identifier: 
0 Drug Package Insert ~ No DYes If Yes, insert identifier: 
0 Data Collection Tool (with a key to all field headings) o No ~ Yes If Yes, insert identifier: 
0 Advertisements / Flyers / Patient Information Sheets ~ No DYes If Yes, insert identifier: 
0 Other, Please Explain: D No DYes If Yes, insert identifier: 
0 Other, Please Explain: o No DYes If Yes, insert identifier: 
11b, RESEARCH-RELATED USE OF ANY OF THE FOllOWING: 
0 Investigational Drugs/Biologics: ~ No DYes If Yes, insert IND#: 
FDA Approved Drug(s) for an Unapproved Use 
If Off-label Use, an IND ~ not ahNays required. If spoosor cooperating o No DYes Comments: 
with goal of extending use of drug an INO is required 
FDA Approved Drug(s) for an Unapproved Subject Group 
If Off·Label Use, an INO is not always required. If sponsor cooperating o No DYes Comments: 
with goal of extending use of drug an INO is required 
0 Investigational Devices: ~ No DYes IDE#: and Date: 
--
-~--.--
-
Risk Assessed by Sponsor D Significant Risk (SR) 
D Non-Significant Risk (NSR) 
0 Humanitarian Device Exemption: ~ No DYes HDE#: 
11c. DESIGN OF STuDY: 
0 Placebo Controlled ~ No DYes Comments: 
0 Blinded ~ No DYes If Yes, D Double Blind or 0 Single Blind 
Comments: As described in the attached study 
proposal, the neonates will be randomized to one 
0 Randomized o No ~ Yes of three groups (mask, prongs or alternation of 
mask/prongs every 3-4 hours) when nasal CPAP is 
medically indicated and initiated. 
0 Anonymous Surveyor Questionnaire ~ No DYes Comments: 
0 Banking of Tissue / Specimen / Data ~ No DYes Comments: 
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Comments: NICU admission data will be reviewed 
~ Retrospective Review of Records or Information o No ~ Yes for potential study participants every 24 hours 
which may require retrospective record review. 
0 Registry Study ~ No DYes Comments: 
0 Compassionate Use - Contact IRB office for guidance ~ No DYes Comments: 
0 Other: o No DYes Comments: 
11d. SAFETY MEASURES: 
0 Data/safety monitoring is included in the study. ~ No DYes If yes, details must be provided within the protocol or as an attachment. 
Please specify the type of monHoring: 
0 Local data and safety monitoring plan in place ~ No DYes Comments: 
0 Spensor reviews adverse events, interim findings and ~ No DYes Comments: relevant literature 
0 Data Safety Monitoring Board [DSMB], Data Monitoring ~ No DYes Comments: Committee (DMC) or other similar body in place 
Other measures: 
0 Certificate of Confidentiality (for genetic research ~ No D Yes Comments: involving identified samples) 
0 Other: ~ No DYes Comments: 
11e. USE OF SPECIMENS OR DATA: Tissue/data banking and genetic research require additional protections for subjects. 
0 Genetic research will be done on biologic samples. ~ No DYes If Yes, 0 Samples will be de-identified o Samples will be identified 
0 Gene therapy vectors or recombinant DNA products will ~ No DYes If Yes, EVMS Biosafety Committee Approval be used. # on 
0 Cell lines will be developed ~ No DYes Comments: 
0 Cell lines from unidentified subjects will be used in this ~ No DYes Comments: research study. 
Samples/data will be used and kept for the use of this 
0 study only. ~ No DYes Comments: 
The intent is NOT TO ESTABLISH a 'tissue/data bank. 
Comments: The researcher request permission to 
maintain this dataset for possible future meta-
Samples/data will be storedibanked for the use of the analysis (using this data plus data obtained from 
~ investigators OR others. o No ~ Yes future studies). However, this data will only be 
The intent is TO ESTABLISH a repository or bank. stored and used by this research team (no others). 
~ Samples will be de-identified 
o Samples will be identified 
If yes, provide the IRB # for protocol to govern collection and storage of samples: IRB#: 
0 Certificate of Confidentiality (for genetic research ~ No DYes Comments: involving identified samples) 
11f. SPoNSOR AND/OR GRANTING AGENCY: 
Sponsor is a Federal granting agency. 
0 [If Federally funded by NIH, you must submit the entire ~ No DYes Name of Spensor: 
grant with this application.] 
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0 Sponsor is a commercial company. 1:3:1 No DYes Name of Sponsor: 
0 Sponsor is a non·profit granting entity. 1:3:1 No DYes Name of Sponsor: 
0 Sponsor is academic/hospital department or personal 1:3:1 No DYes Name of Sponsor: funds. 
IF YES TO ANY OF THE ABOVE, PLEASE ANSWER THE FOLLOWING QUESTIONS 
Who is the Principal Investigator on the award? 
To which entity/institution is the primary award made? 
1:3:1 Unsupported, no funding o No 1:3:1 Yes Comments: 
12. TO THE BEST OF YOUR KNOWLEDGE, HAS THIS STUDY ALREADY BEEN APPROVED BY AN EVMS IRB UNDER ANOTHER INVESTIGATOR? 
1:3:1 No I 0 Yes I lf yes, provide: Investigator's Name: and IRB#: 
13. , VERIFICATION OF SCIENTIFIC REVIEW AND ACCEPTANCE STATEMENT: 
It is necessary for each principal investigator to verify the scientific merit of a new study before submitting the study for IRB review. Based on 
information submitted by the principal investigator, the appropriate department chair (or designee), certifies the conduct of the study under 
hisiher department. 
By signing below, you confirm that you have sufficient staff and facilities to conduct this study 
By signing below, you agree to abide by the EVMS IRB Assurance which specifies compliance with OHRP Regulations for Protection of 
Human Research Subjects, and you agree to conduct your research: 1) according to the guidelines of this statement, 2) according to human 
subjects regulations outlined in the human subjects training you have completed, and 3) according to the information you supplied in this 
Application. 
By SIGNING BELOW, YOU UNDERSTAND YOU MUST OBTAIN WRITTEN IRB APPROVAL BEFORE INITIATING ANY RESEARCH PROCEDURES OR ACTIVITY. 
PRINCIPAL INVESTIGATOR SIGNATURE: DATE OF SIGNATURE 
.\ ~~A J.. 
.'l\ . -~'''-- IL / ~ /il 
14, I DEPARTMENT CHAIR CERTIFICATION: 
This protocol has been reviewed by me or an appropriate designee and I agree that this study has scientific merit. 
DEPARTMENT CHAIR OR DIfSIGN,EE OR SlGNf~E: DATE OF SIGNATURE 
Signature: /\ lUV ;7 ""- /2- / 21 / J \ 
Printed Name: f) W Lw,~ , Department: 'f£j)S 
THIS SECTION FOR IRB USE ONLY 
FINAL DISPOSITION: 
REVIEW CATEGORY ACTION CONTINUING REVIEW DEADLINE 
o Exempt )t1J Approved 
-f.I- 1 ~I ~ 
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IfI. Expedited o Disapproved 
o Full (Convened) Board 
X IfL IRS SIGNATURE: I'\. /' 
SIGNED BY: o IRB Chair 1iO IRB Vice Chair o IRBMember 
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Study Title: 
Application for Approval of Research Involving Human Subjects 
Do NOT EXCEED Two (2) PAGES AND Do NOT INCLUDE EXTRA PAGES 
Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) 
Related Skin Breakdown when using Different Nasal Interfaces in the Extremely Low 
Birth Weight (ELBW) Neonate 
Principal Investigator: Katherine M. Newnam, PhD (c), RN, NNP-BC 
1_ CLEARLYSTATETHE PuRPOSE OF THE STUDY: 
IRB Number: 
The primary aim of this study will be to determine differences in the frequency, severity and specific types of nasal injuries described when 
comparing different nasal CPAP interfaces (prongs/mask) used to treat respiratory distress syndrome. These outcome measures will be 
calculated based on recorded information included in the neonatal skin condition score (NSCS), a three parameter tool that evaluates skin 
breakdown, erythma and dryness. A secondary aim of the study will be to identify those risk those factors associated with nasal injury and 
skin breakdown during nasal CPAP administration. Lastly an exploratory aim will be to identify and describe nursing strategies that can 
support the reduction of nasal injuries in this vulnerable population during nasal CPAP administration. Additional data will be collected 
during the study which will include the agitation levels of the infants during nasal CPAP administration and the respiratory stability of the 
patients as measured by blood gases. These measures will be used to explore other potential factors associated with nasal injury and skin 
breakdown. The hypotheses for this comparative effectiveness study are: 1) Is there a difference in the incidence andlor severity of skin 
breakdown of the ELBW preterm neonate (less than 1500 grams) when nasal CPAP is administered using three types of (standard-{)f-care) 
nasal interfaces: 1) continuous nasal prongs, 2) continuous nasal mask or 3) alternating the nasal mask and prongs every 4 hours? 2)Are 
the differences in the incidence andlor severity of skin breakdown related to other predisposing risk factors such as gestational age, birth 
weight, length of therapy, environmental humidity level, amount of CPAP flow administered andlor nursing interventions that include 
positioning techniques, nasal suctioning devices and the use of nasal saline during suctioning? 3)Will the frequency and severity of nasal 
injury be accurately measured with the NSCS? 4) Is there a correlation between agitation scores as measured by the N-PASS and the 
incidence andlor severity of nasal injury during the use of nasal CPAP in the ELBW preterm neonate? 5)ls there a correlation between 
blood gas results, specifically respiratory acidosis reflected in the pH, C02 and base excess levels and the incidence of nasal injury in the 
ELBW preterm neonate? 
2. PROVIDE A BRIEF DESCRIPTION OF DESIGN: 
A three group prospective randomized experimental study design is currently planned. This would include recruitment into the study 
following admission to the neonatal intensive care unit (NICU) when infants are typically intubated during the mechanical ventilation phase 
of treatment. Upon extubation to nasal CPAP (the typical care for these infants) the participants would be randomized into three groups to 
include, 1) a continuous nasal prong group, 2) a continuous nasal mask group or 3) an alternating mask/prongs every 4 hours group. All 
infants will be managed with the same type of nasal CPAP delivery system. Infants transported from the delivery room or outlying hospital 
that are initially treated with nasal CPAP would be considered for enrollment if consent was obtained and randomization could occur within 
8 hours. Following parental consent, infants would be clearly identified by a star placed on respiratory care providers clipboard to remind 
caregivers to enroll participants as the medical condition of the patient was appropriate for transition from current therapy to nasal CPAP 
following physician or neonatal nurse practitioner (NNP) order to extubate the patient. Infants who meet study inclusion criteria and who 
have been consented and self extubate will also be randomized for nasal CPAP trial if medically appropriate as dictated by physician or 
nurse practitioner order. No infants will be placed on nasal CPAP unless medically warranted; therefore patients who are extubated to high 
flow or regular nasal cannula will be excluded unless nasal CPAP is used in those patients at a later time as medically indicated. Following 
parental consent the infants recruited for the study will be block stratified according to weight into four categories according to birth weight: 
< 750 grams, 750-1000 grams, 1001-1250 grams and> 1251-1500 grams. After stratified the subjects will be randomly allocated into the 
three groups described above. Randomization will accomplished using serially numbered opaque sealed envelopes developed by the 
researcher which will be located close to the storage area which houses the CPAP equipment within the NICU. Routine skin assessments 
will be completed every 3-4 hours which is consistent with current care practice. A small group of skin experts (advanced NP's), described 
as the Core Research Team, will be responsible for twice a day skin care evaluations on enrolled participants during the infant's routine 
nursing care as well as completion of the data collection fOIlll (de-identified patient data). Patients randomized to the nasal prongs group 
and conventional prongs are not able to fit according to manufacture guidelines (rare event) will be removed from the study as exclusion. 
I 3. PARTICIPANT INFORMATION: 
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Duration of individual subject's total involvement (provide all details - active; long·term follow·up, etc.): 
Following parental consent the infants recruited for the study will be block stratified according 10 weighl inlo four categories according to 
birth weight:<7S0 grams,7S0·1000 grams,1001-12S0 grams and >12S1-1S00 grams. After stratified the subjects will be randomly allocaled 
into three groups, 1) a continuous nasal prong group, 2) a continuous nasal mask group or 3) an alternating mask/prongs every 4 hours 
group. Randomization will be accomplished using serially numbered opaque sealed envelopes developed by the researcher. Skin 
assessmenls will continue every 3-4 hours per unit protocol. Dala collection will be completed every 12 hours by the Core Research Team 
and includes the following assessment tools: 1 )Biographical data: to include infant's gestational age, birth weight and current weight. 2) 
Information collected relaled to therapy: CPAP liter flow, day of CPAP, humidification of environment as measured on the incubator 
humidity gauge (Giraffe ©), and temperalure of the nasal CPAP humidifier. 3)Neonalal Skin Condition Scale (NSCS) is a skin condition 
scoring system that was developed for the AWHONN/NANN skin care research based projecl and adapled using a visual skin scoring 
system.The tool uses three clinical outcome calegories which includes dryness, erythma and breakdown or excoriation of the skin. Each of 
these categories is graded one through three. The score of one in each category indicates a heallhy skin assessment and the score of two 
or three indicates an increasing level of skin breakdown wilh a total score of nine (three in each category) being Ihe worse skin evaluation 
score possible. Pictorial representation of each calegory with examples of skin that represented each score was developed to use as an aid 
for the clinician during the assessment of neonatal skin. 4)Agitation levels olthe infants will be monitored using the Neonatal Pain, Agitation 
and Sedation Scale (N-Pass) was developed as a clinically relevant tool to assess primarily acute or chronic pain as well as sedation level 
in preterm infants who are not capable of self report.S)Blood gases will be recorded in an effort to establish relationships between 
increased respiralory distress symptoms as demonstrated by increased carbon dioxide levels and skin breakdown measure. Interrater 
reliability will be tested through the use of two experts assessing 10% of study participants to assure score agreement. Patients will be 
monitored during nasal CPAP administration only without scheduled follow up after transition to alternate method of respiratory support. 
How will subjects be recruited? 1) Subjects will be identified based on current respiratory management (mechanical ventilation or nasal 
CPAP) and birth weight SOO-1 SOD grams. 2) Parents or guardians of those patients who are admitted to the NICU and who meet the study 
inclusion criteria will be approached following admission to the unit. The research study will be explained to each family providing adequate 
time to answer questions related to the proposed research plan. Parents who are unable to visit the NICU because of geographic or other 
barriers will be contacted by phone to explain the research study, reading informed consent in its entirity and invite participation similar to 
the process of obtaining blood or operative consents over the phone. In this special case (rare) after reading the consent and answering all 
questions, copies will be mailed to parents home address. 3) The initial contact with the parent will be made by the Core Research Team if 
the neonate meets inclusion criteria. 
Inducements to participate: None offered 
Inclusion Criteria: Infants who are initially treated with or weaned from mechanical ventilation to nasal CPAP and who are birth weight 
SOD grams to IS00 grams. Infants with a birth weight under SOD grams will not be considered based on documented overall concerns with 
skin integrity in this group (Sardesai, Komacka et al. 2011) which could influence study results. 
Exclusion Criteria: Infants who have been diagnosed with major cardiac disease or congenital malformation which could impair the nasal 
CPAP performance would be excluded. Patients who are not consented within 8 hours of nasal CPAP initiation or who had nasal skin 
breakdown at enrollment would be excluded and patients outside of the weight inclusion described above would be excluded. 
4. BENEFITS TO SUBJECTS (Do NOT USE WORDING SUCH AS "YOU", ·YOUR", ETC.): 
There are no direct benefits to the study participants at present; however, changes in how nasal CPAP is administered to this patient 
population may provide benefits in future neonatal care. 
5. RISKS TO SUBJECTS (Do NOT USE WORDING SUCH AS "YOU", "YOUR", ETC.): 
There are no anticipated risks/discomforts associated with participation in this research study. Individual risk to individual patients are 
considered minimal and consistent with the risk experienced with current standard nasal CPAP use for the identified neonatal population. 
6. MEASURES TO MlNIIIIZE RISKS: 
Risk Reduction: Frequent patient skin assessment (at least every 4 hours) by the bedside registered nurse and/or respiratory care therapist 
is required by both unit and research protocol. Signs of hyperemia, erylhma or excoriation will be reported to the health care team and 
treatment ordered as necessary which is consistent with current medical care. Intolerance to nasal CPAP treatment will be addressed in 
the usual manner with increased medical care to include escalating respiratory support up to and including endotrachael intubation (current 
practice). All three described nasal interfaces are currently in use within the NICU research setting. No changes in the standard unit care 
are anticipated based on the use of the type of nasal interface during the administration of nasal CPAP in the preterm infant. 
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APPLICATION FOR WAIVER OF AUTHORIZATON FOR THE USE OF PHI 
EVMS Inslitutional Review Board 
FWA #00003956 
July 2007 
NOTES: 1. This applicalion accompanies your "Application for Approval of Research Involving Human Subjects" if you will require access 
to Protected Health Information to complete your research. 
HELP: If you are unsure how to complete a field, press F1 while on the field and a help box will appear. 
Study Title: 
HANDWRITTEN DOCUMENTS WILL NOT BE ACCEPTED BY THE IRB OFFICE. 
ALL DOCUMENTS INCLUDED IN THE SUBMISSION MUST BE PAGINATED. 
A Comparative Effectiveness Study of Continuous Positive Airway Date Submitted: (IRB USE ONLY) 
Pressure (CPAP) Related Skin Breakdown when using Different Nasal 
Interfaces in the Extremely Low Birth Weight (ELBW) Neonate. 
Principal Investigator: Katherine M. Newnam, PhD (c), RN, NNP-BC 
PI Dept / Address 
City / State / Zip 
Children's Hospital of the Kings Daughters, NICU 
601 Children's Lane 
Norfolk, Virginia 23507 
Phone Number(s): (757) 668-7452 E-Mail: katherine.newnam@chkd.org 
I AM REQUESTING A WAIVER OF AUTHORIZATION FOR THE USE OF PROTECTED HEALTH INFORMATION (PHI). THE FOLLOWING 
VERIFICATION IS PRESENTED IN SUPPORT OF THIS WAIVER: 
(ALL SECTIONS MUST BE COMPLETED) 
PHI WAIVER JUSTIFICATION 
• Provide a brief description of the specific PHI to which you are requesting access (be sure to list each item). 
DISCUSS IN DETAIL YOUR PLAN: 
The specific Protected Health Information (PHI) that will be examined will be the patients name, medical record number, birth 
weight and current respiratory support (ie mechanical ventilation/nasal CPAP). As part of screening for neonates who meet 
study criteria following admission to the Neonatal Intensive Care Unit (NICU) each patient's admission information will be 
retrospectively reviewed every 24 hours. Specifically the birth weight and respiratory support required by that neonate will be 
screened. If the neonates birth weight is between 500 and 1500 grams and the patient is currently receiving mechanical 
ventilation or nasal CPAP the parent of that neonate will be contacted for consent to participate in the research study. 
Following consent the PHI screened will be maintained on the consent form only and then patient information will be de-
identified for all other data collection and analysis. This screened information for patients who do not meet study criteria will 
not be maintained /recorded by the research team unless the patient consent is received and the neonate is enrolled in the 
study. 
• The research could not practically be conducted without access to and use of the PHI. 
DISCUSS IN DETAIL YOUR PLAN: 
Without the described review of pertinent inclusion criteria described above, it would be necessary to consent every admitted 
infnat to the NICU and then exclude all neonates who do not meet weight or respiratory support inclusion criteria described in 
the study protocol. This would be a significant burden to the patients parents as well as the study team. 
• The research could not practicably be conducted without the alteration or waiver. 
DISCUSS IN DETAIL YOUR PLAN: 
PAGE 1 Of 2 
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As above 
• The use or disclosure of PHI involves no more than minimal risk to the individuals, based on, at least, the presence of the 
following elements: 
la. An adequate plan to protect the identifiers from impJ2fJer use/disclosure ~ 
DISCUSS tN DET AtL YOUR PLAN: 
The use of PHI involves no risk to the patient as the data will be reviewed only and not recorded in any manner unless 
the infant meets study criteria and is consented for enrollment in the research study. Of note: all members of the 
research team who will review admission information of patients prior to contacUconsent are members of the advanced 
practitionter staff in the NICU. 
b. An adequate plan to destroy the identifiers at the ear/iest opportunity consistent with the conduct of the rese~ 
unless there is a health or research justification for retaining identifiers or suclLretention is otherwise ~uired by law 
DISCUSS IN DETAIL YOUR PLAN: 
As described in the research proposal. all information will be de-identified by the research team. The only link between 
identified PHI (patinet name/ MR number) and each research participant will be the consent form which will be 
maintained under lock and key in a secure location to protect confidentiality. No identified recording of patients who do 
not meet criteria will be completed as study participation is excluded. 
C. Adequate written assurances that PHI wiff not be reused/disclosed to any other person or entity, except as required ~~ 
law, for authorized oversight of research project or for other research for which use/disclosure of PHI would bej 
. permitted by this subpart 
DISCUSS IN DETAIL YOUR PLAN: 
No PHI will be reused/disclosed to any person or entity as described above and in the research proposal. The informed 
consent which will be the only form to contain the actual patients name with a link to the assigned patient enrollment 
number (for de-identification purposes) will be held in a locked cabinet in a locked office within the School of Nursing at 
Virginia Commonwealth University. Until transfer to the VCU School of Nursing the form will be kept in a locked drawer 
within the Nurse Practitioner office in the NICU. This office is also locked and not accessible to the general public. 
THIS SECTION FOR IRB USE ONLY 
FINAL DISPOSITION: 
IRB SIGNATURE: 
SIGNED BY: 
Above cited justifications meet the criteria 
required to grant a Waiver of Authorization for the 
Use of Protected Health Information 
o IRBMEMBER 
PAGE 2 OF 2 
DATE: / :2..5/ / 
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FORM DATE: 12122111 CONSENT FORM VERSION: VERSION 1 
Data Collection Consent Form 
Eastern Virginia Medical School (EVMS) Institutional Review Board 
Study Title: A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) Related Skin 
Breakdown when using Different Nasal Interfaces in the Extremely Low Birth Weight (ELBW) Neonate. 
Name of Investigator: Katherine M. Newnam, PhD (c), RN, NNP-BC 
Sponsor: N/A 
Name of Subject: 
For participants less than 18 years old, all references to "you" in this consent form are referring to "you", 
"your child" or a "minor for whom you are a legally appointed representative". 
You are being asked to participate in a research study involving the collection of information in the form of data 
from your child's medical record. The purpose of the research project is to compare the different types of 
equipment that we use to deliver nasal continuous positive airway pressure (CPAP) to your baby who weighs 
between 500 and 1500 grams at birth. Nasal CPAP is a breathing machine that is secured to your babies' nose 
through the use of short soft nasal prongs, a soft nasal mask or a rotation between the mask and prongs in order to 
provide constant air flow or air pressure into the baby's nose and airways to help the baby breath more effectively. 
Although both the nasal prongs and mask are effective in providing respiratory support to your baby and both types 
of nasal equipment are routinely used in our Neonatal Intensive Care Unit (NICU) we would like to know if one type 
is more comfortable for your baby or may cause less skin irritation where the skin comes in contact with the 
respiratory machine. 
Your baby will be randomly placed into one of three groups, the nasal prong group, the nasal mask group or the 
rotation group which rotates the two nasal devices every 3 to 4 hours during infant care. The random assignment is 
like flipping a coin with equal choices for the infant to be placed into one of the three identified groups. 
During the time your infant is treated with nasal CPAP your infant's skin will be examined by one of the nurses or 
nurse practitioners to identify any skin redness or skin irritation around the respiratory equipment. Your baby's 
nurse also examines your infant's skin during nursing care every 3-4 hours with the respiratory therapist. The 
amount of agitation is also measured by your baby's bedside nurse prior to and during care. These measurements 
are recorded in the medical record. Routine blood gases are also followed at intervals determined by your baby's 
medical team. These blood gases help to determine if your infant is tolerating the respiratory treatment of CPAP or 
may need more or less respiratory support. The blood gas results are also recorded in your child's medical record. 
After we measure the amount (if any) of skin irritation we will compare this information between the different 
group that we are studying to decide if one method of nasal CPAP may be more comfortable or better for infant's 
skin than the other. If your infant has redness or irritation develops under the nasal CPAP machine your baby will 
have the skin cared for by your medical team with current standards. Each of the examinations by the research 
nurses will be conducted during times your baby is awake and handled by the bedside nursing or respiratory staff. 
When your baby is no longer treated with nasal CPAP according to the medical team, your baby will have 
completed his/her enrollment in the study. Because all of the requested information is routinely collected as part of 
nasal CPAP care in the NICU we are asking for permission to record the information from your babies record so 
that we can look at differences between these nasal CPAP types. 
You will not be reimbursed for your participation. There are no additional costs to you associated with taking part in 
this study. 
Although the results of this research may not benefit you directly the researchers hope that the information collected 
will be used to improve nasal CPAP care in our NICU and therefore might benefit other infants who have nasal 
CPAP therapy in the future. The final results of this research study will be made available to you upon request. 
SOP VERSION 
JULv2007 Page 1 of 1-
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FORM DATE: 12/22111 CONSENT FORM VERSION: VERSION 1 
There are no specific risks related to your infant's participation, but there may be other risks not yet identified. 
All protected health information (PHI) will be maintained in strict confidence as required by law and for the purposes 
of this research your infant's information will be de-identified through the use of an assigned number. The only link 
between your babies name and the collected PHI will be this consent form which contains your infant's name and 
assigned patient number. It is also important to understand that your protected health information may be disclosed 
if required by law. Once your protected health information is disclosed for research, such as to the sponsor or 
EVMS Institutional Review Board, federal privacy laws may no longer protect the information. 
• If you refuse to give your approval for your personal information to be shared as described in this consent form, 
you will not be able to be in this study. However, your choice will not affect any medical benefits to which you 
are entitled. 
• By signing this consent form to participate in the study, you are allowing the research team to share PHI, as 
described in this consent form. 
• You have the right to cancel your approval for the sharing of PHI. If you cancel your approval, you will have to 
leave the study. All information collected about your infant before the date you cancelled may be used. To 
cancel your approval, you must notify Katherine Newnam RN, NNP in writing at Children's Hospital of the Kings 
Daughters (CHKD) Neonatal Intensive Care Unit (NICU), 601 Children's Lane, Norfolk, Va. 23507. 
• Your approval for the sharing of personal information about your infant for this study expires at the end of the 
study. 
• You also have the right to review your research records, or someone you designate may review your research 
records on your behalf, once the study has ended unless prohibited by law. 
• Any research information in your medical record will become a permanent part of that document. 
Your study records may be reviewed and/or copied in order to meet state and/or federal regulations. The only 
reviewer identified is the Eastern Virginia Medical School Institutional Review Board. 
Information learned from this research may be used in reports, presentations and publications. None of these will 
personally identify your infant. 
Taking part in this study is your choice. If you decide not to take part, your choice will not affect any medical 
benefits to which you are entitled. You may choose to leave the study at any time if you revoke your authorization 
to participate. 
We will tell you about new information that may affect your health, welfare, or willingness to stay in this study. 
In the event of injury resulting from this research study, Eastern Virginia Medical School (EVMS) provides no 
financial compensation plan or free medical care 
If you have any questions pertaining to this research you may contact Katherine Newnam at 757-668-7452 or 
Jacqueline McGrath at (804) 828-1930. If you believe you have suffered an injury as a result of your participation in 
this study, you should contact the principal investigator, Katherine Newnam at (757) 668-7452. You may also 
contact Dr. Robert Williams, an employee of Eastern Virginia Medical School, at (757) 446-8423. If you have any 
questions pertaining to your rights as a research subject, you may contact a member of the Institutional Review 
Board through the Institutional Review Board office at (757) 446-8423. 
SOP VERSION 
JULY 2007 Page 1 of l 
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FORM DATE: 12/22/11 CONSENT FORM VERSION: VERSION 1 
SIGNATURE 
You will get a copy of this signed form. You may also request information from the investigator. By signing your 
name on the line below, you agree to take part in this study and accept the risks. A child who is a ward of the state 
cannot be enrolled until the IRB has assigned an individual advocate, relative to this potential enrollment, to act on 
behalf of the child in addition to the guardian or in loco parentis. 
_1_1-
Signature of ParticipantlLAR Typed or Printed Name Relationship to Subject MMI DD/YY 
_1_1-
Signature of ParticipantlLAR Typed or Printed Name Relationship to Subject MMI DD/YY 
WITNESS (required for oral presentations) 
This signature must be present if the consent was presented orally to a subject in any manner. The witness may 
not be an individual named as an investigator or a person authorized to negotiate informed consent. 
_1_1-
Signature of Witness Typed or Printed Name MMI DD/YY 
D Witnessed Consent Process 
STATEMENT OF THE INVESTIGATOR OR ApPROVED DESIGNEE 
I certify that I have explained to the above individual the nature and purpose of the study, potential benefits, and 
possible risks associated with participation in this study. I have answered any questions that have been raised and 
have witnessed the above signature. I have explained the above to the volunteer on the date stated on this consent 
form. 
Signature of Investigator or Approved Designee 
IRBAPPROV; 
DATE: Q~ 'Iv 
EXPIRES 
DATE: a ~btt/J 
IRB -# ,g.' g )' <:M;"QQ/3 
SOP VERSION 
JULY 2007 Page 1 of 1-
_1_1-
MMI DD/YY 
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 “A Comparative Effectiveness Study of Continuous Positive Airway Pressure (CPAP) Related 
Skin Breakdown when using Different Nasal Interfaces in the Extremely Low Birth Weight 
(ELBW) Neonate” a research proposal  
 Katherine Newnam 
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Introduction: 
     The use of nasal CPAP has become widely accepted by health care providers who care for 
preterm infants in the treatment of respiratory distress syndrome (RDS), yet few studies have 
used comparative effectiveness research to examine the performance of various nasal interfaces 
within this group to determine differences in either the incidence or severity of nasal skin 
breakdown, a well described side effect of this useful treatment.  
     Following a systematic literature review of 111 articles related to the use of nasal CPAP on 
the preterm infant, only a single study was reviewed which included the study aim of comparing 
nasal interfaces to determine the frequency of skin breakdown (Rego and Martinez 2002).  This 
research study, conducted in Sao Paulo, Brazil evaluated the performance of two types of nasal 
prongs, Argyle and Hudson, to deliver nasal CPAP to preterm infants.  The conclusion of the 
study was the prongs were found to be equally effective in the delivery of CPAP, the Argyle 
prong was more difficult to maintain in the infant’s nares and had a higher incidence of nasal 
hyperemia, the first sign of skin breakdown when compared to the Hudson prong.  No 
comparison studies were reviewed between prongs, mask or a rotation of devices that have been 
described antidotally as a strategy to reduce pressure on nasal skin during the use of nasal CPAP 
(Robertson, McCarthy et al. 1996; McCoskey 2008; Squires and Hyndman 2009).  Additionally, 
there is universal agreement that nasal injury is a potential risk factor when using the nasal 
interfaces with CPAP delivery with clear directives for attention to skin assessment and 
increased nursing care and expertise which was mentioned in 44 of the 111 reviewed articles.  
Specific Aims: 
     The primary aim of this study will be to determine differences in the frequency, severity and 
specific types of nasal injuries described when comparing different nasal CPAP interfaces 
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(prongs/mask) used to treat respiratory distress syndrome. These outcome measures will be 
calculated based on nurses recording information included in the skin condition score (NSCS), a 
three parameter tool that evaluates skin breakdown, erythma and dryness. A secondary aim of the 
study will be to identify those risk those factors associated with nasal injury and skin breakdown 
during nasal CPAP administration. Lastly an exploratory aim will be to identify and describe 
nursing strategies that can support the reduction of nasal injuries in this vulnerable population 
during nasal CPAP administration.  Additional data will be collected during the study which will 
include the agitation levels of the infants during nasal CPAP administration and the respiratory 
stability of the patients as measured by blood gases. These measures will be used to explore 
other potential factors associated with nasal injury and skin breakdown and are part of the 
standard neonatal care while neonates are hospitalized in the NICU. 
For this Comparative Effectiveness Study the Hypotheses are: 
1) Is there a difference in the incidence and/or severity of skin breakdown of the ELBW
preterm neonate (less than 1500 grams) when nasal CPAP is administered using three 
types of nasal interfaces: 1) continuous nasal prongs, 2) continuous nasal mask or 3) 
alternating the nasal mask and prongs every 4 hours?  
2) Are the differences in the incidence and/or severity of skin breakdown related to other
predisposing risk factors such as gestational age, birth weight, length of therapy,
environmental humidity level, amount of CPAP flow administered and/or nursing
interventions that include positioning techniques, nasal suctioning devices and the use of
nasal saline during suctioning?
3) Will the frequency and severity of nasal injury be accurately measured with the NSCS?
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4) Is there a correlation between agitation scores as measured by the N-PASS and the
incidence and/or severity of nasal injury during the use of nasal CPAP in the ELBW
preterm neonate?
5) Is there a correlation between blood gas results, specifically respiratory acidosis reflected
in the pH, CO2 and base excess levels and the incidence of nasal injury in the ELBW
preterm neonate?
Background and Significance: 
     The dynamic approach to respiratory care of the preterm neonate has progressed following 
scientific evidence which clearly demonstrates advantages to early nasal continuous positive 
airway pressure (CPAP) or early extubation to nasal CPAP  in this population.  It is now well 
understood that reduced mechanical ventilation in high-risk preterm infants has many advantages 
which includes; decreased chronic lung disease, decreased incidence of ventilator associated 
pneumonia as well as overall reduction in blood stream infections, reduction in the incidence of 
periventricular luekomalacia (PVL) previously associated with long term ventilation, improved 
neurodevelopmental outcomes and shortened hospital length of stay (De Paoli, Davis et al. 2008; 
Squires and Hyndman 2009).  These small infants however require some adjunct to maintain 
functional residual capacity (FRC) as well as improve the symptoms of respiratory distress 
syndrome (Buettiker, Hug et al. 2004).  Nasal continuous positive airway pressure (CPAP) is 
often used to support this need.   
     Nasal CPAP is a non invasive method for providing a constant distending pressure during 
both the inhalation and exhalation phase of respiration.  Used in the spontaneously breathing 
preterm infant it provides stability of the infant’s FRC, improves oxygenation, conserves 
surfactant, aids in the prevention of atelectasis, improves gas exchange and aids in the prevention 
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of obstructive and central apnea (Davis, Jankov et al. 1998; Diblasi 2009; Squires and Hyndman 
2009).  First described in 1914 in a German textbook about the diseases of the newborn, a system 
of hoses placed into a water filled receptacle, a face mask with a gas source was used on a 
newborn who had symptoms of respiratory distress to provide continuous airway pressure 
(Diblasi 2009). Ventilator delivered CPAP first was reported in the late 1970’s and 1980’s that  
were adapted from adult models (Gregory, Kitterman et al. 1971); then in the 90’s free standing 
nasal CPAP delivery systems were designed and widely adapted into routine practice (Verder 
2007; Diblasi 2009). 
     Three major types of nasal CPAP are used in the neonatal population, traditionally classified 
by the technique used to control the gas flow to the patient (Gupta, Sinha et al. 2009).  These 
include constant flow or bubble CPAP, variable flow which are devices that have fluidic control 
to maintain the CPAP pressure and finally ventilator delivered CPAP generally delivered through 
an endotracheal tube (ETT) or a long single nasal pharyngeal tube.  All devices share in four 
components, 1) a heated/humidified blended gas source, 2) a nasal interface, 3) a patient circuit 
and 4) a pressure-generating apparatus (Diblasi 2009).   
     Risks attributed to the use of nasal CPAP in this population have also been described.  These 
include abdominal distension, inability to provide enteral nutrition secondary to gut disturbance, 
slightly increased incidence of necrotizing enterocolitis (NEC), pneumothorax and nasal injury 
or nasal mucosal damage (Verder 2007; Squires and Hyndman 2009)  The current CPAP devices 
are effective in maintaining needed positive end expiratory pressure (PEEP) but also place 
constant pressure on the nares, nasal septum and forehead leading to decreased skin integrity and 
injury (De Paoli, Davis et al. 2008).  Research is needed to 1) compare nasal CPAP interfaces 
commonly used to determine differences in frequency and severity of skin break down and 2) to 
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identify strategies to reduce skin breakdown during nasal CPAP use in extremely low birth 
weight (ELBW) infants.   
          The overall clinical management of preterm infants whose respiratory status is supported 
through the use of nasal CPAP is based on anecdotal experience and unit standards rather than on 
scientific evidence.  Nursing skill level and experience with positioning, frequent assessment and 
intervention, all of which takes significant nursing time has been well described by nearly half of 
the reviewed articles.  Practices vary widely from unit to unit making standardization of nursing 
care to protect vulnerable preterm infant skin during this therapy difficult.   
     We clearly understand the advantages of using nasal CPAP in this population which 
outweighs the observed risk to this therapy.  We must now examine the different delivery 
methods and nasal interface devices while providing non-invasive nasal CPAP to preterm infants 
to best manage the preterm infant’s respiratory distress syndrome using scientific evidence to 
create and test best clinical practices.  In a meta analysis completed on the devices and pressure 
sources for the administration of nasal CPAP,  implications for further research included 
determining which nasal interface device is the least traumatic to the infant nose, particularly the 
very low birth weight infant (De Paoli, Davis et al. 2008).  Additionally, a systematic review of 
non-invasive ventilation strategies described nasal prongs and newer nasal masks for use in the 
neonate.  The masks were described to require less pressure to remain in place but “will need 
empiric testing to determine safety in this population” (Courtney and Barrington 2007). 
     Empiric evidence based on current scientific literature is needed to support nursing 
interventions to reduce iatrogenic skin injury of the nose, face and head during nasal CPAP 
administration to provide improved long term outcomes. Specific attention to those details of 
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nursing care to this patient population to addresses strategies for optimal outcomes are clearly 
needed. 
Research Method and Design:      
     A three group prospective randomized experimental study design is currently planned. This 
would include recruitment into the study following admission to the neonatal intensive care unit 
(NICU) when infants are typically intubated during the mechanical ventilation phase of 
treatment. Upon extubation to nasal CPAP (the typical care for these infants) the participants 
would be randomized into three groups to include, 1) a continuous nasal prong group,  2) a 
continuous nasal mask group or 3) an alternating mask/prongs every 4 hours group. All infants 
will be managed with the same type of nasal CPAP delivery system.  Infants transported from 
the delivery room or outlying hospital that are initially treated with nasal CPAP would be 
considered for enrollment if consent was obtained and randomization could occur within 8hours.  
     Following parental consent, infants would be clearly identified by a star placed on the 
respiratory care provider’s bedside chart to remind caregivers to enroll participants as the 
medical condition of the patient was appropriate for transition from current therapy to nasal 
CPAP following physician or neonatal nurse practitioner (NNP) order to extubate the patient.  
Infants who meet study inclusion criteria and who have been consented and self extubate will 
also be randomized for nasal CPAP trial if medically appropriate as dictated by physician or 
nurse practitioner order.  No infants will be placed on nasal CPAP unless medically warranted; 
therefore patients who are extubated to high flow or regular nasal cannula will be excluded 
unless nasal CPAP is used in those patients at a later time as medically indicated.  
     Following parental consent the infants recruited for the study will be block stratified 
according to weight into four categories according to birth weight: < 750 grams, 750-1000 
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grams, 1001-1250 grams and > 1251-1500 grams. Known differences in the skin integrity have 
been demonstrated with the lowest birth weights proven the most vulnerable. Stratification 
according to infant’s birth weight will keep the groups more homogeneous as it is expected that 
the smallest group will have the least patients.  After stratified the subjects will be randomly 
allocated into the three groups, 1) a continuous nasal prong group, 2) a continuous nasal mask 
group or 3) an alternating mask/prongs every 4 hours group.   Randomization will accomplished 
using serially numbered opaque sealed envelopes developed by the researcher which will be 
located close to the storage area which houses the CPAP equipment within the NICU. 
     A flow diagram (algorithm) will be placed beside the aforementioned sealed envelopes to 
provide a quick reference to the respiratory team collecting the necessary equipment for the 
infants ordered transition to nasal CPAP (see appendix 1). This diagram will visually describe 
the information required (birth weight) in order for the respiratory therapist to determine from 
which group of envelops they should select from which will determine group assignment.  The 
equipment would then be collected by the respiratory staff to place the infant on nasal CPAP 
with continuous nasal prongs, continuous nasal mask or alternating each device every four hours. 
     Routine skin assessments will be primarily a nursing responsibility but collaboration between 
the bedside nurse and respiratory therapist for scoring will be encouraged to be consistent with 
the current standard of practice. A small group of skin experts, described as the Core Research 
Team, which includes four advance practice nurses will be responsible for twice a day skin care 
evaluations on enrolled participants using the NSCS, the only additional data collected for study 
purposes and will be conducted in addition to those skin assessments described by the bedside 
caregiver.  The additional skin evaluations will be completed during the infant’s routine nursing 
care without additional interruption or examination for the neonate.  This will be accomplished 
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through communication with the bedside nursing staff to coordinate assessment times in an effort 
to protect the infant’s quiet environment. 
      Tool and interrater reliability and of the NSCS (reported as Cohen’s Kappa and chronbach’s 
alpha) will be tested through the use of two experts assessing 10% of the study participants in 
conjunction with scheduled assessments described above (see appendix #5).  Skin measurements 
using the NSCS will continue at the described intervals during the course of nasal CPAP 
administration.  Skin assessment measurements as well as described extrapolated data from the 
medical record will be imported into an Excel spread sheet for analysis using SPSS.       
     Assessment Tools: 
1) Biographical data: to include infant’s gestational age, birth weight and current weight
will be extrapolated from the medical record (see appendix #3 and #4).
2) Information collected related to therapy: CPAP liter flow, day of CPAP, humidification
of environment as measured on the incubator humidity gauge using the Giraffe ©, and
temperature of the humidifier device connected to the nasal CPAP will be extrapolated
from the participant’s medical record (see appendix #3 and #4).
3) Neonatal Skin Condition Scale (NSCS) is a skin condition scoring system that was
developed for the AWHONN/NANN skin care research based project and adapted using
a visual skin scoring system originally developed by Lane and Drost (1993).  The tool
uses three clinical outcome categories which includes dryness, erythma and breakdown or
excoriation of the skin.  Each of these categories is graded one through three.  The score
of one in each category indicates a healthy skin assessment and the score of two or three
indicates an increasing level of skin breakdown with a total score of nine (three in each
category) being the worse skin evaluation score possible. Pictorial representation of each
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category with examples of skin that represented each score was developed to use as an 
aid for the clinician during the assessment of neonatal skin.   The tool has been tested for 
both validity and reliability and for interrater reliability during the project (Lund, Kuller 
et al. 2001; Lund and Osborne 2004). Skin assessments using the tool will be performed 
by the Core Research Team of advanced practice nurses every 10 to 12 hours in 
coordination with the participant’s routine nursing care (see Appendix #2 and #5).   
4) Agitation levels of the infants will be monitored using the Neonatal Pain, Agitation and
Sedation Scale (N-Pass) was developed as a clinically relevant tool to assess primarily
acute or chronic pain as well as sedation level in preterm infants who are not capable of
self report (Hummel, Puchalski et al. 2008).  This scale has been well validated in the
preterm population and is currently used as a measure of agitation at the proposed
research site; therefore information will be extrapolated from the medical record (see
appendix #6).
5) Blood gases typically obtained as part of routine medical care will be recorded in an
effort to establish relationships between increased respiratory distress symptoms as
demonstrated by increased carbon dioxide levels and skin breakdown measure. No
additional blood gas measures will be required of study participants.
     This proposed research study will utilize the multidisciplinary expertise from nursing, 
medicine and respiratory therapy that provide the health care team while these vulnerable 
patients are in the Neonatal Intensive Care Unit (NICU) during nasal CPAP administration. 
Data Analysis Plan:   
     Demographic information from each participant will be collected for descriptive purposes and 
the means of each group will be compared using a one way analysis of variance (ANOVA) to 
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identify group differences.  Data analysis will be performed at both the individual and group 
levels for descriptive and comparison purposes. 
     Specific intended study analysis will be discussed according to study aim: 
1) The primary aim of this study will be to determine differences in the frequency, severity and
specific types of nasal injuries described when comparing different nasal CPAP interfaces 
(prongs/mask) used to treat respiratory distress syndrome. Analysis will be conducted using the 
previously described NSCS scores every 10-12 hours with an incidence of skin breakdown 
classified as mild, moderate or severe.  Incidence of breakdown per group will be calculated for 
all three groups and one-way ANOVA will be used to analyze continuous variables. 
2) A secondary aim of the study will be to identify those risk those factors associated with nasal
injury and skin breakdown during nasal CPAP administration. This descriptive analysis will 
examine those factors such as gestational age, birth weight, nutritional support, liter per minute 
of CPAP flow and compare findings between groups using ANOVA.  Regression analysis may 
also be considered. 
Study Limitations: The study will employ a convenience sampling method, which may generate 
a non-representative sample.  The study will be conducted at a single NICU site which may not 
be representative of all neonatal patients in the NICU that are 500-1500 grams and require nasal 
CPAP.  Control for extraneous variables would be impossible during the care of these acutely ill 
neonates who are cared for in the NICU.  Blinding to treatment groups will not be possible and 
may influence measurements. Data collection phase is estimated to be between 4 and 6 months 
with multiple changes anticipated in this dynamic environment including the implementation of 
an electronic medical record (EMR) and staffing pattern changes in the NICU to accommodate 
the national reduction in resident and intern working hours which impacts neonatal coverage. 
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Study Site: 
     The neonatal Intensive care unit at the Children’s Hospital of the King’s Daughters (CHKD) 
in Norfolk Virginia will be utilized as the study site for this project.  This is a 62 bed level III 
NICU that serves a large geographic territory from Northeastern North Carolina to 
Williamsburg, Virginia.  Based on unit statistics from 2011 (January-June) there were 58 patients 
admitted to the CHKD NICU who required nasal CPAP and were birth weight between 500 and 
1500 grams. The range of CPAP days was from 1-16 days for a mean of 3.9 CPAP days.  The 
average patient’s birth weight was 834 grams.  This data was collected as a feasibility projection 
for this planned research study.   
     A large evidence based project (EBP) was completed by this researcher earlier this year 
(2011) using the same proposed data collection site in an effort to standardize routine nursing 
and respiratory care administered to nasal CPAP patients.  This EBP project was aimed at 
improving patient care outcomes, educating the nursing and respiratory staff on the importance 
and mechanics of nasal CPAP as well as reducing the extraneous variables which could influence 
the results of this proposed study.   
Human Subjects: 
Inclusion criteria:  Infants who are initially treated with or weaned from mechanical 
ventilation to nasal CPAP and who are birth weight 500 grams to 1500 grams.  Infants 
with a birth weight under 500 grams will not be considered based on documented overall 
concerns with skin integrity in this group (Sardesai, Kornacka et al. 2011) which could 
influence study results. 
Exclusion criteria:  Infants who have been diagnosed with major cardiac disease or 
congenital malformation which could impair the nasal CPAP performance would be 
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excluded.  Patients who are not consented within 8 hours of nasal CPAP initiation or who 
had nasal skin breakdown at enrollment would be excluded and patients outside of the 
weight inclusion would not be included.   
Parents less than 18 years of age:  Mothers and fathers who are under the age of 18 that 
have infants that meet inclusion criteria for this research project will be excluded 
secondary to informed consent limitations. 
Research material:  There will not be any research materials solicited or used for the 
purposes of this study. 
Recruitment Plan: 
      Parents or guardians of those patients who are admitted to the NICU and who meet the study 
inclusion criteria will be approached following admission to the unit. The research study will be 
explained to each family providing adequate time to answer questions related to the proposed 
research plan. Those parents who are unable to visit the NICU because of geographic or other 
barriers will be contacted by phone to explain the research study and invite participation. 
     A power analysis using a significance level of p < 0.05 was performed to meet the described 
primary aim of the study which was to determine differences in the frequency, severity and 
specific types of nasal injuries described when comparing different nasal CPAP interfaces 
(prongs/mask) used to treat respiratory distress syndrome in the preterm infant less than 1500 
grams.  The analysis was focused on the frequency parameter of this aim and a total sample size 
of 72 with 24 in each of the three groups (continuous nasal prongs, continuous nasal mask or 
alternating nasal mask and prongs every 4 hours) was adequate to determine significant 
differences between groups. 
Privacy of Participants: 
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     The privacy of the participants will be supported through the use of participant identifier as 
described in section “Confidentiality of Data”.  The group that each patient is randomized which 
dictates the type of nasal interface utilized to deliver nasal CPAP will be recorded as part of the 
health care record which is standard care for patients receiving nasal CPAP.  All research records 
with all patient identifiers removed will be removed from the patient’s bedside daily and placed 
into a secure location on the unit for later analysis. 
Confidentiality of Data: 
     All information will be de-identified by assignment of research assigned patient number 
which will be used on all study records. The process of assignment will start with the number (N) 
001 through (N) 024 for the first patient in the continuous nasal prong group; (M) 101 through 
(M) 123 for the continuous nasal mask group, and (R) 201 through (R) 224 for the rotation 
group.  This patient identifier will be recorded on all maintained study records. The consent 
which will contain patient names and medical record number will be related to assigned patient 
identifier as described above using a key which will be available to the PI and other research 
investigators only.  This information will be kept under lock and key in the Virginia 
Commonwealth University School of Nursing (the location of PI’s faculty advisor, Dr. McGrath) 
and will be destroyed three (3) years following the close of the study as required by the IRB.  
De-identified data will be maintained for an undetermined length of time and may be used in 
future meta-analysis as described in this protocol. 
     Use of de-identified data for future publications and presentations are planned by the PI 
(student researcher).  The study findings will be used as part of the requirements for graduation 
(PhD) at Virginia Commonwealth University (VCU).  Electronic submission of the research 
findings of this study will be filed in the VCU library as part of the researcher dissertation 
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requirement. Additional secondary analysis as well as future study using this data set for meta-
analysis is included as future research plans for the PI. 
Potential Risks: 
    There are no anticipated risks or discomforts associated with participation in this research 
study.   Individual risk to individual patients are considered minimal and consistent with the risk 
experienced with current standard nasal CPAP care for the identified population within the 
NICU. 
Risk Reduction: 
     Frequent patient skin assessment (at least every 4 hours) by the bedside registered nurse 
and/or respiratory care therapist is required by both unit and research protocol.  Signs of 
hyperemia, erythma or excoriation will be reported to the health care team and treatment ordered 
as necessary.  Intolerance to nasal CPAP treatment will be addressed in the usual manner with 
increased medical care up to and including intubation. If infant’s are randomized to the nasal 
prong group and the smallest size prongs cannot be fit according to manufactures direction (rare 
event), the infant will be transitioned to the nasal mask for CPAP delivery (current standard-of- 
care) and removed from the study.  No changes in the standard unit care are anticipated based on 
the use of the type of nasal interface during the administration of nasal CPAP in the preterm 
infant.  
Risk/Benefit: 
     There are no direct benefits to the study participants at present; however, changes in how 
nasal CPAP is administered to this patient population may provide benefits in future neonatal 
care. 
Compensation Plan for Study Participants: 
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     No compensation is planned for study participants or their families. 
Consent Process: 
     Informed consent will be obtained by the researcher or his/her designees (Core Research 
Team) which are advanced practice nurses who are experienced in obtaining informed consent. 
Each parent or guardian of the qualifying patients will be asked to sign a consent form which 
will describe the study aim, the study design and various steps to be employed during the study.  
The parents of the participants will be encouraged to discuss any items or words that are unclear 
or that they do not understand during the consent process. In special rare circumstances, parents 
are unable to travel to the NICU because of maternal health following delivery or other barriers 
that impede travel to Children’s Hospital of the Kings Daughters.  In these rare cases informed 
consents may be obtained by phone.  The process for the phone consent in these cases will 
require a full reading of the informed consent including time to answer all parental questions.  
Witnessed signature will also be required for phone consent. This process will be utilized only 
when all other means of face-to-face contact by the Core Research Team fails. 
     The parents of the participants will be provided a copy of the signed consent with contact 
information for the primary investigator (PI) in person at the conclusion of signing or by mail if 
phone consent process described above was necessary.  The EVMS Internal Review Board (IRB) 
contact information will be included for parental questions not answered by the PI or research 
team.   
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Proposed Algorithm for Study 
Birth weight 500-1500 grams 
Admitted to the NICU on Mechanical 
Ventilation Screened for 
inclusion/exclusion criteria (airway, 
cardiac or major congenital anomaly) 
Birth weight 500-1500 grams 
Admitted to the NICU on Nasal CPAP 
Screened for inclusion/exclusion 
criteria (airway, cardiac or major 
congenital anomaly) 
Contact parent and  obtain 
consent for study within 8 
hours of admission 
Medically ready for extubaton-MD/NNP 
order written for nasal CPAP.  
Patient randomized to 3 groups 
Contact parent and obtain 
consent for study prior to 
extubation to nasal CPAP 
YES NO 
(Excluded) 
YES 
YES 
YES NO 
(Excluded) 
Patient randomized to 1 of 3 groups 
Flag patient’s 
bedside for study 
enrollment  
Respiratory 
therapy flow 
sheet here 
PRONGS MASK 
PRONGS 
ALTERNATE 
Patient randomized to 1 of 3 groups 
NO 
(Excluded) 
MASK ALTERNATE 
YES 
Respiratory 
therapy flow 
sheet here 
Data Collection as described on Page 2 
Data Collection as described on Page 2 
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Page 2-Algorithm for Study--Data Collection 
FOR ALL ENROLLED PARTICIPANTS FOLLOWING RANDOMIZATION 
1) Bedside RN/RRT assess skin under nasal interface and CPAP hat every 3-4 hours using
NSCS tool, recording measurements on Nursing and/or Respiratory Care Flow sheet. 
2) Core research team (experts) assess skin of all participants every 10-12 hours (twice
daily) using NSCS. 
3) Core research team complete Data Collection Sheet (see data collection Sheet)
4) File Data Collection Sheet in Secure Location on NICU for future data analysis
NICU patient transitioned from Nasal CPAP to Room air or 
other medically indicated form of respiratory support   
Conventional medical 
assessment by NNP/MD and 
intervention as directed by NICU 
medical team 
NO YES 
Nasal or other skin breakdown 
detected during every 3-4 hour 
nursing/RRT assessments or every 
10-12 hours skin assessments by 
Core Research Team 
YES 
Conclude data collection and release participant from study 
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Respiratory Care Algorithm for Study—Appendix 1 
FOR ALL CONSENTED PARTICIPANTS FOLLOWING EXTUBATION 
ORDER BY NNP/MD  
1) Obtain birth weight for patient.
2) Obtain the Frontal Occipital Circumference (for CPAP hat size).
Flag patient’s bedside as enrolled participant 
Perform ordered extubation and place infant on 
nasal CPAP (per randomized group).  Document 
skin assessment and tolerance per unit standard 
(every 3 to 4 hours).   
Select randomization 
envelop using birth weight -
open envelop for group 
assignment. 
To supply room to collect 
equipment for appropriate 
nasal interface according to 
randomization. 
If patient is randomized to alternating 
prong/mask group-protect PEEP 
administration during interface 
rotation every 3-4 hours. 
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Appendix C. 
 
Agreement form between the IRB’s of EVMS and VCU  
 
  179
Appendix D. 
Data Collection Instruments 
a) Enrollment 
b) Daily 
c) Weekly 
Neonatal Skin Condition Scale (NSCS) 
Neonatal Pain and Sedation Scale (N-PASS) 
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Page 1 of 3 
11.9.11 
Comparative Effectiveness Patient ID: 
Newnam, K. (appendix #3) Date:  /            / 
Data Collection Form – Enrollment Time: 
Inclusion/Exclusion criteria assessment: 
1. Birth weight between 500 to 1500 grams:    No, not eligible  Yes, eligible 
2. No presence of a congenital airway anomaly:  No, not eligible  Yes, eligible 
Parental consent obtained? No  Yes 
Must have “yes” for all three above to continue. 
_____________________________________________________________________________________ 
1. Patient’s birth weight:   Grams 
2. Patient’s current weight:          Grams 
3. Patient’s gestational age at birth:     Weeks     Days 
4. Patient’s current age:  Weeks      Days 
5. Length of CPAP:  Days 
6. CPAP flow:  4L/min   5L/min   6L/min   Other_____________ 
7. CPAP temperature: .        Celsius
8. FiO2:    % 
9. Incubator humidity:  % 
10. Nasal interface:          Prongs   Mask  Alternating prongs and mask 
11. Number of times suctioned since last data collection:          Times 
12. Type of suctioning provided:  Nasal           Oral        Both 
13. Was nasal saline used?     No     Yes   Not applicable since no nasal suctioning 
14. Is there documented bleeding with suctioning?  No   Yes 
B
o
t
h
    
Y
e
s
   181
Page 2 of 3 
11.9.11 
Comparative Effectiveness Patient ID: 
 Newnam, K. (appendix #3) Date:  /            / 
Data Collection Form – Enrollment Time: 
15. Has a blood gas been obtained since last data collection?    No     Yes 
If so, what are the results? 
.     pH 
  CO2 
 Base Excess 
16. Was a skin injury reported to the patient’s medical team?     No      Yes 
17. Was an intervention provided for the skin injury?     No      Yes 
18. What type of skin intervention was provided?
  Watchful waiting 
  Ointment applied 
  Skin massage/pressure relief 
  Skin care consult 
  Other:____________________________________________________________________ 
19. Location of nasal or skin injury:
 Forehead       
 Nasal bridge       
 Nasal septum 
 Other:___________________________________________________________________ 
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11.9.11 
Comparative Effectiveness Patient ID: 
Newnam, K. (appendix #3) Date:  /            / 
Data Collection Form – Enrollment Time: 
20. NSCS score now:
Erythema:          1   2        3 
Dryness:     1   2        3 
Excoriation:     1   2        3 
21. N-PASS score now:
Crying:                    -2             -1  0       1             2 
Behavior state:      -2          -1   0  1             2  
Facial expression:    -2            -1    0      1    2   
Extremity tone:      -2          -1   0  1             2  
Vital signs:        -2             -1    0      1    2   
22. Clinical concerns:
Sepsis 
Feeding intolerance 
Operative procedure 
Apnea and bradycardia events 
Other:_________________________________________________________________________ 
23. Individual care strategies:
Pectin barrier in place?     No  Yes 
Developmental positioning?           No        Yes 
Symmetrical hat placement?          No        Yes 
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11.9.11 
Comparative Effectiveness Patient ID: 
Newnam, K. (appendix #4) Date:  /            / 
Data Collection Form – Daily Time: 
1. Patient’s current weight:     Grams 
2. Patient’s current age:    Weeks     Days 
3. Length of CPAP:  Weeks       Days 
4. CPAP flow:  4L/min      5L/min  6L/min               Other ___________ 
5. CPAP temperature:       .       Celsius 
6. FiO2:  % 
7. Incubator humidity:        % 
8. Nasal interface:  Prongs  Mask     Alternating prongs and mask 
9. Number of times suctioned since last data collection:         Times 
10. Type of suctioning provided:        Nasal      Oral            Both 
11. Was nasal saline used?  No    Yes        Not applicable since no nasal suctioning 
12. Is there documented bleeding with suctioning?     No   Yes 
13. Has a blood gas been obtained since last data collection?          No           Yes 
If so, what are the results of the latest blood gas? 
      .              pH 
    CO2 
     Base Excess 
14. Was a skin injury reported to the patient’s medical team?    No    Yes 
15. Was an intervention provided for the skin injury?  No    Yes 
18. What type of skin intervention was provided?
 Watchful waiting 
 Ointment applied 
 Skin massage/remove pressure 
 Skin care consult 
 Other:____________________________________________________ 
B
o
t
h Y
e
s
 184
Page 2 of 2 
11.9.11 
Comparative Effectiveness Patient ID: 
Newnam, K. (appendix #4) Date:  /    /
Data Collection Form – Daily Time:    
19. Location of nasal or skin injury:
 Forehead       
 Nasal bridge    
 Nasal septum 
 Other:_________________________________________________________ 
20. NSCS score now:
Erythema:         1      2             3 
Dryness:   1      2             3 
Excoriation:      1      2             3 
21. N-PASS score now:
Crying:         -2             -1       0             1        2  
Behavior state:                 -2  -1        0     1             2 
Facial expression:            -2  -1        0     1             2 
Extremity tone:         -2  -1        0     1             2 
Vital signs:         -2  -1        0     1             2 
22. Clinical concerns:
Sepsis 
Feeding intolerance 
Operative procedure 
Apnea and bradycardia events 
Other:__________________________________________________________________ 
23. Individual care strategies:
Pectin barrier in place?  No  Yes 
Developmental positioning?      No Yes 
Symmetrical hat placement?           No     Yes 
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11.9.11 
Comparative Effectiveness Patient ID: 
Newnam, K. (appendix #5) Date:            /            / 
Data Collection Form – Weekly Time:      
Inter-rater reliability Data Collector Initials:  
1. NSCS score now:
Erythema:      1      2             3 
Dryness:   1      2             3 
Excoriation:      1      2             3 
Total score:  __________________ 
2. N-PASS score now:
Crying:         -2             -1    0       1        2  
Behavior state:                 -2  -1        0     1             2 
Facial expression:            -2  -1        0     1             2 
Extremity tone:         -2  -1        0     1             2 
Vital signs:         -2  -1        0     1             2 
Total score:                _________________________________ 
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Katherine Marie Newnam 
1104 Hillston Court 
Chesapeake, Virginia 23322 
newmankm2@vcu.edu 
Katherine Newnam was born July 6, 1957 in Norfolk, Virginia as an American citizen. 
Employment/ 
Experience 
  
2007 to present                       Neonatal ICU                                  CHKD 
Neonatal Nurse Practitioner  
Assessment, diagnosis and treatment for the critical ill neonate within the 
ICU under the direct supervision of the neonatologist.   
 1994-2001 and 2005-2007      Neonatal ICU                                 CHKD  
Staff Nurse 
Continual assessment and treatment of neonates under the direction of 
the neonatologist, resident staff and /or neonatal nurse practitioner.  
Assist with additional staffing when needed.  Participate in the family 
support committee to enhance family centered care within the NICU. 
 
2001-2002 and 2005-2006    Old Dominion University          Norfolk, VA 
Adjunct Faculty 
Taught pediatric dyadic content (Nursing 705; 3 credit course) to family 
nurse practitioner students under the direction of Graduate Program 
Director, L. Garzon, PhD.  Instruction included on site lecture and 
testing to students on campus with live feed to distance students across 
the state of Virginia (10-25 students).  Grading of presentations and 
term papers were also conducted. 
2000-2005 Renaissance Pediatrics Chesapeake, VA 
Certified Pediatric Nurse Practitioner 
With the oversight of a supervising physician I assessed, diagnosed and 
treated patients including prescriptive authority.  Patient load was 
approximately 22 assigned pediatric patients daily from newborn to age 
21 years.  Focus on well and preventative care with a focus in lactation 
and asthma support and teaching.  Supervised office nursing and support 
persons while assigned to assist in my daily functions.  Phone triage at 
night as assigned; weekly and hospital visits as required.   
 
2001-2006 Hospital Lactation Support CHKD 
Lactation consultant 
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Assist with any lactation issues throughout the inpatient units and the 
Emergency department.  Hands on participation with latch techniques 
and pumping equipment and support. 
 
1988-1994 Progressive Care Unit    CHKD 
Unit Director, Progressive Care Unit 
Twenty four hour accountability for the operation of the Progressive 
Care Nursing Unit.  This included staffing, patient care, education, budget 
analysis and development, policy development and departmental 
representation for the Progressive Care Unit.  Implemented 
departmental relocation to the third floor and unit expansion from 10-13 
beds.  Directly supervised and evaluated the performance of fifty 
professionals and paraprofessionals with the assistance of two assistant 
nurse managers. 
1986-1988    Assistant Unit Director NICU 
1983-1986    Staff Nurse Infant & Toddler Unit/NICU 
 
Education 
May 1983     Old Dominion University        Norfolk, VA 
Bachelor of Science                Nursing 
 
August 1990                          Old Dominion University         Norfolk, VA  
Master of Science                    Nursing Administration 
 
December 1999                    Old Dominion University         Norfolk, VA 
Post Master’s Certification    Certified Pediatric Nurse Practitioner 
 
December 2006                     East Carolina University        Greenville, NC 
Post Master’s Certification    Neonatal Nurse Practitioner  
 
August 2008-Current            VA Commonwealth Univ.    Richmond, Va.                       
(graduation 5/11/13)               PhD in Nursing 
 
 
  
Presentations   
Newnam, K. M.  Hyperbilirubinemia: Guidelines for Care in the Newborn. 
Presentation to Tidewater Area Lactation Consultant Association (TALCA), 
9/2005. 
 
Newnam, K. M. Hyperbilirubinemia: Guidelines for Care in the Newborn. 
NICU staff educational podium presentation, 10/2005. 
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Newnam, K. M. Improving Fluid Management and Decreasing PDA by 
improving the Neonatal Environment. National Association of Neonatal 
Nurses (NANN) 24th Annual conference, poster presentation, 10/07. 
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Fl., Poster Presentation, 2/2011. 
 
Newnam, K. M. Prevention of Skin Injury Related to Nasal Continuous 
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